Organizations and Foundations

Agrupacion Amigos de Parkinson, Chile
Alliance for Aging Research, USA
American Parkinson Disease Association, USA
Asociación Civil Enfermedad de Parkinson, Argentina
Asociación Peruana Para La Enfermedad De Parkinson, Peru
Asociatia Antiparkinson, Romania
The Bachmann-Strauss Dystonia & Parkinson Foundation, USA
Brooklyn Parkinson Group, USA
Bulgaria Parkinsonism Foundation, Bulgaria
Catalan Association of Parkinson, Spain
Central Ohio Parkinson Society, USA
Connecticut Parkinson Working Group, USA
Courageous Steps for Parkinson’s, USA
Croatian Parkinson’s Disease & Movement Disorder Association, Croatia
Cyprus Disease Parkinson Association, Cyprus
Dallas Area Parkinsonism Society, USA
Davis Phinney Foundation, USA
Delta Hungarian Parkinson Association, Hungary
Edmond J. Safra Philanthropic Foundation, Liechtenstein
EPIKOUROS kinisis, Greece
Estonian Parkinson’s Association, Estonia
European Parkinson Disease Association
Fédération Française Des Groupements de Parkinsoniens, France
Firefighter with Parkinson’s Disease Foundation, USA
Focus on a Cure Foundation for Parkinson’s, USA
Fondazione Grigioni, Italy
Geriatric Mental Health Foundation, USA
German Parkinson Disease Association, Germany
Hong Kong Parkinson’s Disease Foundation, Hong Kong
Houston Area Parkinson Society, USA
Icelandic Parkinson’s Disease Association, Iceland
International Parkinson Fonds Nederland, The Netherlands
Internationale Parkinson Fonds Deutschland, Germany
Japanese Parkinson Disease Association, Japan
Lithuanian Parkinson’s Disease Society, Lithuania
Malaysian Parkinson Disease Association, Malaysia
Melvin Weinstein Parkinson’s Foundation, USA
Michael J. Fox Foundation for Parkinson's Research, USA
Michigan Parkinson Foundation, USA
Movers and Shakers, USA
Muhammad Ali Parkinson Center, USA
National Institutes of Neurological Disorders and Stroke - NIH, USA
National Parkinson Foundation, USA
Neuro Challenge Foundation, USA
New Rhythms Foundation, USA
Norges Parkinsonforbund, Norway
Northeast Parkinsons and Caregivers, Inc, USA
Northwest Georgia Parkinson Disease Association, USA
Northwest Parkinson’s Foundation, USA
Pakistan Parkinson’s Society, Pakistan
Parkinson Association of Alabama, USA
Parkinson Association of the Carolinas, USA
Parkinson Association of the Rockies, USA
Parkinson Association of Northern California, USA
Parkinson Educational Program of Greater Cleveland, USA
Parkinson Foundation of the Heartland, USA
Parkinson Foundation of the National Capital Area, USA
Parkinson Hilfe Deutschland e.V., Germany
Parkinson Luxembourg, Luxembourg
Parkinson Pipeline Project, USA
Parkinson Selbsthilfe Österreich, Austria
Parkinson Society British Columbia, Canada
Parkinson Society Canada, Canada
Parkinson Society of Southern Alberta, Canada
Parkinson Support Center of Kentuckiana, USA
Parkinson Switzerland, Switzerland
Parkinson Vereniging, The Netherlands
Parkinson’s Action Network, USA
Parkinson’s Association of Ireland, Ireland
Parkinson’s Australia, Australia
Parkinson’s Awareness Association of Central Indiana, USA
Parkinson’s Disease & Related Movement Disorders Association, South Africa
Parkinson’s Disease Association of San Diego, USA
Parkinson’s Disease Foundation, USA
Parkinson’s Disease Society, UK
Parkinson’s Disease Society of Slovenia, Slovenia
Parkinson’s New Zealand, New Zealand
Parkinson's Resource Organization, USA
Parkinson’s Resources of Oregon, USA
Parkinson’s Western Australia, Australia
Parkinson’s Victoria, Australia
People Living with Parkinson’s, USA
Portuguese Parkinson Disease Association, Portugal
Project Spark Foundation, USA
Southeast Parkinson Disease Association, USA
Strutters Parkinson’s Center, USA
Swedish Parkinson’s Disease Association, Sweden
Taiwan Parkinson Association, Taiwan
The Cure Parkinson’s Trust, UK
The Ohio Parkinson Foundation Northeast, USA
The Parkinson Alliance, US
Turkish Parkinson’s Disease Society, Turkey
Unidos contra el Parkinson, Spain
Well Spouse Association, USA
Wisconsin Parkinson Association, USA
WobblyWilliams.com, UK
World Parkinson Disease Association
Young Parkinsons of Indiana, USA
Professional Associations and Societies

AGILE: Chartered Physiotherapists Working with Older People, UK
Albanian Society of Neurology, Albania
Alliance of Scottish Parkinson’s Disease Nurse Specialists, UK
American Academy of Nurse Practitioners, USA
American Academy of Physical Medicine and Rehabilitation, USA
American Association for Geriatric Psychiatry, USA
American Association of Neuroscience Nurses, USA
American Brain Coalition, USA
American Geriatric Society, USA
American Neurological Association, USA
American Physical Therapy Association, USA
American Society of Neuroimaging, USA
American Society of Neurorehabilitation, USA
American Speech-Language-Hearing Association, USA
Atlantic Euro Mediterranean Academy of Medical Science, Bulgaria
Argentine Neurological Society Movement Disorders Group, Argentina
Association of Physiotherapists Parkinson Disease Europe, Luxembourg
Australasian Neuroscience Nurses Association, Australia
Austrian Parkinson Society, Austria
Austrian Society of Neurology, Austria
Belgian Neurological Society, Belgium
Booth Gardner Parkinsons Care Center, USA
Brazilian Movement Disorders Group, Brazil
British and Irish Neurologists’ Movement Disorders Group, UK
British Association of Neuroscience Nurses, UK
British Geriatrics Society Movement Disorders Section, UK
Bulgarian Neurological Society, Bulgaria
California Institute for Regenerative Medicine, USA
Canadian Association of Neuroscience Nurses, Canada
Center for the Study of Motor Disorders, Chile
Danish Movement Disorder Society, Denmark
Dutch Movement Disorders Study Group, The Netherlands
Estonian Ludvig Puusepp Society of Neurologists and Neurosurgeons, Estonia
European Neurological Society
German Parkinson’s Society, Germany
Grupo de Desórdenes del Movimiento del Ecuador, Ecuador
Israel Neurologic Association, Israel
Italian Association for PD and Extrapyramidal Disorders, Italy
Kingston Centre, Southern Health, Australia
Korean Movement Disorder Society, Korea
LSTV Foundation, USA
Melvin D. Yahr International Parkinson’s Disease Foundation, USA
National Alliance for Caregiving, USA
Neuroscience Nursing Foundation, USA
Parkinson Study Group, USA/Canada

Parkinson’s Disease and Movement Disorder Society of India, India
Parkinson’s Disease Nurse Specialist Association, UK
Peruvian Neurological Society, Peru
Philips-University, Department of Neurology, Germany
Sociedad Latinoamericana de Movimientos Anormales, Uruguay
Society for Neuroscience, USA
Society of Indian Neuroscience Nurses, India
Swedish Movement Disorder Society, Sweden
The Movement Disorder Society
The Parkinson’s Institute and Clinical Center, USA
Taiwan Movement Disorder Society, Taiwan
VA Parkinson’s Disease Research, Education and Clinical Centers & the National VA Parkinson’s Disease Consortium
WE MOVE, USA
WFN - Association Parkinsonism and Related Diseases
World Federation of Neuroscience Nurses

These 158 Organizational Partners, that signed on by September 5, 2010, play a very important role in the World Parkinson Congresses. They help promote the WPC to their members, supporters and community and in short, help make the WPC the most diverse, high-level, inclusive Parkinson’s conference on the planet. We could not host the WPC without their involvement and support. We are grateful for their partnership, and their contribution to the WPC legacy.
Dear Attendees:

On behalf of the Steering Committee and World Parkinson Congress leadership, we would like to welcome you to the Second World Parkinson Congress and to Glasgow, Scotland.

WPC 2010 will once again unite the global Parkinson community for a high-level, inspirational Congress with four days of plenary sessions, workshops, and discussions on the most recent and cutting edge scientific and clinical research as well as advances in care and quality of life for people living with Parkinson’s disease (PD).

We have registrants from 66 countries who represent people living with PD, caregivers, neuroscientists, clinicians, nurses, allied health professionals, policy makers and others. Our nearly 160 Organizational Partners from 45 countries have graciously endorsed the Congress and by doing so have helped to ensure the success of the WPC 2010 and the diversity of our delegates.

Be sure to visit the exhibit area to view the 450 scientific posters and 50 Living-with-Parkinson’s posters. We encourage you also to visit with the exhibitors, both from industry and the non-profit community of Parkinson’s organizations from around the world. While there, be sure to stop by the Creativity & PD Exhibit, where for the first time, the Parkinson’s Quilt Project, with panels designed by 600 people from 14 countries is being displayed. It is the largest quilt ever created to raise awareness about Parkinson’s.

The World Parkinson Congresses are the only global Parkinson’s conferences that bring the whole community together, including not only the dedicated researchers and health professionals that study the disease and care for the people living with it, but also the people and carers who live with Parkinson’s day in and day out – the real experts.

This is just the second time the WPC has convened, and we expect to follow the success we had at the first WPC in 2006 as we continue to build a stronger, more cohesive PD community with a better understanding of Parkinson’s and the treatment options available as we move closer to a cure. We hope you will take advantage of this unique learning opportunity and mingle with the different members of the Parkinson’s community. The success of the meeting depends on your participation.

We look forward to meeting many of you during the Congress and welcome your feedback.

Sincerely,

Stanley Fahn, M.D.
Co-Chair, Steering Committee

Andrew Lees, M.D.
Co-Chair, Steering Committee
Dear Attendees,

On behalf of the Program Committee, I would like to thank you for your participation in the Second World Parkinson Congress this week in Glasgow, Scotland.

The process of creating this program started more than two years ago with the selection of the outstanding members of the Program Committee who worked extensively to build the program you have in front of you now. We aimed at creating a vibrant and thorough program that would appeal to the diverse audience we have today by inviting some of the top people from the international community to share their knowledge and experience with our attendees. Sessions have been created for patients and caregivers, neuroscientists, clinicians and movement disorder specialists, nurses, allied health professionals and others.

We organized a pre-congress day on September 28th, at the request of delegates in 2006, with three day-long courses on science, healthcare teams, and Fundamentals of PD and expect each of these programs to be outstanding learning opportunities for those of you who can attend.

The core program begins each day in the Clyde Auditorium with Hot Topics presentations highlighting some of the outstanding poster abstracts we received this year. After these talks each morning, we will then hold the daily morning plenaries, which have been structured for maximum cross-fertilization of the diverse delegation. Following these plenaries, we have several, more intimate, parallel sessions, workshops and poster sessions that build upon and explore the topics raised earlier in the morning.

In addition to the various sessions and workshops, we are offering sessions in the Renewal Room where you can try your hand at laughter therapy, clay therapy, dance and movement or even tai chi. Next to this room, you’ll find the Rest & Regeneration Room where you can sign up for a shoulder massage to work out those knots that formed after sitting and listening all day to our top-notch presenters.

We hope that the program meets your needs and that you walk away after the Congress knowing more than when you arrived.

I welcome you to Scotland and look forward to meeting you during the Congress.

Kindest regards,

Ted M. Dawson, M.D., Ph.D.
Chair, Program Committee
The purpose of the WPC 2010 is to create a worldwide dialogue to discuss the multifaceted problems of Parkinson’s disease (PD), propose solutions including new approaches to research, build innovative collaborations, and create better treatment options for people with PD. It is the only meeting in the field of PD that addresses a need to bring the whole PD community together for high-level scientific sessions and discussions on current work being done to advance science, improve care for people with PD and help sensitize researchers to the needs of people with PD and conversely help patients understand the challenges researchers and health professionals face in their effort to find a cure and offer better care.
Committees

**Steering Committee**
Stanley Fahn, M.D. *(Co-Chair)*
Andrew Lees, M.D. *(Co-Chair)*
Judith Blazer, M.S.
Ted M. Dawson, M.D., Ph.D.
Robin Elliott
Marian Emr
Donald Grosset, M.D.
Howard Federoff, M.D., Ph.D.
Steve Ford
Katie Hood
Tom Isaacs
Joseph Jankovic, M.D.
Karl Kieburtz, M.D.
Yoshikuni Mizuno, M.D.
Knut-Johan Onarheim
C. Warren Olanow, M.D.
Gianni Pezzoli, M.D.
Werner Poewe, M.D.
Amy Comstock Rick, J.D.
Ira Shoulson, M.D.
Philip Thompson, M.B., Ph.D.
Eduardo Tolosa, M.D.
Erik Wolters, M.D., Ph.D.

**Program Committee**
Ted M. Dawson, M.D., Ph.D. *(Chair)*
Patrick Aebischer, M.D., Ph.D.
Anders Björklund, M.D., Ph.D.
Kieran Breen, B.Sc., Ph.D.
David Brooks, M.D., D.Sc.
Marie-Françoise Chesselet, M.D., Ph.D.
Mark Cookson, Ph.D.
Alessandro Di Rocco, M.D.
Stanley Fahn, M.D.
Col. Karl Friedl, Ph.D.
Thomas Gasser, Ph.D.
Nir Giladi, M.D.
Gladys González-Ramos, Ph.D.
Mariella Graziano, P.T.
Donald Grosset, M.D.
Peter Hagell, R.N., Ph.D.
Ruth Hagestuen, R.N.
Etienne Hirsch, Ph.D.
Tom Isaacs
Joseph Jankovic, M.D.
Anthony Lang, M.D.
Andrew Lees, M.D.
Susanna Lindvall
Karen Marder, M.D.
C. Warren Olanow, M.D.
Werner Poewe, M.D.
Beth-Anne Sieber, Ph.D.
Todd Sherer, Ph.D.
Ira Shoulson, M.D.
Lisa Shulman, M.D.
Caroline Tanner, M.D., Ph.D.
Eduardo Tolosa, M.D.
Anne Buckingham Young, M.D., Ph.D.

**Patient Advisory Committee**
Tom Isaacs *(Chair)*
Greg Wasson
Liz Wostenholme, C.B.E.
Bryn Williams
John-Pascal van Houden

**Organization & Government Relations Committee**
Mary Baker, M.B.E. *(Co-Chair)*
Robin Elliott *(Co-Chair)*
Lizzie Graham
Tom Isaacs
Susanna Lindvall
Shannon MacDonald
Tanith Muller
Karen Northrop
John Silk, O.A.M.
Greg Wasson
Liz Wolstenholme, C.B.E.

**Communications Committee**
Steve Ford *(Co-Chair)*
Nicola Brian *(Co-Chair)*
Jean Burns
Marian Emr
Lizzie Graham
Ed Kalkman, M.D., Ph.D.
Bryn Williams

**Local Organizing Committee**
Donald Grosset, M.D. *(Chair)*
Graeme Macphee, M.D. *(Chair)*
Peter Fletcher, M.D.
Richard Glasspool, R.N.
Katherine Grosset, M.D.
Nick Miller, Ph.D.
Joy Reid, B.N., R.N.
Lynn Rochester, Ph.D.

**Fundraising Committee**
Joseph Jankovic, M.D. *(Chair)*
Patrick Aebischer, M.D. *(Co-Chair)*
Werner Poewe, M.D. *(Co-Chair)*
Murat Emre, M.D.
Ed Kalkman, M.D., Ph.D.
Wolfgang Oertel, M.D.
Olivier Rascol, M.D.
Heinz Reichmann, M.D.
Anthony Schapira, M.D.
Fabrizio Stocchi, M.D.

**Budget Committee**
C. Warren Olanow, M.D. *(Chair)*
Elizabeth Pollard
Jeffrey Wallerstein

**Audit Committee**
Patric Donaghaue, M.B.A, E.A. *(Chair)*
Philip Coulmery, F.C.A.
Bryan Sweet

Legal Counsel: Jerry Terrill, Esq.
Congress Manager: Elizabeth Pollard
Badges
The name badge issued to delegates at registration serves as an admission pass to all scientific sessions, the exhibition and inclusive social events. Delegates are asked to wear their name badge at all times. Badges are color coded as follows:
- **White** - Non-medical delegates (access all sessions, non-medical exhibition area, poster area and creativity area)
- **Orange** - Medical delegates (access all sessions, all exhibition areas, poster area and creativity area)
- **Purple** - Accompanying persons
- **Yellow** - Exhibitors
- **Black** - Media
- **Blue** - Staff & Volunteers

Bank
An ATM machine is located on the Concourse at the SECC. Branches of all the major UK banks may be found in the centre of Glasgow. Generally, weekday opening hours for banks are 09:15 - 16:45 hrs, although this does vary. A limited number are open on Saturday mornings. The Glasgow Tourist Board located in George Square is open from 09:30 - 18:00 hrs every day, including Saturday and Sunday for the purposes of exchanging foreign currency and travellers cheques.

Business & Information Centre
There is a Business Centre on the Concourse, which provides fax and photocopying services. These services are used at the delegates’ own expense. The Business & Information Centre will be open during the Registration opening hours. Local and tourist information is also available here.

Car Parking
Delegate car parking is available at the SECC at a cost of £6.00 car, per visit.

Certificate of Attendance
A Certificate of Attendance will be packed into your delegate bag.

Cloakroom and Left Luggage Facilities
There will be cloakroom facilities available at the SECC during the registration opening hours. There is a charge of £1.00 per item left. Left luggage facilities will be available on Tuesday, September 28 and Friday, October 1, 2010. Luggage may be left in the Cloakroom on Wednesday and Thursday. There will be a charge of £1.00 per item left.

Credit Cards
Commonly accepted credit cards in hotels, restaurants and stores are: American Express, Visa, Mastercard and Diners.

Dress Code
You may dress informally for the Congress. The dress code for the Welcome Reception is also informal.

Disclaimer
The Organising Committee, WPC and Congrex UK Ltd accept no liability for injuries or losses of whatever nature incurred by participants and/or accompanying persons, or for loss, theft or damage to their luggage and/or personal belongings.

Disclosure
All invited speakers’ disclosures can be found on an insert in the delegate bag. However, if there are any changes to any invited speaker disclosures, the speaker concerned will make an announcement from the lectern before commencing their presentation.

Electricity
The voltage in the United Kingdom is 220-240V.

Exhibition
To comply with the ABPI (Association of British Pharmaceutical Industry) Code of Practice non-medical delegates (delegates who do not work in the medical profession) cannot access the medical exhibition. Please note that if you have a white colored badge then you cannot access the medical exhibition. There is a non-medical exhibition available for all delegates. Exhibition opening times are as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, September 28</td>
<td>19:30 - 21:30 hrs</td>
</tr>
<tr>
<td>Wednesday, September 29</td>
<td>11:00 - 18:00 hrs</td>
</tr>
<tr>
<td>Thursday, September 30</td>
<td>11:00 - 18:00 hrs</td>
</tr>
<tr>
<td>Friday, October 1</td>
<td>11:00 - 15:00 hrs</td>
</tr>
</tbody>
</table>
General Information

First Aid
A fully staffed first aid post will be open at all times during the Congress opening hours. The first aid room is situated on the Concourse at the SECC.

Internet Facilities
There are free wireless facilities available throughout the SECC and there will also be Cyber Café facilities in both the medical and non-medical exhibitions in Hall 4.

Journal Supplement
Speaker and scientific poster abstracts will be printed in the journal supplement The Movement Disorder Society to all MDS members. All non-MDS members have the chance to purchase a copy of this print piece for £28.00 at the registration desk while they last.

Language
English is the official language of the Congress. No translation will be provided.

Lost Property
Enquiries regarding items lost or found can be made at the Registration Desks located in Hall 4. To minimise losses, please ensure that you do not leave your Delegate Bag in any of the session halls and that your name is written inside your copy of the Final Program and Abstract Book.

Mail
There is a mail box located outside the east entrance of the SECC, which is emptied daily. Stamps are sold at the newsagent situated on the Concourse. The nearest Post Office is located at:

1170 Argyll Street, Glasgow G3 8YW
Tel: 0141 248 7611

Messages and Correspondence
Messages for delegates should be handed into the Registration Desks in Hall 4. Notification of messages will be displayed on the Board next to the desks. Please check the Board daily and pick up your messages.

Mail can be forwarded to delegates at the SECC. Mail should be addressed:
c/o WPC 2010, Hall 4, Scottish Exhibition & Conference Centre, Glasgow, G3 8YW, Scotland, UK.

Telephone and fax messages can be received for delegates at the Registration Desks. The telephone number is +44 (0)141 576 3405 and the fax number is +44 (0)141 576 3409.

Mobile Telephones
Mobile phones must be switched off in session halls.

Newspapers
The newsagent located on the concourse within the SECC sells a good selection of newspapers.

Posters
Posters will be displayed in Hall 4 for the duration of the Congress. However, poster presenters have been asked to be at their poster to discuss this with any delegates at specific dates and times.

Refer to the poster information cards for details on when you should put your poster up and take it down. Refer to the Final Program for details on when posters will be hosted.

Public Telephones
Public telephones (coin, credit card and cardphone operated) are located at various points on the Concourse. Phone cards can be purchased at the newsagent.

Refreshments and Catering
Coffee, tea & lunch will be served in Hall 4. Tea and coffee are included in your registration fee. Cash catering for lunch will be available in Hall 4 and there are also various other cash catering facilities available at the SECC where coffee and snacks may be purchased. There are also several restaurants in close proximity to the SECC - Yen, India Quay, Crowne Plaza Hotel and the City Inn.

Please refer to the program pages for official break times.

Registration Opening Times
The registration area in Hall 4 will be open at:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, September 28</td>
<td>07:00 - 21:30 hrs</td>
</tr>
<tr>
<td>Wednesday, September 29</td>
<td>07:00 - 18:30 hrs</td>
</tr>
<tr>
<td>Thursday, September 30</td>
<td>07:30 - 17:30 hrs</td>
</tr>
<tr>
<td>Friday, October 1</td>
<td>07:30 - 17:00 hrs</td>
</tr>
</tbody>
</table>
Rest & Regeneration Room
The Rest and Regeneration Room will be located in the Staffa Room in the Crowne Plaza Hotel. The room will be open from 12:00 - 17:00 hrs daily Wednesday, September 29 - Friday, October 1, 2010.

Hosted by the College of Holistic Medicine of Scotland (CHM), this is a complimentary space where all are welcome to drop in to rest, relax, get a short massage, talk to a counsellor or even a life coach. This will be a perfect way to work out the kinks that build up from sitting in sessions.

Space is limited for sessions. A sign-up sheet is posted outside the room for interested delegates to secure time for a treatment. The room is open to all delegates.

A special discussion session "How to Preserve Your Own Energy" will be led William O’Connor, Director and Senior Tutor at the Glasgow College of Holistic Medicine on Wednesday and Friday from 13:00 - 14:00hrs in the Orkney Room. All are welcome to join.

The organizers of the Congress wish to thank the CHM in Glasgow for their generosity and enthusiasm for creating this space.

SECC Environmental Policy
The Scottish Exhibition & Conference Centre (SECC), in recognition of the environmental impact that large events such as the WPC 2010 can have on the environment, supports, “Trees for Life”, the conservation charity dedicated to the restoration and regeneration of the Caledonian Forest in the Highlands of Scotland. For every major conference staged at the Centre, SECC will sponsor the planting of an acre of native trees. The objective is to link up several fragments of the Caledonian Forest and re-establish a forest corridor from Glen Moriston to Glen Affric in the north, creating a continuous stretch of native woodland.

Security
Any security problems or concerns should be reported to a uniformed member of staff.

Smoking Policy
On Sunday March 26, 2006 Scotland banned smoking in public places. The law includes all enclosed or partly enclosed public areas. Therefore smoking is not allowed anywhere within the SECC or any of the social venues. 

Speakers’ Room
Speakers are asked to report to the Speakers’ Room, located in Hall 4 at least 2 hours prior to their presentation. Facilities for powerpoint will be available in the Speakers’ Room.

The Speakers’ Room will be open during the Registration opening hours.

Stores
Most stores in central Glasgow are open from 09:00 - 17:30 hrs Monday - Wednesday and Friday - Saturday. Most large department stores and boutiques are open until 19:00 hrs on Thursday evenings and some stores also open from 11:00 hrs - 16:00 hrs on Sundays.

Taxis
Taxis are available for hire outside the SECC or the adjacent Crowne Plaza Hotel. The cost of a taxi to the city centre is approximately £4.00.

Test Tubes
While every session at the WPC is open to all delegates, we wish to give attendees a heads up on the level of science they can expect to experience in each session. We encourage you to visit whatever session most intrigues you, but so you are prepared for what you will see and hear, please refer to the test tube icons below so you know which level science the speakers will be presenting.

- Black icon = High level scientific session
- Orange icon = Moderate level scientific session
- Blue icon = Minimal to no scientific background required

Transport
For delegates who are staying in the city centre a regular rail service operates from Central Station (lower level) to the Exhibition Centre Station (approximately 4 minutes). The Exhibition Centre Station is linked to the SECC by a covered walkway. There is also a regular bus service. First Bus 757 service operates daily (every 30 minutes) to and from Glasgow city centre or the airport from the SECC.

Volunteers
The WPC would like to thank the Parkinson’s UK, WobblyWilliams.com, and Marks & Clerk for encouraging and allowing their staff to volunteer at the WPC 2010.

Their service helps make the WPC possible and ensures a more positive experience for everyone.
Venue
Target Audience

Our target audience is anyone who is touched by PD. Including, but not limited to: bench researchers, neuroscientists, clinical researchers, community health care providers, allied health care professionals, including nurses, physical therapists, occupational therapists, speech language pathologists, social workers, people living with Parkinson's, carers, advocates working to bring about change in government policy regarding healthcare and funding of scientific research as well as policy makers.

At the conclusion of the activity, participants should be able to:

1. Discuss the role of genetics and environment as PD risk factors.
2. List the distinguishing areas where research is exploring biomarkers.
3. Describe the cell biological, neurochemical, neuropathological and neurophysiological aspects of PD.
4. Identify the contributions of inflammation, protein mishandling and oxidative injury in the pathogenesis of PD.
5. Identify experimental therapies for Parkinson's and expectations for future treatments.
6. Explain the research and clinical criteria behind current work on neuroprotection for Parkinson's.
7. List the spectrum of diseases within which PD fits.
8. Explain conventional medical approaches and therapeutic options for the treatment of all stages of PD.
9. Describe surgical approaches and the patients most suitable for these treatment options.
10. Discuss the intrinsic non-motor features of PD and their treatment options.
11. Discuss the iatrogenic non-motor features of PD and their treatment options.
12. Discuss the role of non-pharmacologic, complementary and alternative approaches in the care of PD patients.
13. Explain the complications of medical therapy and approaches to management.
14. Discuss the impact of Parkinsonism on disability and quality-of-life.
15. Describe the relationship between public policy and health care delivery.
16. Discuss the various models of interdisciplinary team care for persons affected by Parkinson’s disease.
17. Discuss the bio-psychosocial changes experienced by persons with PD and caregivers from early diagnosis to advanced stages and end of life.
18. Articulate and understand the role of health care team members, including nurses, occupational, speech and physical therapists, nutritionists, mental health experts and social workers in the treatment provided to those living with PD.
19. Describe the spectrum of neuropsychiatric and cognitive changes in PD.
20. Articulate and understand the multiple stressors experienced by family caregivers and the ways to provide care and support for this population.
21. Describe challenges in the design and implementation of clinical trials for PD.

Accreditation Statement

The ‘Second World Parkinson Congress’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The ‘Second World Parkinson Congress’ is designated for a maximum of 24 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

EACCME Credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Availability of CEU Credits

Details on CEUs offered to allied health professionals can be found at the Continuing Education Desk in the registration area.

Requesting CME/CEU Credits

In order to receive CME or CEU certificates authenticating participation in the education activity, congress participants must complete and submit a CME or CEU request form following their participation in the Congress. Completed forms should be handed to the CME/CEU desk in the registration area.
The Creativity & Parkinson’s Exhibit is a showcase of the first ever global Parkinson’s Quilt, a project developed by the Parkinson’s Disease Foundation (PDF), one of the WPC 2010’s leading Organizational Partners, to help focus the world’s attention on the seven to 10 million people worldwide who are living with Parkinson’s disease (PD).

The project aims to raise awareness of the impact this disease has on people living with Parkinson’s along with their families, caregivers and friends as well as on our continued urgency to find a cure.

The Quilt consists of panels made by 600 individuals and groups affected by Parkinson’s, in honor of the cause, their group or their loved ones affected by PD. Thirty-nine blocks, or sections of the Quilt, are on display for the first time here in the Exhibit Hall.

Congress participants are able to sign or write a personal message on the World Parkinson Congress Living Quilt, which is displayed in this area as well.

If you haven’t made a panel yet and would like to, you can do so right in this exhibit area! You do not need to be a sewing expert to create a panel for the Quilt. We have all the supplies you need. You can use paint, needlework, iron-on transfers or fabric markers. If you are a poet, you can write a poem on the panel or even write it on a piece of firm paper and hand stitch that paper to your panel. Please visit the Creativity & Parkinson exhibit area to design a panel and to become a part of this magnificent project.

Meet the Artists

Join us during lunch breaks as Quilt participants speak about their panels, their experiences in the Quilt Project and the role creativity has played in their or their loved one’s life. Start times are as follows and go in 15 minute intervals:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, September 29</td>
<td>12:45pm</td>
</tr>
<tr>
<td>Thursday, September 30</td>
<td>11:45am</td>
</tr>
<tr>
<td>Friday, October 1</td>
<td>1:00pm</td>
</tr>
</tbody>
</table>

The Creativity & PD Exhibit is supported by the Medtronic International Trading Sàrl and The Movement Disorder Society.

“Like the countless squares that make up this quilt, each can stand alone as a unique creation, but once simply threaded together, the power of its loving message multiplies exponentially.”

Niska | Montreal, QC, Canada
Junior Researchers & Health Professionals

Support from the Melvin Yahr International Parkinson’s Disease Foundation and the Edmond J. Safra Philanthropic Foundation allowed the WPC 2010 to offer nearly 70 travel grants to the following junior researchers and health professionals.

Kakhaber Akhvlediani | Georgia
Catarina Alfonso | Portugal
Yuval Aluf | Israel
Anna Anvret | Sweden
Maria Barretto | India
Amit Batla | India
Elisa Belluzzi | Italy
Chandni Chandiramani | UK
Orly Chillag-Talmor | Israel
Laura Civiero | Italy
Mickael Decressac | Sweden
Josefa Maria Malta Domingos | Portugal
Brittany Duggar | USA
Silke Feldman | Germany
Razagado Hernandez Luis Fernando | Mexico
Elena Filatova | Russia
Paul Fitzsimmons | UK
Romulo Fuentes Flores | USA
Lena Francesco | Italy
Manol Gospodinov | Bulgaria
Amit Gupta | India
Leanne Hall | Australia
Andreja Kancilija | Slovenia
Sebastian Keller | Germany
Amit Suresh Khairnar | Italy
Irine Khatiashvili | Georgia
Hee Jin Kim | Republic of Korea
Ju Yeon Kim | Republic of Korea
Tekle Kishmaraia | Georgia
Han Seok Ko | USA
Puneet Kumar | India
Robyn Lamont | Australia
Jee-Young Lee | Republic of Korea
Oren Levy | USA
Travis B. Lewis | USA
Hanna Lindgren | Sweden
Nino Lobjanidze | Georgia
Ana Paula Cunha Loureiro | Brazil
Yunwen Luo | China
Arpan Kumar Maiti | India
Heather Martin | UK
Margaret J. McCormick | USA
Olalekan Michael Ogundele | Nigeria
Sanjay Pandey | India
Gabriela Pavlic | Republic of Moldova
Mariya Ivanova Petrova | Bulgaria
Anthea Rogers | Australia
Kaitlyn Roland | Canada
Kinnari Sathe | UK
Jessica A.L.H. Saunders | USA
Patrick Schweder | UK
Ruchi Sehgal | India
Elena Semenova | Russia
Maia Shalikashvili | Georgia
Neha Sharma | India
Julian Soto | Mexico
Arlene Speelman | The Netherlands
Joke Spildooren | Belgium
Dawn Tan | Singapore
Joy Lynn Tan | Australia
Xiaodong Tan | China
Svetlana Tomic | Croatia
Marjolein Astrid van der Marck | The Netherlands
Marlies van Nimwegen | The Netherlands
Tarun Vijay | India
Andrew B. West | USA
Uduak Effiong Williams | Nigeria
Timothy Yates | UK
People with Parkinson’s

Support from the Glasgow City Marketing Bureau allowed the WPC to offer travel grants to the following 20 delegates from five countries that are living with Parkinson’s.

Bruce G. Ballenger | USA
Sharon Bensted | Australia
Jin Kyoung Choae | Korea
Gretchen Church | USA
Michael Church | USA
Jackie Hunt Christensen | USA
Gary Coons | USA
Charles A. Coury | USA
Peter Davison | Canada
Steven D. DeWitte | USA
Valerie W. Graham | USA
William George Hanks | Belgium
Kate Kelsall | USA
Linda Morgan | USA
Pamela Quinn | USA
Israel Robledo | USA
Lucy Roucis | USA
Candace Soul | Canada
Margaret Tennant | USA
Ryan Tripp | Canada

We are also grateful for the travel grants offered from many of our Organizational Partners to their members to attend the WPC, including the nearly 100 travel grants offered to UK citizens from the Parkinson’s UK and The Cure Parkinson’s Trust combined as well as the 15 travel grants offered to European residents from the European Parkinson’s Disease Association. Their travel grants helped to increase and ensure the diversity of the patient community enriching the experience for all delegates. The Travel Grants are also supported by Lloyds Banking Group.

TATRC supports the World Parkinson Congress and its efforts to bring the Parkinson’s community together.

The Neurotoxin Exposure Treatment (Parkinson’s) Research portfolio managed by TATRC is dedicated to understanding the development of Parkinson’s disease and Parkinsonian conditions and developing a basis for therapeutic interventions.

Please read more at the TATRC website: www.tatrc.org/parkinsons

Free confidential helpline 0808 800 0303 parkinsons.org.uk
Barra & Jura Rooms, Crowne Plaza

Open to all delegates, the Renewal Room is a space where everyone is welcome to drop in to rejuvenate during the day with sessions on dancing, tai chi, rhythm, clay manipulation and even laughter therapy!

Space is limited for sessions. A sign-up sheet is posted outside the room for interested delegates to secure a spot for the session(s) of their choice.

Wednesday, September 29 13.00 – 18.00

<table>
<thead>
<tr>
<th>Time</th>
<th>Session &amp; Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00 - 13:45</td>
<td>Laugh for Fun with Bob Taylor (UK)</td>
</tr>
<tr>
<td></td>
<td>Laugh for Fun - Would you like more happiness in your life? I believe that most of us would say yes, but just how many people do you know who practice laughing on a daily basis? The Universal Language of laughter (not humour) is a quick start to being in the “NOW”, creating a wholesome environment where our perceived troubles melt away, and our body and mind are treated to a work out. Come and let “the Kid out to play”, and at the same time, learn about the health benefits of Laughter.</td>
</tr>
<tr>
<td>(15 minute break in middle of session)</td>
<td>RGRM Method: Healthcare in Sync with Mind, Body, and Soul - The RGRM Method is a multisensory session which incorporates the use of a color system of red and blue, a sound code with specific matching movements, all done to music and rhythm. This Method is used primarily to help people with central nervous system problems (as well as those with “healthy” brains). It has shown positive results in balance, memory, coordination, concentration and self esteem in a FUN way. Ronnie has worked with the European Parkinson’s Disease Association and others to help make rhythm and music fun and therapeutic.</td>
</tr>
<tr>
<td>15.45 - 16.45</td>
<td>Our Lives Are Funny – Acting &amp; Storytelling with Comedienne Lucy Roucis (USA)</td>
</tr>
<tr>
<td></td>
<td>Our Lives are Funny – Acting &amp; Storytelling - Join Actress and Comedienne Lucy Roucis for an hour of getting those creative juices flowing. This will include a warm up exercise using acting technique that is easy and fun. The remainder will be storytelling - a chance to learn and share jokes and anecdotes people with Parkinson’s have developed because “our lives are funny.” Lucy’s upcoming Twentieth Century Fox feature film, “Love and Other Drugs” will come out in the US in November 2010.</td>
</tr>
<tr>
<td>17.00 - 18.00</td>
<td>Tai Chi with Daniel Loney (Israel)</td>
</tr>
<tr>
<td></td>
<td>Tai Chi - Learn about the five key principles underlying the practice of Tai Chi and how the application of these principles can be used to reduce the symptoms of Parkinson’s including specific exercises that can improve balance, stability, posture, flexibility, coordination, smooth body flow, body awareness, and increase lower body strength. We will also look at the importance of meditation for reducing tension and stress and their effect on health as well as how to negotiate in crowds and prevent falls. We will work to increase our sensitivity and awareness of others intruding into our immediate body space and how to respond to their jostling and pushes. Daniel, who also has PD, teaches Tai Chi in conjunction with the Israel Parkinson’s Association.</td>
</tr>
</tbody>
</table>
Thursday, September 30 12.00 – 17.15

12.00 – 13.30  Dance Class for People with Parkinson’s with Olie Westheimer (US), Amanda Fogg (UK), Joanne Duff (UK) & Amanda Gillespie (UK)

Dance Class for People with Parkinson’s - Join dance leaders who teach Dance for PD classes in UK in a characteristic Dance for PD (DFPD) class. Their London classes are two of the 45 Dance for PD classes that have developed to date in the US, UK, Germany and beyond, based on the Mark Morris Dance Group/Brooklyn Parkinson Group model first created in 2001. Participants will learn dance sequences, specific strategies dancers use to learn and execute movement, and basic choreographic techniques. All delegates are welcome. Olie Westheimer, the Director of Brooklyn Parkinson Group who founded DFPD in collaboration with dancers from Mark Morris Dance Group, will assist and answer questions.

13.45 – 14.30  Laugh for Fun with Bob Taylor (UK)

14.45 – 15.45  Experience the Therapeutic Benefits of Clay Manipulation with Deborah Elkis-Abuhoff, Ph.D. (US)

Experience the Therapeutic Benefits of Clay Manipulation - This workshop will introduce participants to the creative arts therapy process, specifically modeling clay manipulation. Participants will be exposed to, and gain a better understanding of, an alternative creative treatment that could enable individuals to experience an increase in their overall sense of well-being, and experience a decrease in emotional symptomology.

16.00 – 17.00  Experience the Therapeutic Benefits of Clay Manipulation with Deborah Elkis-Abuhoff, Ph.D. (US)

Friday, October 1 10.45 – 16:30

10:45 – 12:15  Dance Class for People with Parkinson’s with Olie Westheimer (US), Amanda Fogg (UK), Joanne Duff (UK) & Amanda Gillespie (UK)

12:30 – 13:30  Tai Chi with Daniel Loney (Israel)

13.45 – 14:45  PD Movement Lab with Pamela Quinn (US)

PD Movement Lab - A dance-based workshop taught by dancer (and PD patient) Pamela Quinn. Using movement, music and games, the class offers coping strategies to help people manage physical problems brought on by PD: difficulty with balance, gait, alignment, arm and leg swinging, moving backwards, etc. Quinn’s Movement Lab originated with and continues to be sponsored by the Brooklyn Parkinson Group whose many classes for PD take place at the Mark Morris center in Brooklyn, NY. She also teaches at the New York College of Osteopathic Medicine in Long Island, NY, and she has a private practice in New York City as well.

15:00 – 16:30  RGRM Method: Healthcare in Sync with Mind, Body, and Soul with Ronnie Gardiner (US & Sweden)

(15 minute break in middle of session)

The Renewal Room is supported by Internationaal Parkinson Fonds Nederland and Merck Serono S.A.
Pre-congress Educational Courses, Hot Topics & The Brain Game

Course#1, Scientific Course
Tuesday, September 28, 2010, 08:00 – 18:15 hrs
The sessions that will make up this course are sponsored by supporting pharmaceutical companies of the WPC 2010 and will only be open to health care professionals as per UK Pharmaceutical Code. These sessions will be designed by the WPC Program Committee and will offer CME credit. (Sponsored by supporting companies) (Health Professionals only)

Course#2, Healthcare Teams Course
Tuesday, September 28, 2010, 09:00 – 18:00 hrs
This course will be of particular interest to members of interdisciplinary teams or to those interested in understanding how to design and benefit from the use of healthcare teams in their centers. The course will be open to all registrants.

Course#3, Fundamentals of PD Course
Tuesday, September 28, 2010, 09:25 – 16:30 hrs
New for the WPC, the sessions in this course are designed for those interested in a comprehensive overview of current treatment options, what’s in the pipeline, medication management, and how to get the most out of the WPC. This course will be taught in a manner accessible to patients, caregivers, allied health professionals, and scientists interested in understanding the clinical aspects of PD. The course will be open to all registrants.

Hot Topics
Daily, 08:00 – 09:00 hrs
The sessions will be held each morning for a selected number of poster abstracts that were chosen by our program committee for outstanding and promising work. Each morning, four poster submitters will be invited to present their work in the plenary hall leading up to the opening of the plenary each morning.

The Brain Game
Friday, October 1, 17:00 – 18:30 hrs
The Brain Game – establishing once and for all who knows the most about the World, Parkinson’s, the Congress and everything else for that matter. Split into seven categories representing all aspects of Parkinson’s, the Brain Game sees the PD community go head-to-head to decipher who are the real experts. The winners will go on to lift the much coveted ‘Basal Ganglia Bucket’ (otherwise known as ‘The Basil!’) and will be given the opportunity to donate their superior brains immediately afterwards! Teams comprising PD Specialists, Healthcare Professionals, Administrators (including students), Pharma, Patient Advocates and Families, Researchers and the Media will do battle in this thrilling finale to the Congress, hosted by author and comedian Tony Hawks and The Cure Parkinson’s Trust. Places are limited so book online when you register and be a part of Parkinson’s history.
Pre-congress Educational Course # 1

Scientific Course – Tuesday, September 28, 2010
Argyll Suite

Note: As per UK pharmaceutical code, these sessions in Course #1 will be open only to health professionals due to the nature of the talks and specific drug treatments that will be discussed. All courses have been designed by WPC leadership.

8:00 – 9:00  Parkinson’s Disease: Update on Etiology, Therapy and Sleep Problems in PD  Chair: Heinz Reichmann (Germany)
Talk#1:  Olfactory Impairment and Other Pre-motor Symptoms in PD – Henk Berendse (The Netherlands)
Talk#2:  Diagnosis and How to Start Treatment – Heinz Reichmann (Germany)
Talk#3:  Sleep Problems in Early and Advanced PD – Ray Chaudhuri (UK)
Supported through an unrestricted educational grant from GlaxoSmithKline

9:15 – 10:15  Deep Brain Stimulation and Parkinson’s Disease  Chair: Eduardo Tolosa (Spain)
Talk#1:  Current Treatment Approaches for Advanced PD – Eduardo Tolosa (Spain)
Talk#3:  How to Communicate DBS Earlier to Patients in the Progression of their Disease – Joachim Krauss (Germany)
Supported through an unrestricted educational grant from Medtronic

10:15 – 10:45  BREAK

10:45 – 11:45  Management of Orthostatic Hypotension in Parkinson’s Disease (PD): Scientific Insights and Therapeutic Opportunities  Chair: Joseph Jankovic (US)
Talk#1:  Norepinephrine Depletion in the Pathophysiology of Motor and Non-motor Dysfunction in PD – Horacio Kaufmann (US)
Talk#2:  Norepinephrine Replacement Therapy for the Treatment of Neurogenic Orthostatic Hypotension – Phillip Low (US)
Supported through an unrestricted educational grant from Chelsea Therapeutics

12:00 – 13:00  Identification and Treatment of Wearing-off in Clinical Practice  Chair: Heinz Reichmann (Germany)
Talk#1:  Introduction to Wearing-off – Heinz Reichmann (Germany)
Talk#2:  Identification of Wearing-off (tools for identifying wearing-off) – Mark Stacy (US)
Talk#3:  Strategies to Treat Wearing-off (including optimizing levodopa) – Werner Poewe (Austria)
Supported through an unrestricted educational grant from Orion Pharma and Novartis Pharma AG

13:00 – 14:00 LUNCH

14:00 – 15:30  Caring for the Advancing PD Patient: Does One Size Fit All?  Chair: John Nutt (US)
Talk#1:  Neuropsychiatric Issues in Advancing PD: Clinical Spectrum and Resulting QoL Implications – Laura Marsh (US)
Talk#2:  Progression of Cognitive Dysfunction in Parkinson’s Disease – Jaime Kulisevsky (Spain)
Talk#3:  Treatment Strategies in Advancing PD – Current Options and Pipeline Expectations – John Nutt (US)
Supported through an unrestricted educational grant from Solvay Pharmaceuticals which is now Abbott

15:30 – 16:00  BREAK

16:00 – 17:00  Slowing Disease Progression in PD  Chair: C. Warren Olanow (US)
Talk#1:  The ADAGIO Trial – Key Results, Facts and Misperceptions – C. Warren Olanow (US)
Talk#2:  Translating Clinical Study Results into Clinical Practice and Treatment Guidelines – Fabrizio Stocchi (Italy)
Talk#3:  Progress Toward a Diagnosis of Pre-Motor PD – Eduardo Tolosa (Spain)
Supported through an unrestricted educational grant from Teva Pharmaceutical Industries and H. Lundbeck A/S

17:15 – 18:15  Advances in Managing PD  Chair: Werner Poewe (Austria)
Talk#1:  Antiparkinson Medication: Clinical Trials Versus Clinical Practice – Donald Grosset (UK)
Talk#2:  Once Daily Drug Delivery in Parkinson’s – Therapeutic Advance or Marketing Instrument? – Werner Poewe (Austria)
Talk#3:  Neuropsychiatric Symptoms in Parkinson’s Disease – Daniel Weintraub (US)
Supported through an unrestricted educational grant from Boehringer Ingelheim Ltd
Healthcare Teams – Tuesday, September 28, 2010

Supported through an educational grant from The National Parkinson Foundation

09:00 – 09:05 Introduction - Robert Iansek (Australia)

09:05 – 09:30 Interdisciplinary Teams: Who is Involved and Why is it Important to Offer this Model of Care?
Speaker: Nir Giladi (Israel)

09:35 – 10:45 Data Blitz by Healthcare Team Members and Their Role on the Interdisciplinary Team
Facilitator: Robert Iansek (Australia)

Nurse - Lidy Tinselboer (The Netherlands)  
Physical Therapist - Marten Munneke (The Netherlands)  
Speech Pathologist - Yael Manor (Israel)  
Occupational Therapist - Margarita Makoutonina (Australia)  
Social Worker - Jackie Kennedy (UK)  
Dietician/Nutritionist - Lucille Leader (UK)  
Caregiver/Spouse - Lyndsey Isaacs (UK)  
Sexologist - Gila Bronner (Israel)

10:45 – 11:15 COFFEE BREAK

11:15 – 12:30 Case Studies I
Case studies on healthcare teams looking at the spectrum of care for people with Parkinson’s and more specifically the motor and non-motor challenges that need to be addressed by healthcare providers and how team members effectively deal with these issues.
Facilitator: Robert Iansek (Australia)
Panelists:
Physical Therapist - Marten Munneke (The Netherlands)  
Speech Pathologist - Yael Manor (Israel)  
Occupational Therapist - Margarita Makoutonina (Australia)  
Dietician /Nutritionist - Lucille Leader (UK)

12:30 – 13:15 LUNCH

13:15 – 14:30 Case Studies II
Case studies on healthcare teams looking at the spectrum of care for people with Parkinson’s and more specifically the motor and non-motor challenges that are regularly addressed by healthcare providers and how team members effectively deal with these issues.
Facilitator: Nir Giladi (Israel)
Panelists:
Nurse - Lidy Tinselboer (The Netherlands)  
Social Worker - Jackie Kennedy (UK)  
Sexologist - Gila Bronner (Israel)  
Caregiver/Spouse - Lyndsey Isaacs (UK)

14:35 – 15:35 Problems and Challenges of Teams and Solutions: Internal and External Barriers
Speakers: Margarita Makoutonina (Australia) and Yael Manor (Israel)

15:35 – 16:00 BREAK

16:00 – 16:40 Real World Implementation of Team Care Model: Where is the Evidence?
Speaker: Marten Munneke (The Netherlands)

16:45 – 17:15 Opportunity through Technology
Speaker: Robert Iansek (Australia)

17:20 – 17:50 Beyond the Barriers and into the Future of Team Care
Speaker: Orna Moore (Israel)

17:55 – 18:00 Closing
Speaker: Nir Giladi (Israel)
## Fundamentals of PD – Tuesday, September 28, 2010

**Lomond Auditorium**

Supported through an educational grant from The *Movement Disorder Society*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:25</td>
<td>Introduction:</td>
<td>Patrick Brundin (Sweden)</td>
</tr>
<tr>
<td>09:30</td>
<td>What is PD?:</td>
<td>Stanley Fahn (US)</td>
</tr>
<tr>
<td>09:45</td>
<td>Pathology of PD:</td>
<td>David Brooks (UK)</td>
</tr>
<tr>
<td>10:00</td>
<td>What causes PD?:</td>
<td>Erik Wolters (The Netherlands)</td>
</tr>
<tr>
<td>10:15</td>
<td>Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Nonmotor features of PD &amp; Detecting PD prior to Onset:</td>
<td>Ray Chaudhuri (UK)</td>
</tr>
<tr>
<td>11:15</td>
<td>Medical therapy:</td>
<td>Eduardo Tolosa (Spain)</td>
</tr>
<tr>
<td>11:30</td>
<td>Surgical therapy:</td>
<td>Joachim Krauss (Germany)</td>
</tr>
<tr>
<td>11:45</td>
<td>Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td><strong>LUNCH BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>What to do when first diagnosed from a doctor's perspective:</td>
<td>Lisa Shulman (US)</td>
</tr>
<tr>
<td>13:40</td>
<td>What to do when first diagnosed from a patient voluntary organization's perspective?:</td>
<td>Steve Ford (UK)</td>
</tr>
<tr>
<td>13:50</td>
<td>Other therapeutic options:</td>
<td>SLP: Cynthia Fox (US)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>PT</em>: Samyra Keus (The Netherlands)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>OT</em>: Ana Aragon (UK)</td>
</tr>
<tr>
<td>14:15</td>
<td>Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Future therapies:</td>
<td>Patrik Brundin (Sweden)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jeffrey Kordower (US)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jonathan Brotchie (Canada)</td>
</tr>
<tr>
<td>15:25</td>
<td>How can a person with PD help advance research and participate in trials?:</td>
<td>Ira Shoulson (US)</td>
</tr>
<tr>
<td>15:40</td>
<td>Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>15:55</td>
<td>Getting the most out of the WPC 2010:</td>
<td>Tom Isaacs (UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Graeme Macphee (UK)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elizabeth Pollard (US)</td>
</tr>
<tr>
<td>16:15</td>
<td>Q&amp;A Panel</td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>Conclusion:</td>
<td>Stanley Fahn (US)</td>
</tr>
</tbody>
</table>
Opening Ceremony

All delegates at the WPC 2010 are welcome to join the Opening Ceremony in the Clyde Auditorium of the Scottish Exhibition & Conference Centre from 18:30 - 19:30hrs. Immediately following the Ceremony, all guests are invited to join us in a Welcome Reception to be held in the WPC Exhibit Hall for canapés, drinks and socializing until 21:30hrs.

Opening Ceremony Emcees:

- Opening music performed by Grace Griffith
- WPC Co-Chairs, Stanley Fahn, M.D. & Andrew Lees, M.D.
- Harry Burns, Chief Medical Officer of Scotland
- Bryn Williams, Founder of WobblyWilliams.com
- Gavin Hastings, former rugby captain of Scotland and the British Lions, presents WPC Video Awards
- Jane Hill, BBC Reporter
- Scottish Pipe Band leads delegates to Welcome Reception

The WPC 2010 is supported in part by a grant from the National Institutes of Health, part of the US Department of Health and Human Services
**Program - Wednesday, September 29**

**Day 1**

**Wednesday, September 29, 2010**

*Causation/Pathogenesis/Underlying Risk Factors/ Lifetime Risks*

08:00 - 09:00 **Hot Topics**

*Clyde Auditorium*

Chair: Howard Federoff (US)

**Topic:** What Features of Parkinson Disease Impact Disability and Quality of Life?

Speaker: Lisa Shulman (US)

**Topic:** A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial of Paroxetine and Venlafaxine Extended Release for Depression in Parkinson’s Disease

Speaker: Irene Richard (US)

**Topic:** Olfactory Testing And Diffusion Tensor Imaging Of Olfactory Tract and Substantia Nigra in Early Parkinson's Disease

Speaker: Harold Robertson (Canada)

**Topic:** Alpha-synuclein is Secreted, Taken up by Neighbouring Cells and Induces Seeding of Endogenous Alpha-synuclein

Speaker: Ann-Louise Bergström (Denmark)

09:10 - 12:30 **Opening Morning Plenary Session**

*Clyde Auditorium*

**Genetics: Inheritance, Risk, Public Policy**

Chair: John Hardy (UK)
Co-Chair: Nicholas Wood (UK)

09:10 **Introduction:** John Hardy (UK)

09:15 **Talk:** Genetics Overview
Speaker: Thomas Gasser (Germany)

09:45 **Q&A**

09:55 **Talk:** Genetic Testing
Speaker: Christine Klein (Germany)

10:25 **Q&A**

10:35 **Break**

11:00 **Talk:** Confidentiality, Ethics and Genetics
Speaker: Oksana Suchowersky (Canada)

11:30 **Q&A**

11:40 **Talk:** Genetics and Me: Patient Perspective
Speaker: David Iverson (US)

12:10 **Q&A**

12:30 - 14:30 Lunch

13:00 - 14:00 **Special Session**

*Orkney Room*

**Talk:** How to Preserve Your Own Energy
William O’Connor (UK)
Glasgow College of Holistic Medicine

14:30 - 15:30 **Workshops**

**Workshop 1**

*Alsh Room*

*Genetics and Beyond: A Q&A session with PD experts*
Facilitator: Christine Klein (Germany)
Panelists: Oksana Suchowersky (Canada), David Iverson (US)

**Workshop 2**

*Dochart Room*

*(Please note: this workshop is 14:30 - 16:00)*

*Funding for Neuroscience Scientific Research - Government Approaches*
Facilitator: Steve Ford (UK)
Panelists: Karl Friedl (US), Story Landis (US), Christopher Kennard (UK), Marlies Dorlöchter (Germany)

**Workshop 3**

*Boisdale Room*

*Brain Banks in the PD Community: How to Plan for this Donation*
Co-presenters: Carol Moskowitz (US) & Kieran Breen (UK)

14:30 - 16:00 **Afternoon Parallel Sessions**

**Parallel Session #1**

*Argyll Suite*

*Neuropathology of Parkinson’s Disease*
Chair: Eduardo Tolosa (Spain)
Co-Chair: Robert Burke (US)

14:30 **Introduction:** Eduardo Tolosa (Spain)

14:35 **Talk:** Clinical Neuropathologic Correlation
Speaker: Andrew Lees (UK)

14:55 **Talk:** Synucleinopathies, Staging and Spread of PD
Speaker: Tamas Revesz (UK)
15:15 Debate: Staging and the Braak Hypothesis
Speakers: PRO: Glenda Halliday (Australia) &
CON: Dennis Dickson (US)

Parallel Session #2  Clyde Auditorium
Environment, Epidemiology and PD
Chair: Alberto Ascherio (US)
Co-Chair: Karen Marder (US)

14:30 Introduction: Alberto Ascherio (US)

14:35 Talk: Epidemiology of PD
Speaker: Caroline Tanner (US)

14:55 Talk: Preclinical Indicators of PD
Speaker: Webster Ross (US)

15:15 Talk: Gene and Environmental Interactions in PD
Speaker: Beate Ritz (US)

15:35 Talk: Caffeine, Adenosine & Urate: from Molecular Epi to Drug Trials
Speaker: Michael Schwarzschild (US)

Parallel Session #3  Castle Suite
Early Diagnosis and PD (Modalities to Monitor Disease Progression)
Chair: Ken Marek (US)
Co-Chair: Ed Kalkman (UK)

14:30 Introduction: Ken Marek (US)

14:35 Talk: DAT and Spect Imaging
Speaker: David Brooks (UK)

14:55 Talk: Olfaction
Speaker: Andrew Siderowf (US)

15:15 Talk: New Imaging Modalities to Monitor PD
Speaker: David Vaillancourt (US)

15:35 Talk: Ultrasound
Speaker: Daniela Berg (Germany)

Parallel Session #4  Hall 1
Multidisciplinary and Comprehensive Care in PD
Chair: Nir Giladi (Israel)
Co-Chair: Lucianne Sawyer (UK)

14:30 Introduction: Lucianne Sawyer (UK)

14:40 Talk: Pros and Cons of Comprehensive Multidisciplinary Care
Speaker: Nir Giladi (Israel)

15:00 Talk: Emerging Models, Evaluation of Impact, and Evidence
Speaker: Orna Moore (Israel)

15:20 Talk: Comprehensive Care in 2020
Speaker: Bastiaan Bloem (The Netherlands)

Parallel Session #5  Forth Room
Genetics: Autosomal Dominant and Complex Genetic Causes of PD
Chair: Thomas Gasser (Germany)
Co-Chair: Peter Heutink (The Netherlands)

14:30 Introduction: Peter Heutink (The Netherlands)

14:35 Talk: Alpha-Synculein
Speaker: Robert Nussbaum (US)

14:55 Talk: LRRK2
Speaker: Matt Farrer (Canada)

15:15 Talk: GWAS
Speaker: Andrew Singleton (US)

15:35 Talk: Gaucher Disease and Parkinsonism
Speaker: Ellen Sidransky (US)
Parallel Session #6  
Lomond Auditorium
How Does the Global PD Community Fit Together, Where are we Headed, and Why Does it Matter?
Chair: David Burn (UK)
Co-Chair: John Silk (Australia)

14:30  Introduction: John Silk (Australia)

14:35  Talk: How Does the Global PD Community Fit Together?
Speaker: Susanna Lindvall (Sweden)

14:55  Talk: How Did the WPC Succeed in Pulling the Parkinson's Community Together . . . and How Can We Keep this Spirit Alive?
Speaker: Robin Elliott (US)

15:15  Talk: How Current Internet and Social Networking Technologies Connect the Global PwP Community and How to Fully Use these Technologies
Speaker: Jean Burns (US)

15:35  Talk: Future Visions for PD Community: Challenges and Possibilities – a Perspective from Someone with Parkinson’s
Speaker: Tom Isaacs (UK)

16:00 - 16:30 Break

16:30 - 17:30 Afternoon Workshops

Workshop 4  
Carron Room
Social Work in the Care of Parkinson’s Disease
Speaker: Jennie Posen (Israel) & Amy Lemen (US)

Workshop 5  
Alsh Room
Caring About the Caregiver
Speaker: Barbara Habermann (US)

Workshop 6  
Dochart Room
Innovative Funding Approaches from the Nonprofit Sector
Facilitator: Robin Elliott (US)
Speakers: Katie Hood (US) & Rachel Connor (UK)

Workshop 7  
Boisdale Room
Art Therapy and Parkinson’s Disease
Speaker: Deborah Elkis-Abuhoff (US)

Parallel Session #7  
Argyll Suite
Biomarkers
Chair: Howard Federoff (US)
Co-Chair: Kieran Breen (UK)

16:30  Introduction: Howard Federoff (US)

16:35  Talk: Alpha-Synuclein
Speaker: Michael Schlossmacher (Canada)

16:55  Talk: Genomics
Speaker: Clemens Scherzer (US)

17:15  Talk: Proteomics
Speaker: Jing Zhang (US)

17:35  Talk: Metabolomics
Speaker: Flint Beal (US)

Parallel Session #8  
Hall 1
Pathophysiology of Dyskinesias
Chair: Anders Björklund (Sweden)
Co-Chair: Jonathan Brotchie (Canada)

16:30  Introduction: Anders Björklund (Sweden)

16:35  Talk: Neurophysiology
Speaker: Paolo Calabresi (Italy)

16:55  Talk: Molecular Insights
Speaker: Jonathan Brotchie (Canada)

17:15  Talk: Post Versus Presynaptic Plasticity
Speaker: Angela Cenci-Nilsson (Sweden)

17:35  Talk: Role of Serotonin Neurons in the Development of L-DOPA-induced Dyskinesias
Speaker: Manolo Carta (Sweden)
Parallel Session #9  
Lomond Auditorium

How to Engage your Government in Health Policy
Considerations for Chronic Disease
Chair: Steve Ford (UK)
Co-Chair: Greg Wasson (US)

16:30  Introduction: Greg Wasson (US)
16:35  Talk: Burden of Chronic Disease and How to Get Your Government to Care
   Speaker: David Colin-Thomé (UK)
16:55  Talk: Case Study: Parkinson Society Canada and the Development of Neurological Health Charities Canada (NHCC) as a National Advocacy Strategy
   Speaker: Shannon MacDonald (Canada)
17:15  Talk: Effecting Change through Grassroots Advocacy
   Speaker: Haley Carpenter (US)

Parallel Session #10  
Castle Suite

Non-Autonomous Cell Death In PD
Chair: Marie-Françoise Chesselet (US)
Co-Chair: Serge Przedborski (US)

16:30  Introduction: Marie-Françoise Chesselet (US)
16:35  Talk: Role of Microglial Cells in Parkinson’s Disease
   Speaker: David Standaert (US)
16:55  Talk: Role of Lymphocytes in Parkinson’s Disease
   Speaker: Etienne Hirsch (France)
17:15  Talk: Molecular Pathways of Non-autonomous Cell Death in PD
   Speaker: Malú Tansey (US)
17:35  Talk: Vaccination for PD
   Speaker: Howard Gendelman (US)

Parallel Session #11  
Forth Room

Treatment of Hyperkinesias Associated with PD
Chair: Eduardo Tolosa (Spain)
Co-Chair: John Nutt (US)

16:30  Introduction: Eduardo Tolosa (Spain)
16:35  Talk: Medical Treatment of Levodopa-related Dyskinesias
   Speaker: François Vingerhoets (Switzerland)
16:55  Talk: Surgical Treatment of Levodopa-related Dyskinesias
   Speaker: Michael Okun (US)
17:15  Talk: Treatment of Blepharospasm and Cervical Dystonia
   Speaker: Joseph Jankovic (US)
17:35  Talk: Bench to Bedside: Discussion of Past & Future Treatments
   Speaker: Eldad Melamed (Israel)
Day 2

Thursday, September 30, 2010

Clinical Features and Assessment

08:00 - 09:00 Hot Topics  Clyde Auditorium
Chair: Beth-Anne Sieber (US)

Topic: ARHGEF7 (beta-Pix) the First Identified Guanine Nucleotide Exchange Factor for LRRK2
Speaker: Karina Haebig (Germany)

Topic: Association Between Cancer and LRRK2 Mutations in Parkinson’s Disease Patients
Speaker: Rivka Inzelberg (Israel)

Topic: Rasagiline 1 mg/d Provides Benefits for Non-motor Symptoms in Patients with Early Parkinson’s Disease: Results from the ADAGIO Study
Speaker: Werner Poewe (Austria)

Topic: How Do Patients with Newly Diagnosed Parkinson’s Disease Cope?
Speaker: Kirsten Lode (Norway)

08:00 - 09:00 Early Morning Session  Forth Room
Response Fluctuations in Parkinson’s Disease: Why Patients are Crucial for Optimal Management
Speakers: Bastiaan R. Bloem (The Netherlands), Fabrizio Stocchi (Italy) & Joy Reid (UK)

Open to all delegates. Supported through an unrestricted educational grant from Orion Pharma and Novartis. Program designed by WPC leadership.

09:10 - 11:10 Opening Morning Plenary Session  Clyde Auditorium

Parkinson’s Disease: How Does it Unravel?
Chair: Donald Grosset (UK)
Co-Chair: Stanley Fahn (US)

09:10 Introduction: Donald Grosset (UK)

09:15 Talk: Parkinson’s Disease and Me: A Patient Perspective
Speaker: Tom Isaacs (UK)

09:35 Q&A

09:40 Talk: Premotor PD: Can We Diagnose it?
Speaker: Anthony Lang (Canada)

10:00 Q&A

10:10 Talk: Nature and Spread of Parkinson’s Disease
Speaker: Glenda Halliday (Australia)

10:30 Q&A

10:40 Talk: Nuts and Bolts of Parkinson’s Disease Progression
Speaker: Stanley Fahn (US)

11:00 Q&A

11:10 Break

11:30 - 13:30 Lunch

11:45 - 13:15 Special Symposium  Lomond Auditorium
Sharing the Burden of Improving PD Care: A Vision for the Future
Chair: Mary Baker (UK)
Panelists: Tom Isaacs; Jean Mossman; Alastair Benbow; Richard Bergstrom; Ken Paterson; Bastiaan Bloem & John Bouis

Open to all delegates, this session will highlight the challenges faced by various stakeholders involved in the care of a PD patient. The session is geared to promote dialogue between the drug developers, regulators, payers and patients/physicians to understand how to set a common agenda, improve care and access to medication for the PD patient of today and tomorrow.

This session is supported by an unrestricted educational grant from Solvay Pharmaceuticals which is now Abbott.

13:30 - 14:30 Workshops

Workshop 1  Alsh Room
Understanding PD Symptoms and Beyond: Q&A with PD Experts
Facilitator: Donald Grosset (UK)
Panelists: Ken Marek (UK), Glenda Halliday (Australia), Stanley Fahn (US)

Workshop 2  Boisdale Room
Dance and Parkinson’s Disease
Speaker: Olie Westheimer (US)
Dancers: Joanne Duff (UK), Anna Gillespie (UK) & Amanda Fogg (UK)

Workshop 3  Forth Room
Exercise & PD: How to Make it Work for You
Speakers: Davis Phinney (US) & Giselle Petzinger (US)
**Workshop 4**  
_Dochart Room_  
**Complementary Drug Options for PD**  
Speaker: Melanie Brandabur (US)  

13:30 - 15:00 **Afternoon Parallel Sessions**

**Parallel Session #1**  
_Argyll Suite_  
**PD and Cognition**  
Chair: Karen Marder (US)  
Co-Chair: Alex Tröster (US)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Introduction: Alex Tröster (US)</td>
</tr>
</tbody>
</table>
| 13:35 | Talk: Cognitive Dysfunction in PD  
Speaker: Dag Aarsland (Norway) |
| 13:55 | Talk: Executive Dysfunction in PD: Experimental Evidence and Clinical Implications  
Speaker: Trevor Robbins (UK) |
| 14:15 | Talk: PDD/ PD Dementia  
Speaker: David Burn (UK) |
| 14:35 | Talk: Depression and Cognitive Dysfunction in PD: What is the Relationship?  
Speaker: Laura Marsh (US) |

**Parallel Session #2**  
_Carron Room_  
**Access to PD Care**  
Chair: Caroline Tanner (US)  
Co-Chair: Alessandro Di Rocco (US)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 13:30 | Overview talk: International Perspective on Access to Care  
Speaker: Alessandro Di Rocco (US) |
| 13:40 | Panelist: Uday Muthane (India)  
Panelist: Njideka Okubadejo (Nigeria)  
Panelist: Joel Gutierrez (Cuba)  
Panelist: Nabila Dahodwala (US) |
| 14:30 | Q&A & Panel Discussion |

**Parallel Session #3**  
_Hall 1_  
**Comprehensive Care: The Role of the Nurse in the Management of PD**  
Chair: Orna Moore (Israel)  
Co-Chair: Richard Glasspool (UK)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 13:30 | Introduction: History of the Role of the PD Nurse  
Speaker: Richard Glasspool (UK) |
| 13:45 | Talk: Patient and Family/Caregiver Health Counselling and PD Education  
Speaker: Julie Carter (US) |
| 14:00 | Talk: Collaboration and Facilitation of Multidisciplinary Care for Better Direct Patient Care and Technical Expertise  
Speaker: Lidy Tinselboer (The Netherlands) |
| 14:15 | Talk: Health Systems Coordination and Evaluation of Outcomes  
Speaker: Robert Iansek (Australia) |
| 14:30 | Talk: Current Evidence of PD Nursing: Where do We Go from Here?  
Speaker: Peter Hagell (Sweden) |
| 14:45 | Panel for Q&A |

**Parallel Session #4**  
_Castle Suite_  
**Genetics: Autosomal Recessive PD**  
Chair: Nobutaka Hattori (Japan)  
Co-Chair: John Hardy (UK)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Introduction: John Hardy (UK)</td>
</tr>
</tbody>
</table>
| 13:35 | Talk: Parkin  
Speaker: Yoshikuni Mizuno (Japan) |
| 13:55 | Talk: Clinical and Molecular Aspects of PINK1-related Parkinsonism  
Speaker: Enza Maria Valente (Italy) |
| 14:15 | Talk: DJ-1  
Speaker: Vincenzo Bonifati (The Netherlands) |
| 14:35 | Talk: Autosomal Recessive PD and Dystonia  
Speaker: Coro Paisan–Ruiz (UK) |

---

**Icons Key:**  
- **Black icon** = High level scientific session  
- **Orange icon** = Moderate level scientific session  
- **Blue icon** = Minimal to no scientific background required
### Parallel Session #5  🎉 Lomond Auditorium
**Taking Charge of Your Parkinson's and Making a Difference in your Community**
Chair: Bryn Williams (UK)
Co-Chair: Liz Wolstenholme (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Introduction: Liz Wolstenholme (UK)</td>
</tr>
</tbody>
</table>
| 13:40 | Talk: Using Your Strengths to Make a Difference in Your Parkinson's Community  
Speaker: Jean Burns (US) |
| 13:50 | Talk: Being Your Own Best Advocate: Things You Can Do to Take Charge of Your PD  
Speaker: Ann Keilthy (Ireland) |
| 14:00 | Talk: Start Small but Think Big: Changes You Can Make in Your Own Community  
Speaker: Fulvio Capitanio (Spain) |
| 14:10 | Talk: Advocacy as Empowerment  
Speaker: Greg Wasson (US) |
| 14:20 | Panel: Q&A                                                            |

15:00 - 15:30 **Break**

15:30 - 16:30 **Afternoon Workshops**

**Workshop 5**  🎉 Alsh Room
**Speech, Swallowing and Parkinsonism**
Speakers: Lorraine Ramig (US) & Yael Manor (Israel)

**Workshop 6**  🎉 Boisdale Room
**PD, Cognition and Dementia**
Speaker: Alex Tröster (US)

**Workshop 7**  🎉 Lomond Auditorium
**What does Physiotherapy Offer People with Parkinson’s Disease?**
Speaker: Meg Morris (Australia)

15:30 - 17:00 **Afternoon Parallel Sessions**

**Parallel Session #6**  🎉 Forth Room
**DBS and Parkinson's: What is it? How does it work? Who does it help?**
Chair: Susan Heath (US)
Co-Chair: Carole Joint (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>Introduction: Susan Heath (US)</td>
</tr>
</tbody>
</table>
| 15:35 | DBS: What is it, How Does it Work and Who is a Good Candidate?  
Speaker: Alim Benabid (France) |
| 16:00 | Impact of DBS of the STN on Cognition, Mood and Psychosocial Adjustment  
Speaker: Marjan Jahanshahi (UK) |
| 16:20 | Panel of Implanted Patients: DBS from the Patient Perspective  
Speakers: Davis Phinney (US) & Ann Keilthy (Ireland) |
| 16:40 | Q&A Panel                                                            |

**Parallel Session #7**  🎉 Hall 1
**PD Depression, Anxiety and Psychosis**
Chair: Laura Marsh (US)
Co-Chair: Dan Weintraub (US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>Introduction: Laura Marsh (US)</td>
</tr>
</tbody>
</table>
| 15:35 | Talk: Depression/Apathy  
Speaker: Paolo Barone (Italy) |
| 15:55 | Talk: Anxiety  
Speaker: Albert Leentjens (The Netherlands) |
| 16:15 | Talk: Psychosis  
Speaker: Susan Fox (Canada) |
| 16:35 | Talk: Impulse Control Disorders & DA Dysregulation  
Speaker: Valerie Voon (US) |

Black icon = High level scientific session
Orange icon = Moderate level scientific session
Blue icon = Minimal to no scientific background required
LRRK2
Chair: Matt Farrer (Canada)
Co-Chair: Thomas Gasser (Germany)

15:30 Introduction: Thomas Gasser (Germany)

15:35 Talk: Biology and Protein Biochemistry
Speaker: Mark Cookson (US)

15:55 Talk: LRRK2 Animal Models
Speaker: Jie Shen (US)

16:15 Talk: LRRK2 Therapeutic Opportunities
Speaker: Valina Dawson (US)

16:35 Talk: LRRK2 PD Phenotypes and Biomarkers
Speaker: Susan Bressman (US)

Care Delivery from a Family Perspective
Chair: Peter Hagell (Sweden)
Co-Chair: Knut-Johan Onarheim (Norway)

15:30 Introduction: Knut-Johan Onarheim (Norway)

15:35 Talk: Family Needs for Young Onset vs Later Onset
Speaker: Julie Carter (US)

15:55 Talk: Nurturing Family Relationships through Crisis and Change from the time of Diagnosis and Onward
Speaker: Jennie Posen (Israel)

16:15 Talk: What Does the Carer Need to Know: Practical Advice
Speaker: Barbara Habermann (US)

16:35 Talk: Symptom Management to Prevent Onset of Disability
Speaker: Margarita Makoutonina (Australia)

Taking Charge of Your Parkinson's
Chair: Pamela Quinn (US)
Panel: Concetta Tomaino (US)
Lucille Leader (UK)
Davis Phinney (US)

Supported through an unrestricted educational grant from Teva Pharmaceutical Industries, Teva Neuroscience, and H. Lundbeck A/S. Program designed entirely by WPC leadership.

DBS: Tips from Patients and Carers
Chair: Carole Joint (UK)
Panel: Ann Keilthy (Ireland)
Gretchen Garie-Church (US)
Michael Church (US)
Torleiv Odland (Norway)

Supported through an unrestricted educational grant from St. Jude Medical. Program designed entirely by WPC leadership.
Day 3

Friday, October 1, 2010

Experimental Therapeutics: How to Treat PD in the Future

08:00 - 09:00 Hot Topics Clyde Auditorium
Chair: Anthony Schapira (UK)

Topic: Over-expression of a-Synuclein Alters Dopamine Neurotransmission In Vivo Before Onset of Behavioral Deficits and Dopaminergic Cell Loss in Rats
Speaker: Martin Lundblad (Sweden)

Topic: Cognitive Deficits Associated with Dopamine Transporter Loss in the Pre-motor Subjects in the PARS Cohort
Speaker: Keith Hawkins (US)

Topic: Rasagiline in Early Parkinson's Disease (PD): Additional Efficacy and Safety Results From the ADAGIO Delayed-Start Study
Speaker: C. Warren Olanow (US)

Topic: Mapping a Hospital Based Parkinson's Service Against National Guidelines with Recommendations on how Quality of Service can be Improved
Speaker: Lisa Brown (UK)

09:10 - 10:45 Opening Morning Plenary Session Clyde Auditorium

Experimental Therapeutics: How to Treat PD in the Future
Chair: Patrik Brundin (Sweden)
Co-Chair: Werner Poewe (Austria)

9:10 Introduction Werner Poewe (Austria)

9:15 Talk: Treatment of Unmet Needs in Parkinson's Disease
Speaker: Ira Shoulson (US)

9:35 Q&A

9:45 Talk: Neuroprotection
Speaker: C. Warren Olanow (US)

10:05 Q&A

10:15 Talk: Gene and Cell Based Therapies
Speaker: Roger Barker (UK)

10:35 Q&A

11:15 - 12:15 Morning Workshops

Workshop 1 Alsh Room
Therapeutic Options and Beyond: Q&A with PD Experts
Facilitator: Ira Shoulson (US)
Panelists: Patrik Brundin (Sweden) & Roger Barker (UK)

Workshop 2 Dochart Room
When to Start, What to Start
Speaker: Donald Grosset (UK)

Workshop 3 Lomond Auditorium
How to Manage Freezing and Falling
Speaker: Samyra Keus (Netherlands)

11:15 - 12:45 Morning Parallel Sessions

Parallel Session #1 Hall 1
Non-Drug Approaches to Treatments for Parkinson's Disease
Chair: Steve Ford (UK)
Co-Chair: Bastiaan Bloem (The Netherlands)

11:15 Introduction: Bastiaan Bloem (The Netherlands)

11:20 Talk: Exercise and PD
Speaker: Giselle Petzinger (US)

11:40 Talk: Physical Therapy and PD: Evidence-based Assessment of Physical Therapy
Speaker: Lynn Rochester (UK)

12:00 Talk: Speech Therapy and PD: Evidence-based Assessment of Speech Therapy
Speaker: Christy Ludlow (US)

12:20 Talk: Nonpharmacological, Cognitive and Psychological Therapies
Speaker: Karen Anderson (US)
Parallel Session #2  
Forth Room
*Treatment of Advanced Parkinson’s Disease: Focus on Dyskinesias*
Chair: C. Warren Olanow (US)
Co-Chair: Susan Fox (Canada)

11:15  **Introduction:** Susan Fox (Canada)

11:20  **Talk:** Treatment of Dyskinesias and Complex Motor Fluctuations
       Speaker: Wolfgang Oertel (Germany)

11:40  **Talk:** Different CDS Delivery Systems - Indications and Contraindications / Challenges and Benefits of CDS in the Long-term Treatment of Parkinson’s Disease
       Speaker: Erik Wolters (The Netherlands)

12:00  **Talk:** Scientific Rationale of Continuous Dopaminergic Stimulation in Advanced PD
       Speaker: Maral Mouradian (US)

12:20  **Talk:** Bench to Bedside Talk - Novel Anti-dyskinetic Treatments being Tested in the Clinic
       Speaker: Joaquim Ferreira (Portugal)

Parallel Session #3  
Boisdale Room
*Must Trial Harder - Perspectives on Improving the Current Clinical Trial System*
Chair: John Zajicek (UK)
Co-Chair: Jean Burns (US)

11:15  **Introduction:** John Zajicek (UK)

11:20  **Talk:** Turning Trials and Tribulations into Triumphs - a Perspective on the Clinical Trials System
       Speaker: Tom Isaacs (UK)

11:40  **Talk:** What You Need to Ask Before Signing up for a Trial or Observational Study
       Speaker: Greg Wasson (US)

12:00  **Talk:** Outcome Measures and What These Mean to Patients
       Speaker: Peter Hagell (Sweden)

12:20  **Talk:** Resources and How to Get Involved
       Speaker: Peggy Willocks (US)

Parallel Session #4  
Clyde Auditorium
*Neuroprotection*
Chair: Stanley Fahn (US)
Co-Chair: Etienne Hirsch (France)

11:15  **Introduction:** Extent of Pathology and Challenges to Neuroprotective Therapy with a Disease that is Multisystem
       Speaker: Stanley Fahn (US)

11:20  **Talk:** Utility of Different Animal Model Approaches
       Speaker: Marie Françoise Chesselet (US)

11:40  **Talk:** Clinical Criteria to Follow Neuroprotection
       Speaker: Karl Kieburtz (US)

12:00  **Talk:** Effective Delivery of the Neuroprotectant to the Brain
       Speaker: Patrick Aebischer (Switzerland)

12:20  **Talk:** Different Disease at Different Stages Require Different Neuroprotective Approaches
       Speaker: Bernard Ravina (US)

Parallel Session #5  
Argyll Suite
*Non-motor Symptoms*
Chair: Werner Poewe (Austria)
Co-Chair: Ron Pfeiffer (US)

11:15  **Introduction:** Werner Poewe (Austria)

11:20  **Talk:** Cardiovascular Features in PD
       Speaker: David S. Goldstein (US)

11:40  **Talk:** Sexual Dysfunction and Bladder Issues with PD
       Speaker: Fabrizio Stocchi (Italy)

12:00  **Talk:** Involvement of the Gastrointestinal Tract
       Speaker: James Greene (US)

12:20  **Talk:** Treatment of Non Motor Features of PD
       Speaker: Anthony Schapira (UK)
Parallel Session #6  Castle Suite
Gene and Cellular Therapy: Regenerative Medicine
Chair: Kieran Breen (UK)
Co-Chair: Michael Kaplitt (US)

11:15 Introduction: Michael Kaplitt (US)

11:20 Talk: DA Differentiation/Guidance Response of Midbrain Dopaminergic Neurons in Development and Disease
Speaker: Ronald McKay (US)

11:40 Talk: Cellular Therapy (ES Cells)
Speaker: Ole Isacson (US)

12:00 Talk: Cellular Therapy (iPS Cells)
Speaker: Lorenz Studer (US)

12:20 Talk: Gene Therapy
Speaker: Deniz Kirik (Sweden)

12:45 - 14:45 Lunch

13:00 - 14:00 Special Session  Orkney Room
Talk: How to Preserve Your Own Energy
William O'Connor (UK)
Glasgow College of Holistic Medicine

13:30 - 14:30 Special Report  Boisdale Room
Parkinson’s Care in Africa and South America: What we have learned and our plans for the future
Introduction: Gianni Pezzoli (Italy)
Speaker: Roberto Cilia (Italy)

In this special report, open to all delegates, speakers will discuss and highlight the ongoing efforts of the World Parkinson Disease Association to better understand the challenges of people living with Parkinson’s in resource poor areas in Africa and South America. They will also discuss ongoing programs and programs being considered to offer better health care to these regions and how the global Parkinson’s community can get involved.

13:00 - 14:30 Special Report  Alsh Room
The NINDS Common Data Element Project: Facilitating Clinical Research in Parkinson’s disease
Chairs: Karl Kieburtz (US) & Caroline Tanner (US)
Presenters: David Burn (UK), Wendy Galpern (US), Stanley Fahn (US), Ronald Pfeiffer (US), Webster Ross (US), Daniel Weintraub (US)

The National Institute of Neurological Disorders and Stroke (NINDS) has established the Common Data Element (CDE) Project to facilitate clinical research in neurological disorders including PD. This effort is aimed at harmonizing data collection in clinical studies to facilitate the analysis and sharing of data across the research community. In this special lunch session, the goals of the CDE project will be reviewed, and the recommendations developed by over 60 PD researchers in the PD CDE Working Group will be presented.

12:45 - 14:15 Special Session  Carron Room
‘Tips and Tricks’ for Parkinson’s
Facilitator: Mariella Graziano (Luxembourg)

In this session, open to everyone, participants will learn about helpful tips and tricks, to help them overcome daily obstacles, such as how to start walking when their feet are glued to the floor or how they can get out of a car easily. Many people with Parkinson’s have discovered and developed strategies that help them maintain movement and improve mobility to overcome their personal obstacles. This session, hosted by the European Parkinson’s Disease Association (EPDA), will encourage participants to view strategies that have already been developed and will also enable them to share their own tips and tricks with others. Willing participants will have their tips and tricks captured on video (those who agree to sign a waiver) and these will be added to the EPDA Coping Strategies – Tips and Tricks website.
Program - Friday, October 1

14:45 - 15:45 Afternoon Workshops

Workshop 4 Dochart Room
Troubleshooting Common Problems in DBS Therapy
Speaker: Susan Heath (US)

Workshop 5 Lomond Auditorium
Music & Parkinson’s Disease
Speakers: Constance Tomaino (US) & Grace Griffith (US)

Workshop 6 Argyll Suite
Nutrition and Dopamine Metabolism in Parkinson’s Disease
Speaker: Lucille Leader (UK)

Workshop 7 Carron Room
Caring for a Patient with Advanced PD
Speaker: Lisette Bunting-Perry (US)

14:45 - 16:15 Afternoon Parallel Sessions

Parallel Session #7 Castle Suite
Alpha-Synuclein
Chair: Robert Nussbaum (US)
Co-Chair: Matt Farrer (Canada)

14:45 Introduction: Robert Nussbaum (US)

14:50 Talk: Alpha-Synuclein Biology and Biochemistry
Speaker: Virginia Lee (US)

15:10 Talk: Alpha-Synuclein Normal Function
Speaker: Ken Nakamura (US)

15:30 Talk: Alpha-Synuclein Animal Models
Speaker: Patrick Aebischer (Switzerland)

15:50 Talk: Alpha-Synuclein Therapeutic Opportunities
Speaker: John Trojanowski (US)

Parallel Session #8 Hall 1
Physical Therapy and PD
Chair: Mariella Graziano (Luxembourg)
Co-Chair: Samyra Keus (Netherlands)

14:45 Introduction: Samyra Keus (Netherlands)

14:50 Talk: Professional Evolution and Scientific Validation of Physical Therapy
Speaker: Bastiaan Bloem (The Netherlands)

15:10 Talk: Preventing Falls and Improving Mobility on PD
Speaker: Meg Morris (Australia)

15:30 Talk: Freezing of Gait: What Does Physiotherapy Have to Offer?
Speaker: Alice Nieuwboer (Belgium)

15:50 Talk: The Effect of Dual Tasking on Gait in PD
Speaker: Lynn Rochester (UK)

Parallel Session #9 Forth Room
Gene Therapy: Regenerative Medicine
Chair: Karl Friedl (US)
Co-Chair: Deniz Kirik (Sweden)

14:45 Introduction: Deniz Kirik (Sweden)

14:50 Talk: Overview of Gene Therapy
Speaker: Krys Bankiewicz (US)

15:10 Talk: Neuroprotection by Trophic Factors
Speaker: Jeffrey Kordower (US)

15:30 Talk: Continuous L-DOPA/Dopamine Delivery
Speaker: Stephane Palfi (France)

15:50 Talk: GAD Enzyme Therapy for Silencing of the Subthalamic Nucleus
Speaker: Michael Kaplitt (US)
Parallel Session #10 Boisdale Room
Maintaining Speech in PD
Chair: Cynthia Fox (US)
Co-Chair: Yael Manor (Israel)

14:45 Introduction: Cynthia Fox (US)
14:50 Talk: Factors Affecting Maintenance of Speech in the Community
Speaker: Nicholas Miller (UK)
15:10 Talk: Beyond Speech Treatment to Speech Exercise and Speech Imaging
Speaker: Lorraine Ramig (US)
15:30 Talk: Innovations in Technology to Facilitate Maintenance of Speech
Speaker: Deborah Theodoros (Australia)
15:50 Talk: Maintaining Speech Post-DBS
Speaker: Cynthia Fox (US)

Parallel Session #11 Alsh Room
Challenges in Design and Conduct for Clinical Trials for PD
Chair: Ira Shoulson (US)
Co-Chair: Cristina Sampaio (Portugal)

14:45 Introduction: Cristina Sampaio (Portugal)
14:50 Talk: Increasing Public Awareness about Clinical Trials
Speaker: Robin Elliott (US)
15:10 Talk: Clinical Trial Designs
Speaker: Joaquim Ferreira (Portugal)
15:30 Talk: Participation in Clinical Trials
Speaker: David Burn (UK)
15:50 Talk: Regulatory Perspective (FDA/EU/Other)
Speaker: Alasdair Breckenridge (UK)
16:15 - 16:45 Break

17:00 - 18:30 PD Game Night Lomond Auditorium
The Brain Game - establishing once and for all who knows the most about the World, Parkinson’s, the Congress and everything else for that matter. Split into seven categories representing all aspects of Parkinson’s, the Brain Game sees the PD community go head-to-head to decipher who are the real experts. The winners will go on to lift the much coveted ‘Basal Ganglia Bucket’ (otherwise known as ‘The Basil’) and will be given the opportunity to donate their superior brains immediately afterwards!

Teams comprising PD Specialists, Healthcare Professionals, Administrators (including students), Pharma, Patient Advocates and Families, Researchers and the Media will do battle in this thrilling finale to the Congress, hosted by author and comedian Tony Hawks and The Cure Parkinson’s Trust. Places are limited so book online when you register and be a part of Parkinson’s history.
# Accelerating access to care in Parkinson's disease: partnership is key

Lomond Auditorium, Scottish Exhibition and Conference Centre (SECC), Glasgow, UK
11.45 – 13.15, Thursday, 30 September, 2010

A major impediment to optimal care in serious neurodegenerative conditions, such as Parkinson's disease, is the time it takes for the patient to gain access to innovative treatments and the best neurological services. There are many complex hurdles on the road from laboratory bench to regulatory approval, reimbursement and, ultimately, implementation of a clinically and cost effective new treatment.

From the perspective of the person with Parkinson's disease, which should be central to healthcare strategy development, the goal is to access new treatments more rapidly. To effect change, patient advocacy groups need to forge alliances with other key stakeholders, including the pharmaceutical and biotech industries, healthcare profession, regulatory institutions and governmental policy makers. Through these alliances, people with Parkinson's disease can develop a strong voice, express their needs effectively, and argue their case with a consistent message.

In turn, decision makers in each of these groups must together identify the key barriers to progress and seek to address these – it is not the sole responsibility of any one of these stakeholders to resolve the issues alone. With mutual respect and understanding, constructive dialogue can take place across professional boundaries.

Join us at this important session to hear how, with the involved patient at the centre of the dialogue, co-operation and partnership will enable us to better meet the challenges that debilitating diseases, such as Parkinson's disease, will pose in the future, and to tackle them successfully together.

## Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.45</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td>12.00</td>
<td><strong>When Will the System Give Me the Treatment I Need?</strong></td>
</tr>
<tr>
<td></td>
<td>- The Patient</td>
</tr>
<tr>
<td></td>
<td>- The Patient Advocate</td>
</tr>
<tr>
<td></td>
<td>- The Industry</td>
</tr>
<tr>
<td></td>
<td>- The Regulator</td>
</tr>
<tr>
<td></td>
<td>- The Health Technology Assessor</td>
</tr>
<tr>
<td></td>
<td>- The Clinician</td>
</tr>
<tr>
<td></td>
<td>- The Policy Maker</td>
</tr>
<tr>
<td></td>
<td><strong>Stakeholder Dialogue</strong></td>
</tr>
<tr>
<td></td>
<td>- Tom Isaacs - Co-founder of The Cure Parkinson’s Trust and Chair of the WPC Patients’ Advisory Committee</td>
</tr>
<tr>
<td></td>
<td>- Jean Mossman – Policy Advisor, EFNA</td>
</tr>
<tr>
<td></td>
<td>- Alastair Benbow – European Brain Council</td>
</tr>
<tr>
<td></td>
<td>- Richard Bergstrom – Managing Director, Swedish Association of the Pharmaceutical Industry</td>
</tr>
<tr>
<td></td>
<td>- Ken Paterson – Chair, Scottish Medicines Consortium</td>
</tr>
<tr>
<td></td>
<td>- Bastiaan Bloem – Consultant Neurologist, The Netherlands</td>
</tr>
<tr>
<td></td>
<td>- John Bowis, OBE – Former UK health minister and MEP, Patron EPDA</td>
</tr>
<tr>
<td>12.30</td>
<td><strong>How Do We Work Together to Improve Access to Best Care?</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Panel Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>Facilitator: Mary Baker, MBE</td>
</tr>
<tr>
<td>13.00</td>
<td><strong>Partnership: From Discussion to Future Reality</strong></td>
</tr>
<tr>
<td></td>
<td>Mary Baker, MBE</td>
</tr>
<tr>
<td>13.15</td>
<td><strong>Meeting close</strong></td>
</tr>
</tbody>
</table>
**Scientific Posters**
Posters presented in the Scientific topic cover areas of research in the field. This includes research in basic and clinical sciences, best practices for care delivery and quality of life and related themes.

**Living with Parkinson's Posters**
Posters presented in the Living with Parkinson's topic are from individuals, groups or organizations who want to highlight and share details of programs and projects being designed and implemented that help people with PD and caregivers to take charge of their situation and bring about change on a local, regional or national level.

All posters will be displayed for the duration of the Congress. Presenters have been asked to be at their posters on:

- **Wednesday, September 29, 2010** 12:30 - 14:30
- **Thursday, September 30, 2010** 11:30 - 13:30
- **Friday, October 1, 2010** 12:45 - 14:45

Posters being shown on each of the above days are listed by day below.

## Scientific Posters

### Wednesday, September 29, 2010 - 12:30 – 14:30

#### Basic Science: Etiology, Genetics, Epidemiology and Toxicants

- **P01.01** Alcohol Consumption And Risk Of Parkinson Disease In A Large Prospective Cohort Of Men And Women
  *Palacios, N; Gao, X; O'Reilly, E; Schwartzchild, M; McCullough, M; Gapstur, S; Mayo, T; Ascherio, A (United States)*

- **P01.02** Prevalence Of Mutations In Parkin, PINK1 And DJ-1 In Early Onset Parkinson’s Disease – A Community Based And Regional Study
  *Pearson, JP; Kilarski, LL; Newsway, V; Majounie, E; Perera, D; Misbahuddin, A; Chinnery, PF; Burn, DJ; Lewthwaite, AJ; Clarke, CE; Morrison, KE; Evans, JR; Sawcer, SJ; Barker, RA; Wickremaratchi, MM; Williams, NM; Morris, HR (United Kingdom)*

- **P01.03** Outdoor Work And Risk For Parkinson’s Disease: A Population-based Case-control Study
  *Kenborg, L (Denmark); Lassen, CF (Denmark); Ritz, B (United States); Schernhammer, ES (United States); Hansen, J (Denmark); Gatto, NM (United States); Olsen, JH (Denmark)*

- **P01.04** Risk For Parkinson’s Disease Among Patients With Osteoarthritis: A Danish Cohort Study
  *Rugbjerg, K (Denmark); Friis, S (Denmark); Jørgensen, TL (Denmark); Ritz, B (United States); Korbo, L (Denmark); Olsen, JH (Denmark)*

- **P01.05** Molecular Genetic Spectrum In Korean Patients With Early-onset Parkinson’s Disease
  *Jeon, BS; Kim, SY; Kim, HL; Kim, SY; Ko, HS; Kim, JY; Park, SS (Republic of Korea)*

- **P01.06** A Splice Isoform Signature Of Parkinson’s Disease In Blood
  *Potashkin, J; Scherzer, C; Ravina, B; Watts, A; Leontovich, A (United States)*
Wednesday Scientific Posters (12:30 - 14:30)

P01.07 Characterization Of Autophosphorylation In The Leucine-rich Repeat Kinase 2 (LRRK2) Gtpase Domain
West, A (United States); Webber, P.J. (United States); Smith, A. (United States); Sen, S. (United States); Biskup, S (Germany); Yue, Z (United States); Mobley, J.A. (United States); Horton, B. (United States)

P01.08 Proteomic Analysis Of The Locus Ceruleus In Parkinson's Disease

P01.09 High Dose Human Paraquat Exposures And The Subsequent Development Of Parkinsonism
Brent, J (United States)

P01.27 ATP13A2 Variants Contribute To The Risk For Parkinson Disease In Taiwan
Chen, CM (Taiwan); Wu, Y R (Taiwan); Lee-Chen, GJ (Taiwan)

P01.28 A Case Control Study Of Multiple System Atrophy In Korean Patients
Kim, JS; Lee, J E; Lee, P H (South Korea)

P01.29 Early Mortality In An Incident Cohort Of People With Parkinson’s Disease And Parkinsonism
Caslake, R; Scott, N; Harris, C; Gordon, J; Counsell, C (United Kingdom)

Basic Science: Cell Death Mechanisms, Neuroprotection and Trophic Factors

P02.01 The Journey From Mice To Men: The Role Of T Cells In The Immunobiology Of Parkinson’s Disease
Saunders, JALH; Stone, DK; Reynolds, AD; Kosloski, LM; Standaert, DG; Mosley, RL; Gendelman, HE (United States)

P02.02 DJ-1 Neuroprotection In Parkinson's Disease: Effects Of Cysteine Oxidation And Subcellular Localization
Rochet, J.-C.; Liu, F.; Lesniak, K.; Mishra, V.; Travers, J. (United States)

P02.03 LUHMES Cells As Human In Vitro Model To Study Mechanisms Of Parkinsonian Neurodegeneration
Pöltl, D.; Schildknecht, S.; Leist, M. (Germany)

P02.04 HIF Prolyl Hydroxylase Inhibition Increases Cell Viability And Potentiates Dopamine Release In Dopaminergic Cells
Thirstrup, K; Johansen, J.L; Sager, T.N; Mørk, A; Bergström, A; Egebjerg, J (Denmark)

P02.05 Phosphorylation Of Parkin By The C-Ab1 Protein Tyrosine Kinase Inhibits Parkin’s Ubiquitination And Protective Function.
Ko, HS; Lee, YJ; Shin, JH; Karuppagounder, SS; Gadad, BS; Koleske, AJ; Pletinkova, O; Troncoso, J.C; Dawson, V.L; Dawson, T.M (United States)

P02.17 Regulation Of Neuronal Survival Factor MEF2D By Chaperone-mediated Autophagy
Yang, Q.; She, H.; Gearing, M.; Colla, E.; Lee, M.; Shacka, J.; Mao, Z. (United States)

P02.18 Effect Of R-apomorphine On Gene Expression Of Neurotrophins & Inflammatory Markers In The Striatal 6-hydroxydopamine Rat Model Of Parkinson’s Disease
Varcin, M; Mertens, B; Kooijman, R; Michotte, Y; Soree, S (Belgium)

Basic Science: Protein Misfolding and Handling

P03.01 Unraveling The Role Of Peptidyl-Prolyl Isomerases In The Aggregation Of Alpha-Synuclein
Deleersnijder, A; Gérard, M; Debyser, Z; Baekelandt, V. (Belgium)
Wednesday Scientific Posters (12:30 - 14:30)

P03.02 Effects Of Membrane Binding And Post-Translational Modifications On Alpha-Synuclein Toxicity In Parkinson's Disease
Rochet, J; Strathearn, K; Griggs, A; Hindupur, J; Schieler, J; Head, K (United States)

P03.06 Modeling LRRK2 Function With LRRK1
Lewis, P (United Kingdom)

Basic Science: Mitochondria, Oxidative Stress, Inflammation and Other Pathogeneses

P04.03 An Ill-fated Substantia Nigra Through The Systems Looking Glass An Energetic Overview
Francis, F; Garcia, MR; Wellstead, P; Middleton, R (Ireland)

P04.04 Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-like Degeneration In A Transgenic Mouse Model
Stefanova, N (Austria); Eriksson, H (Sweden); Georgievksa, B (Sweden); Poewe, W (Austria); Wenning, GK (Austria)

P04.05 Fcγ Receptors Are Required For NF-kappaB Signaling, Microglial Activation And Dopaminergic Neurodegeneration In An AAV α-synuclein Mouse Model Of PD
Standaert, DG; Cao, S; Theodore, S (United States)

P04.17 Levels Of Reduced And Oxidized CoenzymeQ-10 And 8-hydroxy-2-Deoxyguanosine In The Cerebrospinal Fluid Of Patients With Living Parkinson’s Disease
Isobe, C; Abe, T; Hattori, N; Terayama, Y (Japan)

P04.18 Effect Of Caffeine And Selective Adenosine A1 And A2A Antagonists On MDMA Induced Dopaminergic Neurotoxicity In Mouse Brain
Khairnar, A; Frau, L; Plumitallo, A; Fenu, S; Morelli, M (Italy)

Basic Science: Pathology

P05.01 Pathologic Considerations Of The Pedunculopontine Nucleus And Locus Coeruleus In Rapid Eye Movement Behavior Disorder
Dugger, B.N; Murray, M.E; Boeve, B.F; Benarroch, E.E; Ferman, TJ; Dickson, D.W (United States)

P05.02 Does Levodopa Affect Progression Of Neuropathology In Parkinson’s Disease? A Clinico–Pathological Study
Parkkinen, L (United Kingdom); O’Sullivan, S (United Kingdom); Kuoppamäki, M (Finland); Collins, C (United Kingdom); Kallis, C (United Kingdom); Holton, JL (United Kingdom); Revesz, T (United Kingdom); Lees, AJ (United Kingdom)

Basic Science: Animal and Cellular Models

P06.06 LRRK2, A Gene Mutated In Parkinson’s Disease, Promotes Synaptic Vesicle Endocytosis
Matto, S; Morais, V A; Mandemakers, W; Vilain, S; De Strooper, B; Verstreken, P (Belgium)

P06.07 Study On Functional Redundancy Of LRRK1 And LRRK2
Mandemakers, WJ; Matto, S; Morais, VA; Snellinx, A; De Strooper, B (Belgium)

P06.08 Modeling Parkinson’s Disease In Adh1 And Adh1/4 Knockout Mice
Anvret, A (Sweden); Ran, C (Sweden); Westerlund, M (Sweden); Lindqvist, E (Sweden); Pernold, K (Sweden); Lundström, K (Sweden); Duester, G (United States); Felder, M.R (United States); Galter, D (Sweden); Carmine Belin, A (Sweden)
Wednesday Scientific Posters (12:30 - 14:30)

**P06.09** A Rat Lipopolysaccharide Model For Parkinson’s Disease Neurodegeneration: Inflammatory Cells And Cytokines In Brain Tissue
Bick, R; Schurdell, MS; Young, LM; Osuagwu, U; Poindexter, BJ; Doursout, MF; Bick, DL; Ellmore, T; Schiess, MC (United States)

**P06.10** Predominant Expression Of Mutant A30P Alpha-synuclein In Olfactory Bulb Of A Conditional Mouse Model: Implications For Early Stage Of Parkinson’s Disease
Nuber, S (Germany); Petrasch-Parwez, E (Germany); Arias-Carrion, O (Germany); Nguyen, H (Germany); von Hoersten, S (Germany); Teismann, P (United Kingdom); Schulz, JB (Germany); Velavan, TP (Germany); Fendt, M (Switzerland); Schmidt, T (Germany); Kohl, Z (Germany); Boy, J (Germany); Fischer, K (Germany); Calaminus, C (Germany); Hoeglinger, G (Germany); Winkler, J (Germany); Pichler, B (Germany); Riess, O (Germany)

**P06.17** Neuroprotective Effect Of Human Mesenchymal Stem Cells In An Animal Model Of Double-toxin-induced Multiple System Atrophy-parkinsonism
Lee, PH; Lee, JE; Kim, JS; Park, HJ (South Korea)

**P06.18** Overexpression Of α-synuclein Alters Dopamine Neurotransmission In Vivo Before Onset Of Behavioral Deficits And Dopaminergic Cell Loss In Rats
Lundblad, M; Decressac, M; Björklund, A (Sweden)

**Basic Science: Brain Physiology and Circuitry**

**P07.01** Chronic Effect Of The Dopamine D3 Receptor Agonist And BDNF On The Motor Deficit In The Rat Model Of Parkinson’s Disease
Razgado-Hernandez, LF; Sierra, A; Martinez-Fong, D; Jimenez, I; Anaya, V; Aceves, J (Mexico)

**Basic Science: Dopamine, Receptors and Other Neurotransmitters**

**P08.01** Therapeutic Potential Of Caffeine Derivate 1-methylxanthine, As A2A Adenosine Receptor Antagonist On Striatopallidal Pathway
Jimenez-Botello, LC; Ávila-Costa, MR; Carillo-Ruiz, JD; Correa-Basurto, J; Picazo, O; Querejeta-Villagomez, E (Mexico)

**Basic Science: Neuropharmacology**

**P10.01** Antioxidative Potential Of Quercetin Analogues Against MPP+ Toxicity In Dopaminergic Cells
Rausch, WD (Austria); Ma, C (China); Wichart, I (Austria); Moldzio, R (Austria); Riederer, P (Germany); Yan, Y (China)

**P10.02** PYM50028 (Cogane™), An Orally Active Neurotrophic Factor Modulator Enhances The Effect Of L-DOPA In MPTP-lesioned Macaques
Johnston, TH (Canada); Koprich, JB (Canada); Fox, SH (Canada); Ward, CL (United Kingdom); Hickling, RI (United Kingdom); Howson, PA (United Kingdom); Brotchie, JM (Canada)

**P10.05** Topiramat In Treatment Of Essential Tremor©
Zalyalova, Z (Russia)

**P10.06** Changes In Extracellular Noradrenalin Levels After L-DOPA Administration In The Normal Rat Striatum And Cerebral Cortex
Kannari, K; Ishizawa, E (Japan)
Basic Science: Electrophysiology

P11.01 Evaluation Of Sex And Stage Progression Of Parkinson’s Disease During Functional Tasks
Roland, K; Jones, G; Jakobi, J (Canada)

P11.06 Reflexive And Voluntary Saccades In Patients With Parkinson’s Disease
Bogdanov, RR; Turbina, LG; Litvinova, AS; Ratmanova, PO; Napalkov, DA (Russian Federation)

P11.07 Quantitative Estimation Of Parkinson Patients EEG Wavelet Spectrograms Disorganization.
Korolev, MS; Gabova, AV (Russia)

Clinical Science: Symptoms, Signs, Clinical Features and Progression

P13.01 Isometric Quickness Protocol As An Objective Assessment Of Bradykinesia In Parkinson’s Disease
Pretzer-Aboff, I; Knight, C (United States)

P13.02 Are Results From PD Trials Generalizable? The NPN Database Reveals A Mismatch Between Typical Clinic Populations And Subjects In PD Trials
Schmidt, PN (United States); Okun, MS (United States); Siderowf, A (United States); Nutt, JG (United States); O’Conner, GT (United States); Bloem, BR (Netherlands); Olmstead, EM (United States); Guttman, Mark (Canada); Simuni, T (United States); Cheng, E (United States); Parashos, S (United States); Marsh, L (United States); Malaty, IA (United States); Giladi, N (Israel); Wu, S (United States); Oberdorf, J (United States)

P13.03 Objective Measures Of Parkinson’s Disease Functional Motor Impairment With Finger And Toe Tapping
McNames, J; Kernan, F; Holmstrom, L; Aboy, M; Casady, B; Katz, E; Boureen, J; Horak, F; Nutt, J (United States)

P13.04 A Clinicopathological Study Of A Case Of Parkinson’s Disease
Doherty, K; Silveira-Moriyama, L; Ahmed, Z; Revesz, T; Holton, J; Lees, A (United Kingdom)

P13.05 Pisa Syndrome (PS) And Striatal Hand In Parkinson’s Disease Patient
Pandey, S; Mehndiratta, MM (India)

P13.06 Clinic Based Videotaped Assessment Of Turning Patterns In Parkinson’s Disease
Jog, M; Salmon, A; Kumar, H; South, A (Canada)

P13.07 Bradykinesia In Parkinson’s Disease And Related Conditions
Ling, H; Massey, LM; Lees, AJ; Brown, P; Schwingsenschuh, P; Bhatia, K; Day, BL (United Kingdom)

P13.08 Camptocormia Due To Neuro-oncologic Lumbar Spine Surgery With Instrumentation Technique In A Non Parkinsonian Patient
Casas Parera, J; Igiro Gamero, JL; Tafur Canabal, J; Baez, A; Baez, M; Cardozo Oliver, J (Argentina)

P13.09 Identification Of Physical, Cognitive, And Affective Variables That Relate To Falls In Parkinson’s Disease
Elmer, L; Wilhelm, J; Masterson, M (United States)

P13.10 Early Use Of Amantadine May Postpone Levodopa-induced Dyskinesia And Cognitive Impairment In Patients With Parkinson’s Disease
Yates, TJV; Ward, T; Lennox, GG (United Kingdom)
Wednesday Scientific Posters (12:30 - 14:30)

P13.11 Switching Directions Of The Eyes And Leg: Relationship To Freezing In Parkinson Disease
Lohnes, CA; Earhart, GM (United States)

P13.12 Bedside Clinical Evaluation Of Ocular Features In Atypical Parkinsonian Syndromes
Nehru, R; Batla, A; Vijay, T; Sharma, J B (India)

P13.13 Detection And Quantification Of Freezing Of Gait Using A Repetitive Stepping In Place Task
Nantel, J.; de Solages, C.; Bronte-Stewart, H.M (United States)

P13.38 Parkinson’s Disease Or Parkinson’s Complex: Cardinal Motor Signs Dissociations Figures And Parkinson’s District Clinics / Sections
Echebarria Mendieta, Sabino Guillermo (Spain)

P13.39 Hemiparkinsonism And Bilateral Blepharoconulosis Due To A Mesencephalic-subthalamic Nucleus Cavernoma: A Case Report
Singer, C; Moore, H; Heros, R (United States)

P13.40 Postural Instability And Cognitive Dysfunction In Patients With Early-stage Parkinson’s Disease: A Computerized Dynamic Posturographic Study
Koh, SB (South Korea); Lee, J (South Korea); Chae, S (South Korea); Shin, HE (Republic of Korea)

Clinical Science: Non-motor Features

P14.01 Prospective Study Of Bowel Movement Frequency And Parkinson Disease Risk
Gao, X; Chen, H; Schwarzschild, M; Ascherio, A (United States)

P14.02 Tolerability Of Apomorphine Infusion In Advanced Parkinson’s Patients With Hallucinations And Gastrointestinal Symptoms: Implications For Treatment
Chandiramani, C (United Kingdom); Reddy, P (United Kingdom); Martin, A (United Kingdom); Chaudhuri, KR (United Kingdom); Canesi, M (United Kingdom); Martinez-Martin, P (United Kingdom); Antonini, A (Italy); Todorova, A (United Kingdom); Odin, P (Sweden); Henriksen, T (United Kingdom); Falup-Pecurariu, C (United Kingdom); Falup-Pecurariu, C (United Kingdom); Falup-Pecurariu, C (United Kingdom); Brooks, DJ (United Kingdom); Naidu, Y (United Kingdom); Tluk, S (United Kingdom); Trenkwalder, C (United Kingdom); Aarsland, D (United Kingdom); Van Hilten, JJ (United Kingdom); MacPhee, G (United Kingdom)

P14.03 A Virtual Arena Test Indicates Deficient Striatal Spatial Memory Strategies In Mild Parkinson’s Disease
Gudmundsdottir, T (Sweden); Doeller, CF (United Kingdom); Burgess, N (United Kingdom); Bergquist, F (Sweden)

P14.04 L-Dopa/carbidopa Gel Dose-response Relationships With Cognitive, Emotional And Motor Features In Patients With Advanced Parkinson’s Disease
Nissen, T (Germany); Honig, H (Germany); Rüssmann, A (Germany); Fox, K (Germany); Brown, R (United Kingdom); Odin, P (Germany)

P14.05 Measuring Quality Of Life In Patients With Parkinson’s Disease Using The McGill Quality Of Life Questionnaire
Jag, M; Goffon, T; Kumar, H; South, A; Speechly, M (Canada)

P14.20 Lower Basal Leg Vascular Tone And Larger Plasma Volume In Parkinson’s Disease Patients With Orthostatic Hypotension
Groothuis, JT; Esselink, RAJ; Seeger, JPH; Bloem, BR; Hopman, MTE (Netherlands)
Wednesday Scientific Posters (12:30 - 14:30)

P14.21 Measuring Perception Of Subjective Visual Vertical Using The Computerised Rod And Frame Test In Parkinson’s Disease Patients
   Amar, K; Docherty, S; Bagust, J; Wellington, R; Khattab, A (United Kingdom)

Clinical Science: Biomarkers and Neuroimaging

P15.01 Abnormalities Of White Matter Architecture And Connectivity In Parkinsonian Gait Freezing: Implications For Treatment
   Schweder, PM; Green, A; Hansen, P; Stein, J; Aziz, TZ (United Kingdom)

P15.02 A Structural Morphometric Imaging Analysis Of The Brainstem And Cerebellum In A DBS Cohort Of Parkinson’s Disease
   Schweder, PM; Joint, C; Hansen, P; Quaghebeur, G; Green, A; Aziz, TZ (United Kingdom)

P15.03 F-18 FDG-PET Is A Useful Tool In Clinical Practice For Diagnosing Corticobasal Ganglionic Degeneration
   Tripathi, M; Nehru, R; Battlo, A; Sharma, R; Mondal, A; Vijay T (India)

P15.04 Serotonergic Involvement In L-DOPA-induced Dyskinesia
   Politis, M; Wu, K; Loane, C; Kiferle, L; Molloy, S; Bain, P; Brooks, DJ; Piccini, P (United Kingdom)

P15.05 Significance Of Hand Tremorography And Symmetrical Sensorimotor Coordinometry In Patients With Parkinson’s Disease
   Gospodinov, MI (Bulgaria)

P15.06 The PARS Study: Identifying Pre-diagnostic Parkinsonian Features In A Healthy Hyposmic Cohort
   Jennings, D; Siderowf, A; Stern, M; Marek, K; PARS Study Investigators, (United States)

P15.24 Association Between High-sensitivity C-reactive Protein And Risk Of Early Idiopathic Parkinson’s Disease
   Lee, K; Song, I; Kim, J; Chung, S; Kim, H (Republic of Korea)

Clinical Science: Medical Therapy

P16.01 Side-effects And Withdrawal Rates For Oral Non-ergot Dopamine Agonists Used As Monotherapy In Routine Clinical Practice
   King, SM; Newman, EJ; Grosset, KA; Macphee, G; Grosset, DG (United Kingdom)

P16.02 Iti-007: A Novel Treatment For Sleep Disorders And Dyskinesia In Parkinson’s Disease
   Vanover, KE (United States); Davis, RE (United States); Snyder, GL (United States); Hendrick, JP (United States); Fisone, G (Sweden); Fienberg, AA (United States); Wennogle, LP (United States); Mates, S (United States)

P16.03 Development Of Novel PDE1 Inhibitors As Dose-sparing Medications In Parkinson’s Disease
   Snyder, GL (United States); Vanover, KE (United States); Zhu, H (United States); Zhang, L (United States); Li, P (United States); Hendrick, JP (United States); Fisone, G (Sweden); Davis, RE (United States); Fienberg, AA (United States); Wennogle, LP (United States); Mates, S (United States)
Wednesday Scientific Posters (12:30 - 14:30)

P16.04 Patient Perspectives Towards Levodopa Therapy In Japan And The United States - Results Of Two Patient Surveys
Fujimoto, K (Japan); Hattori, N (Japan); Kondo, T (Japan); Murata, M (Japan); Stacy, M (United States)

P16.05 Drug Treatment Characteristics For People With Parkinson's In United Kingdom
Drutyte, G; Breen, K (United Kingdom)

P16.06 Novel Metal Ligands Prevent Neuronal Loss And Motor Deficits In Wild Type And Alpha-synuclein Transgenic Mice Treated With 6-Hydroxydopamine Or MPTP
Cherny, RA; George, JL; Gunawan, L; Critch, N; Cortes, M; Liu, X; Nurjono, M; Laughton, K; Volitakis, I; Parsons, J; Barnham, KJ; Gautier, E; Bush, A; Finkelstein, DI (Australia)

Clinical Science: Surgical Therapy

P17.01 Urological Interventions In Parkinson's Disease:the Kokilaben Hospital Experience
Sanjay, P; Bhatt, M (India)

P17.02 Deep Brain Stimulation Alters Subthalamic Nucleus Connectivity: Neuroimaging Evidence
Schweder, PM; Joint, C; Green, A; Quaghebeur, G; Aziz, TZ (United Kingdom)

P17.03 Subthalamic Nucleus Functional Connectivity In Parkinson's Disease
Schweder, PM; Joint, C; Quaghebeur, G; Green, A; Aziz, TZ (United Kingdom)

P17.09 Application Of The Stimulus Screening Tool In The Pre-selection For Deep Brain Stimulation In Patients With Parkinson’s Disease
Lena, F. (Italy); Rossi, C. (Italy); Brotni, S. (Italy); Bianco, G. (Italy); Battisti, C. (Italy); Modugno, N. (Italy); Ceravolo, R. (Italy); Rossi, S. (Italy); Maffei, D. (Italy); Stoevelaar, H. (Belgium)

P17.10 Relationship Between The Decline In Verbal Fluency And Deep Brain Stimulation Of The Subthalamic Nucleus: A Case Report
Tommasi, G (Italy); Yelnik, J (France); Bertolasi, L (Italy); Sala, F (Italy); Ricciardi, GK (Italy); Bardinet, E (France); Fincati, E (Italy); Fiaschi, A (Italy)

Clinical Science: Complications of Therapy

P18.01 Entacapone Adverse Effects In Clinical Practice
Wai Ho, C; Newman, EI; Grosset, KA; Macphee, G; Grosset, DG (United Kingdom)

P18.04 Plasma Homocysteine Levels Increased Risk Of Levodopa-induced Dyskinesia In Parkinson's Disease
J.J., Lin; K.Y., Yueh (Taiwan)

P18.05 A Study On The Prevalence And Predictors Of Levodopa Induced Dyskinesias In Parkinson's Disease
Norlinah, MI; Hasnur, ZH; W NurNafisah, WY; Tan, HJ; Raymond, AA (Malaysia)

Clinical Science: Clinical Trials

P19.01 Multi-center, Placebo-controlled, Double-blind Trial To Examine The Safety And Efficacy Of Pimavanserin In The Treatment Of Psychosis In PD
Friedman, J (United States); Ravina, B (United States); Mills, R (United States); Williams, H (United States); Bahr, D (United States); Peters, P (United States); Tison, F (France); Burn, D (United States)
P19.02 Interim Analysis Of An Open-label Extension Study To Examine The Long-term Safety And Tolerability Of Pimavanserin In The Treatment Of PD Psychosis.
Mills, R; Bahr, D; Williams, H; Peters, P; Isaacson, S (United States)

P19.03 Predicting Exposure And Response To Safinamide In Parkinson’s Disease (PD) Using Population Pharmacokinetic And Pharmacodynamic Modelling
Campioni, M (Switzerland); Krösser, S (Switzerland); Thapar, MM (United Kingdom); Hayes, SC (United Kingdom); Gibiansky, E (United States); Lucini, V (Italy); Anand, R (Switzerland)

P19.04 Effects Of Safinamide As Add-on To L-Dopa On Symptom Severity And Aspects Of Daily Living In Patients With Mid- To Late-stage Parkinson’s Disease
Szasz, J (Romania); Borgohain, R (India); Bhatt, M (India); Rossetti, S (Italy); Lucini, V (Italy); Anand, R (Switzerland); for Study 016 investigators,

P19.05 Rasagiline 1 Mg/d Provides Benefits For Non-motor Symptoms In Patients With Early Parkinson’s Disease: Results From The ADAGIO Study
Poewe, W (Austria); Hauser, RA (United States); Lang, AE (Canada)

P19.06 Treatment With Rasagiline Provides Benefits In The Symptoms Of Fatigue In Patients With Early Parkinson’s Disease
Stocchi, F (Italy)

P19.07 Effect Of Safinamide On Dyskinesia In Patients With Mid- To Late-stage Parkinson’s Disease: Data From A Post Hoc Analysis
Bhatt, M (India); Chirileanu, D (Romania); Meshram, C (India); Stanzione, P (Italy); Forrest, EC (Italy); Lucini, V (Italy); for Study 016 Investigators,

P19.08 An Open-label Safety, Efficacy And Pharmacodynamic Investigation Of SYN118 In Patients With Parkinson’s Disease
Al-Tawil, N (Sweden); Tedroff, J (Sweden); Carlström, C (Sweden); Hallström, Y (Sweden); Varrone, A (Sweden); Meya, U (Switzerland)

P19.27 An Actively Transported Levodopa Prodrug (XP21279) In Patients With Parkinson’s Disease
LeWitt, PA; Ellenbogen, AL; Chen, D; Lal, R; McGuire, KH; Zomorodi, K; Luo, WC; Huff, FJ (United States)

Clinical Science: Non-pharmacologic Therapies

P20.01 Long Term Impact Of A Restorative Care Intervention For People With Parkinson’s In The Community Setting
Pretzer-Aboff, J; Resnick, B; Galik, E (United States)

P20.02 Clowning Improves Mobility In Parkinson’s Disease
Volpe, D (Italy); Signorini, M (Italy); Marchetto, A (Italy); Bulgari, V (Italy); McNeer, R (United Kingdom); MacDonald, P (United Kingdom)

Clinical Science: Rating Scales

P21.01 Measuring Severity Of Impulse Control Disorders In Parkinson’s Disease Using Objective Validated Questionnaire
Wu, K; Politis, M; Warsi, S; Loane, C; O’Sullivan, S; Lees, A; Piccini, P (United Kingdom)

P21.02 Nintendo™ Wii Remote Quantifies Finger Tapping In Parkinson’s Disease
Davis, T; Chambers, A; Yokely, J; Fang, J (United States)
Wednesday Scientific Posters (12:30 - 14:30)

P21.03 Balance Assessment In Parkinson Disease: The BESTest And The Mini-BESTest
Leddy, AL; Crowner, BE; Earhart, GM (United States)

P21.04 Clinical Assessment Of Motor Control In Parkinson Disease: Past, Present, And Future
Melo, F; Godinho, C; Domingos, J; Figueiredo, C; Ferreira, N (Portugal)

P21.13 Validity Of The New Test Of Upper Limb Apraxia (TULIA) In Parkinson's Disease
Vanbellingen, T; Baronti, F; Müri, R; Bohlhalter, S (Switzerland)

Clinical Science: Behavioral Disorders

P22.01 Action And Object Naming In PSP (Progressive Supranuclear Palsy)
Sehgal, R; Nehru, R (India)

P22.02 Premorbid Personality As Vulnerability Factor In The Development Of Impulse Control Disorders And Punding In Parkinson’s Disease
Signorini, M; Marchetto, A; Volpato, C; Volpe, D (Italy)

P22.07 Patterns And Changes Over Time In Antipsychotic Prescribing In Parkinson’s Disease
Weintraub, D; Chen, PJ; Ignacio, RV; Mamikonyan, E; Kales, H (United States)

Clinical Science: Cognition

P23.01 Use Of A Brief Computerized Test Battery To Identify Cognitive Changes In Parkinson’s Disease
Kane, ; Short, P; Wulff, L; Grattan, L; Kutz, S; Schulman, L; Stern, S; Cernich, A; Reich, S; Weiner, W (United States)

P23.02 [18F]FDG PET Is A Useful Marker For Posterior Cortical Dysfunction In Lewy Body Dementia
Lee, Chong Sik; Kim, JY; Kim, Y; Kim, SJ; Kim, JS (Republic of Korea)

P23.03 Navigation In A Virtual Reality Environment In Parkinson’s
Jag, M; Angela, S; Harishesh, K; Garrett, K; Vedran, V; Mike, K; Rachna, J (Canada)

P23.04 Reliability And Utility Of The ANAM-PD Computerized Test Battery For The Assessment Of The Neuropsychological Features Of Parkinson Disease
Hawkins, K; Jennings, D; Marek, K; Gilliland, K; Vincent, A (United States)

P23.05 Cognitive Deficits Associated With Dopamine Transporter Loss In The Pre-motor Subjects In The PARS Cohort
Hawkins, K; Jennings, D; Marek, K; Siderowf, A; Stern, M; PARS Study Investigators, PARS (United States)

P23.16 Significance Of Subjective Memory Complaints In Non-demented Patients With Parkinson’s Disease
Lou, PN; Chong, MS; Lim, WS; Au, WL; Tan, LCS (Singapore)

P23.17 How Do Patients With Newly Diagnosed Parkinson’s Disease Cope?
Lode, K; Bronnick, K; Tysnes, OB; Larsen, JP (Norway)

P28.12 Development of a Health Professionals Webpage on the Movement Disorder Society Website
Brown, RG; Brown-Moskowitz, CB; Bunting-Perry, L; Gaba, A; Goldman, J; Graziano, M; Heath, S; Makoutina, M; Manor, Y; Moore, O; Rao, AK; Rochester, L; Thomson, F; Williamson, F
1United Kingdom; 2United States; 3Luxembourg; 4Australia; 5Israel
Clinical Science: Sleep Disorders/Fatigue

P24.01 Carotid Intima-media Thickness In Patients With Idiopathic Restless Legs Syndrome
Baik, J; Han, S (Republic of Korea)

Community & Quality of Life: Family Care, Caregiving, Relationships

P25.01 Measuring Existential, Psychological And Physical Contributors To Quality Of Life In Parkinson's Disease Using The McGill Quality Of Life Tool
Jog, M; Kumar, H; Gofton, T (Canada)

P25.02 Couples Living With Parkinson’s Disease: Needs And Concerns At Advanced To End Stage
Habermann, B; Miller, W; McLennon, S; Chen, H; Rafail, L; Wojcieszek, J (United States)

P25.07 The Situation Of Caregivers For Persons With Parkinson’s Disease (PD)
Leiknes, I (Norway)

Community & Quality of Life: Fitness, Wellness, Nutrition

P26.01 The Effect Of Exercise On Self Reported Quality Of Life: Efficacy Of Exercise Based On Age, Disease Duration And Gender
Hatton, P (United States); Hatton, P (United States); Pan, Di (United States); Dhall, Rohit (United States Minor Outlying Islands); Coles, MA (United States)

P26.02 Yoga Teacher Training For Students With Parkinson’s Disease
LeVerrier, R; Rork DeAngelis, T; Thomas, CA (United States)

Community & Quality of Life: Alternative And Complementary Therapies/Creativity, Music and Dance

P27.01 The Effects Of A Music Accompanied Walking Program On Obstacle Crossing Behaviours In People With Parkinson’s Disease
de Bruin, N; Doan, J; Turnbull, G; Bonfield, S; Suchowersky, O; Hu, B; Brown, L (Canada)

P27.02 Rhythmic Auditory Stimulation (RAS) To Aid Gait In Patients With Parkinson Disease
Myskja, A (Norway)

Community & Quality of Life: Education: Lay and Professional / Health Literacy

P28.01 Effect Of PD Specific Education On Self-reported Quality Of Life
Dhall, Rohit; Coles, Margaret Anne; Hatton, P; Pan, Di; Henderson, C (United States)

P28.02 Influencing Clinical Study Participation Through Peer To Peer Education: The Impact Of A Multi-disciplinary Training For People With Parkinson’s
Todaro, V; Elliott, R (United States)

P28.03 United States Health Reform: How Patients With Parkinson’s Disease View Its Impact On Their Medical Care
Arney, KB; Davis, TL (United States)
Wednesday Scientific Posters (12:30 - 14:30)

P28.04 Training Multiple Disciplines To Work Together In Parkinson's Teams: Building A Model Interdisciplinary Training Program
Hagestuen, R; Gonzalez-Ramos, G; Cohen, E (United States)

Community & Quality of Life: Disability and Quality of Life Outcome Measures

P29.01 Determinants Of Quality Of Life Improvement After DBS Surgery
Dhall, R; Coles, MA; Hatton, P; Pan, D (United States)

P29.02 Current Peculiarities Of Disability Due To Parkinsonism In Ukraine
Golyk, V A; Ipatov, A V; Zholob, O A; Moroz, O M; Rusina, H V; Bogouslavskyy, D.D. (Ukraine)

P29.03 Community Walking: The Perception Of People With Parkinson Disease
Lamont, R; Morris, ME; Brauer, SG (Australia)

P29.04 Community Based Falls In People With PD: A Prospective Analysis Of The First Reported Fall Over 12 Months
Lamont, RM; Morris, ME; Watts, JJ; McGinley, JL; Menz, HB; Iansek, R; Murphy, AT; Waller, ER; Brauer, SG (Australia)

P29.13 Coping And Quality Of Life In Parkinson's Disease: The Deep Brain Stimulation Effect
Montel, S; Bonnet, A; Bungener, C (France)

P29.14 Coping And Quality Of Life As Related To Depression And Anxiety In Parkinson's Disease
Montel, S; Bonnet, A; Bungener, C (France)

P29.15 12–month Results From A Novel Test Battery Used In A Duodenal Levodopa Infusion Trial
Westin, J; Nyholm, D; Johansson, A; Memedi, M; Dougherty, M; Groth, T; Pålhagen, S (Sweden)

Community & Quality of Life: Patient / Caregiver / Doctor Community or Healthcare Teams

P30.01 A Cross-cultural Lens Analysis Of Health Care Practitioners' Perceptions Of People With Parkinson's Disease
Bogart, K (United States); Tickle-Degnen, L (United States); Ma, H (Taiwan)

P30.02 Effect Of Facial Masking On Practitioner Judgments Of Men And Women With Parkinson's Disease: A Cross-cultural Study
Tickle-Degnen, L (United States); Zebrowitz, LA (United States); Ma, H (Taiwan)

P30.03 Direct Cost Of Illness In Japanese Patients With Parkinson's Disease
Yoritaka-Saito, A; Hattori, N (Japan)

P30.09 Pharmacotherapy For Parkinson’s Disease — Patients’ Priorities
Wüllner, U; Fuchs, G; Reketat, N; Randerath, O; Kassubek, J (Germany)

P30.10 Coordination Of Care Across Multiple Contact Points In A Comprehensive Care Model For People With Parkinson
Gardiner, RE; Iansek, R; Winkler, B (Australia)
Wednesday Scientific Posters (12:30 - 14:30)

Community & Quality of Life: Palliative Care

P31.01 Defining And Developing Good Palliative Care For People Living With Parkinson’s In Victoria, Australia, A Work In Progress
   McConvey, V (Australia)

Community & Quality of Life: Health Services Accesibility/Underserved Populations

P32.01 Telephone Based Nursing Management Of Movement Disorders Patients-maximizing Health Utility
   Hall, L; Jog, M (Canada)

P32.02 Audit Cycle Of National Standards Related To Parkinson’s Disease Care
   Singh, I; Ebenezer, L; Raha, S (United Kingdom)

Community & Quality of Life: Sexuality and Intimacy

P33.01 Quality Of Sexual Life (QoSL) In Parkinson Disease (PD): Perception Of Patients And Spouses

Community & Quality of Life: Physical and Occupational Therapy

P35.01 Can Occupational Therapy Have A Neuroprotective Effect On Functional Activities For Persons With Parkinson’s Disease?
   Moyer, EA (United States)

P35.02 An Exploration Of Individuals’ Perspectives On The Impact Of Parkinson’s Disease On Self-care, Work And Leisure Activities
   Connolly, D.; Cassidy, C; Ni Mhurchú, E; Nolan, E (Ireland)

P35.03 Defining UK Physiotherapy In Parkinson’s Disease: A Modified Delphi Survey
   Meek, C; Sackley, CM; Clarke, CE; Shah, S (United Kingdom)

P35.04 Long-term Individual Fitness Enablement (LIFE) For Parkinson’s Disease: A Feasibility Study
   Meek, C; Sackley, CM; Clarke, CE; Soundy, AA; Winward, C; Esser, P; Patel, S; Dawes, H (United Kingdom)

P35.05 Unilateral Auditory Cueing To Improve Freezing During Turning In Parkinson’s Disease
   Spildooren, J; Vercreusse, S; Desloovere, K; Vandenberghe, W; Vandenbossche, J; Nieuwboer, A (Belgium)

P35.06 The Development Of Occupational Therapy Best Practice Guidelines For People With Parkinson’s
   Aragon, A. (United Kingdom)

P35.07 Comparative Study Of Conventional Physiotherapy And Virtual Rehabilitation Using Wii Fit For Improvement Of Balance In Parkinson’s Disease Patients
   Loureiro, APC; Stori, FR; Chen, R; Ribas, CG; Loureiro, CC (Brazil)

P35.20 Supporting Evidence-based Physiotherapy In Parkinson’s Disease: The Association Of Physiotherapy In Parkinson’s Disease Europe (APPDE)
   Graziano, M (Luxembourg); Jone, D (United Kingdom); Nieuwboer, A (Belgium); Munneke, M (Netherlands); Keus, SHJ (Netherlands); Hubert, M (Belgium); Lindop, F (United Kingdom)
Late Breaking Abstracts

LBP36.01 Mitochondrial Alterations In Relation To Synaptic Pathology In Parkinson’s Disease
Baloyannis, S; Baloyannis, IS (Greece)

LBP36.03 Sleep Disorders In Patients With Early-onset Parkinson’s Disease (EOPD) In A Specialty Hospital In Mexico
Bautista de la Cruz, H (Mexico)

LBP36.04 Whole Exome And Targeted Re-sequencing In Parkinson Patients
Biskup, S; Boehm, D; Scheurenbrand, T; Schulte, C; Gasser, T (Germany)

LBP36.05 Pharmacokinetic Analysis Of Levodopa Titration Strategies With New Stalevo®75 And 125 Dose Strengths
Ingman, K; Naukkarinen, T; Korpela, I; Kuoppamäki, M; Ellmén, J (Finland)

LBP36.12 A Case-control Study Of Restless Legs Syndrome In De Novo Previously Untreated Patients With Parkinson’s Disease. Preliminary Results.
Calzetti, S; Negrotti, A; Angelini, M; Marchesi, E; Bonavina, G (Italy)

LBP36.15 A Cost-effectiveness Analysis Of Levodopa/carbidopa Intestinal Gel (LCIG) Compared To Usual Care In Advanced Parkinson’s Disease In The UK
Morris, S (United Kingdom); Chaudhuri, R (United Kingdom); Findley, L (United Kingdom); Wood, E (United Kingdom); Bergman, A (Switzerland); Schifflers, M (United Kingdom); Lowin, J (United Kingdom); Roeder, C (United Kingdom)

Community & Quality of Life: Working, Driving

P37.01 Predictors Of Disability Retirement In Newly Diagnosed PD: The Role Of Motor Impairment And Neuropsychiatric Symptoms
Dahle, H.A.; Alves, Guido; Larsen, J.P.; Simonsen, K.; Tysnes, O.B.; Brønnick, K.S. (Norway)

P37.02 Parkinson’s, Employment & Quality Of Life: The Role Of Job Control, Social Support And Self-efficacy
Cooper, L; Knowles, S; Moore, S (Australia)
Basic Science: Etiology, Genetics, Epidemiology and Toxicants

P01.10 ARHGEF7 (beta-Pix) The First Identified Guanine Nucleotide Exchange Factor For LRRK2
Haebig, K; Gloeckner, CJ; Gillardon, F; Ueffing, M; Riess, O; Biskup, S; Bonin, M (Germany)

P01.11 PARK9-associated ATP13A2 Regulates Neuronal Integrity And Intracellular Cation Flux
Ramonet, D; Kosinska, A; Glauser, L; Moore, D.J.(Switzerland)

P01.12 A Cohort Study Of Diet And Risk Of Parkinson's Disease
Sääksjärvi, K; Knekt, P; Lundqvist, A; Heliövaara, M; Männistö, S; Rissanen, H; Järvinen, R (Finland)

P01.13 DNA Methylation In Lymphocytes And Brain Samples Of Parkinson's Disease Patients
Kaut, O; Schmitt, I; Wüllner, U (Germany)

P01.14 The Incidence Of Progressive Supranuclear Palsy, Multiple System Atrophy And Vascular Parkinsonism In North-east Scotland (the PINE Study)
Caslake, R; Gordon, J; Harris, C; Primrose, W; Counsell, C. (United Kingdom)

P01.15 Dementia With Lewy Bodies: A Role For Dementia And Parkinson’s Disease Genes?
Meeus, B; Verstraeten, A; Nuytemans, K; Crosiers, D; Engelborghs, S; Van den Broeck, M; Brys, J; Mattheijssens, M; Peeters, K; Corsmit, E; Elinck, E; Pickut, B; Cras, P; Vandenbergh, R; De Deyn, PP; Van Broeckhoven, C; Theuns, J (Belgium)

P01.16 Relative Significance Of SCA2, SCA3 And SCA17 In Korean Patients With Parkinsonism
Jeon, BS; Yun, JY; Lee, WW; Kim, HJ; Kim, JS; Kim, JM; Kim, SY; Kim, YK; Kim, SE; Kim, YE (Republic of Korea)

P01.17 Characterisation Of LRRK2-tubulin Interactions In Parkinson's Disease
Berwick, DC; Law, BMH; Sancho, RM; Harvey, K (United Kingdom)

P01.18 Personality Characteristics And Motor Skills Attributed To Occupations In Parkinson's Disease
Gatto, N; Bordelon, Y; Gatz, M; Ritz, B (United States)

P01.22 Using Drug Purchase Data To Estimate The Occurrence Of Parkinson's Disease In Israel, 1998-2008
Chillaq-Talmor, O; Giladi, N; Linn, S; Gurevich, T; El-Ad, B; Silverman, B; Friedman, N; Peretz, C (Israel)

P01.30 Parkinsonism Incidence In North-east Scotland (the PINE Study): The Incidence Of Parkinson’s Disease And Parkinsonism
Caslake, R; Harris, C; Gordon, J; Primrose, W; Counsell, C. (United Kingdom)

P01.31 Association Of The Glucocerebrosidase N370s Allele And Parkinson’s Disease In Two Separate Chinese Han Populations Of Mainland China
Xu, Yanming; Xi, Jing; Hu, Fayun; Liu, ling; He, Xianghua; Liu, Zhuolin; Zou, Xiaoyi (China)

P01.32 Lack Of Replication Of Association Between Polymorphism In The 3’UTR Of The Alpha-synuclein Gene And Parkinson’s Disease In Chinese Subjects
Xu, Y; Hu, W; Hu, F; Liu, L; Yu, L; Xi, J; He, X; Zhu, M; Liu, Z (China)
Thursday Scientific Posters (11:30 - 13:30)

Basic Science: Cell Death Mechanisms, Neuroprotection and Trophic Factors

P02.06 9-Methyl-β-carboline Inhibits Monoamine Oxidase Activity And Stimulates The Expression Of Growth Factors By Astrocytes
Keller, S.; Reichmann, H.; Gille, G. (Germany)

P02.07 Stress Is A Predisposing Factor For Parkinson’s Disease In Males But Not Females
Dexter, D; Allen, R; Gillies, G; Buckingham, J (United Kingdom)

P02.08 Glial Cell Derived Neurotrophic Factor Does Not Provide Neuroprotection Against Alpha-synuclein-induced Toxicity In A Rat Model Of Parkinson’s Disease
Decressac, M; Ulusoy, A; Kirik, D; Bjorklund, A (Sweden)

P02.09 The Stress Protein RTP801 Is Required For Neuronal Death Induced By Alpha-synuclein
Levy, O.A.; Malagelada, C.; Greene, L.A. (United States)

P02.10 Fluorescent Demonstration Of Neurodegeneration Via Gold Conjugate Immunolabelling Invitro
Ogundele, OM; Ghazal, OK; Jimoh, OR; Caxton-Martins, EA (Nigeria)

P02.19 14-3-3theta Protects Against Neurotoxicity In PD Models Through The Inhibition Of The Apoptotic Factor Bax
Yacoubian, TA; Slone, SR (United States)

Basic Science: Protein Misfolding and Handling

P03.03 14-3-3 Protein Can Act As A Molecular Chaperon That Inhibits -synuclein Aggregation In Vitro
Tessari, I.; Brucale, M.; Tosatto, L.; Munari, F.; Plotegher, N.; Kumar, D.; Capaldi, S.; Bisaglia, M.; Samori, B.; Monaco, H.L.; Bubacco, L. (Italy)

P03.04 Proteasome Inhibition In Medaka Brain Induces The Features Of Parkinson Disease
Matsui, H; Ito, H; Taniguchi, Y; Inoue, H; Takeda, S; Takahashi, R (Japan)

P03.07 Development Of Alpha-synuclein As A Potential Molecular Marker For Parkinson’s Disease
Foulds, Penelope; Foulds, P.G.; Mann, D.M.; Mitchell, J.D.; Diggle, P.J.; Allsop, D. (United Kingdom)

Basic Science: Mitochondria, Oxidative Stress, Inflammation & Other Pathogeneses

P04.01 Pink1 Depletion Affects Mitochondrial Homeostasis
Heeman, B (Belgium); Van den Haute, C (Belgium); Aelvoet, SA (Belgium); Valsecchi, F (Netherlands); Rodenburg, R (Netherlands); Debyser, Z. (Belgium); Koopman, WJH (Netherlands); Willems, PHGM (Netherlands); Backelandt, V (Belgium)
Thursday Scientific Posters (11:30 - 13:30)

P04.02 Phosphorylation Of Htra2 By Cyclin Dependant Kinase 5
*Fitzgerald, JC; Plun-Favreau, H* (United Kingdom)

P04.06 Role Of Pink1 In Parkinson’s Disease And Mitochondrial Function: Pink1 Regulates Complex I Activity
*Morais, V.A. (Belgium); Caressaerts, K. (Belgium); Snellinx, A. (Belgium); Overbergh, L. (Belgium); Helbig, A. O. (Netherlands); Heck, A. J. R. (Netherlands); Mandemakers, W. (Belgium); Wurst, W. (Germany); De Strooper, B. (Belgium)

P04.07 Structural Characterization Of The Interaction Between Dj-1 And Dopamine-derived Quinones
*Girotto, S.; Bellanda, M.; Sturlese, M.; Tessari, I.; Mammi, S.; Bisaglia, M.; Bubacco, L.* (Italy)

P04.08 PARIS, A Parkin Substrate, Transcriptionally Represses PGC-1α Leading To Neurodegeneration In Parkinson’s Disease
*Shin, J.H; Ko, H.S; Kang, H; Lee, Y; Pletinkova, O; Troconso, J.C; McCaffery, J.M; Lee, Y.I; Dawson, V.L; Dawson, T.M* (United States)

P04.09 Covalent Modifications Of Superoxide Dismutase 2 By Dopamine Oxidation Products
*Belluzzi, E.; Bisaglia, M.; Polverino de Laureto, P.; Bubacco, L.; Beltramini, M.* (Italy)

P04.10 HMGB-1 –an Inflammatory Mediator In MPTP Induced Neuronal Damage
*Sathe, Kinnari* (United Kingdom); Mustafa, Sarah (United Kingdom); Martin, Heather (United Kingdom); Tracey, Kevin (United States); Teismann, Peter (United Kingdom)

P04.11 The Differential Proteome Of The Striatum Of 6-OHDA Lesioned Rats
*Schmitt, O; Lessner, G; Haas, S; Wree, A; Michael, K; Stefan, M; Glocker, M* (Germany)

P04.19 Primary Complex I Defects Linked To AIF Deficiency Sensitizes Dopaminergic Neurons To Parkinsonian Neurotoxins
*Perier, C (Spain); Bove, J (Spain); Dehay, B (Spain); Jackson-Lewis, V (United States); Rabinovitch, P.S. (United States); Przedborski, S (United States); Vila, M (Spain)

P04.20 Single-cell Redox Imaging Demonstrates A Peculiar Response Of Dopaminergic Neurons To Oxidative Insults
*Horowitz, MP (United States); Milanese, C (United States); Di Maio, R (United States); Hu, X (United States); Montero, LM (United States); Sanders, LH (United States); Tapias, V (United States); Burton, Ed (United States); Greenamyre, JT (United States); Mastroberardino, Pier G (Netherlands)

Basic Science: Pathology

P05.03 Validation Of 4E-BP1 As A Putative LRRK2 Substrate: In Vivo Evidence
*Bandopadhyay, R.; Phan, B; Mamais, A; Lashley, T; Lees, A* (United Kingdom)

P05.04 Characterization Of Lewy Body Pathology In 12- And 16-year Old Intrastralital Mesencephalic Grafts Surviving In A Patient With Parkinson’s Disease
*Li, J; Englund, E; Widner, H; Rehncrona, S; Björklund, A; Lindvall, O; Brundin, P* (Sweden)

Basic Science: Animal and Cellular Models

P06.02 NRF2/SKN-1-dependent GST-PI Inhibits Dopamine Neurodegeneration In Caenorhabditis Elegans Models Of Parkinson’s Disease And Manganism
*Nass, R; Settivari, R; LeVora, J* (United States)

P06.03 A PINK1 Mutant Zebrafish Model Of Early Onset Parkinson’s Disease
*Bandmann, O; Flinn, L; Mortiboys, H* (United Kingdom)
Thursday Scientific Posters (11:30 - 13:30)

P06.04 The Ginseng Extract, G115, Is Neuroprotective In A Novel Progressive Rodent Model Of PD
Baranowski, D; Robertson, HA; Shaw, CA; Kay, DG; VanKampen, JM (Canada)

P06.05 The State Of The Pre-synaptic Compartment Determines The Induction And The Maintenance Of L-DOPA Induced Dyskinesia
Ulusoy, A; Sahin, G; Kirik, D (Sweden)

P06.19 Inhibition Of Ras-GRF1 Signaling In The Striatum Reverts Motor Symptoms Associated To L-DOPA-induced Dyskinesia
Fasano, S (Italy); Bezard, E (France); D’Antoni, A (Italy); Indrigo, Ma (Italy); Francardo, V (Sweden); Qin, L (China); Dovero, S (France); Cerovic, M (United Kingdom); Ghiglieri, V (Italy); Bagetta, V (Italy); Picconi, B (Italy); Calabresi, P (Italy); Cenci-Nilsson, A (Sweden); Brambilla, R (Italy)

P06.20 Functional Interactions Between LRRK2 And Recessive Parkinson Disease Genes (Parkin, PINK1 And DJ-1) Mediate The Response To Mitochondrial Dysfunction
Wolozin, B; Guillily, M; Li, H; Ferree, A; Pyenson, N; Saha, S; Collins, J.J. (United States)

P06.21 Alterations In The Autophagy Pathway In Aged Horses With A Spontaneous α-synucleinopathy And Dopaminergic Neurodegenerative Disease
McFarlane, D; McDaniel, K; Hill, K; Cordero, M (United States)

Basic Science: Dopamine, Receptors and Other Neurotransmitters

P08.02 Sequential Changes In Behavioral And Biochemical Parameters In Rotenone Induced Parkinson’s Disease Model : Therapeutic Potentials Of Vitamin E
Sharma, N; Nehru, B (India)

Basic Science: Neuropharmacology

P10.03 Cannabinoid Receptor Activation Reduced Dyskinesias And Tyrosine Hydroxylase Loss In Caudate-putamen Of 6-OHDA Lesioned Mice Treated With L-DOPA
Garcia-Gutiérrez, MS; Leiva, C; Manzanares, J (Spain)

P10.07 PYM50028 (Cogane™), A Neurotrophic Factor Modulator, Increases Dopaminergic Receptor Density And Bdnf And Tyrosine Hydroxylase Levels In Aged Rats
Zhang, Y. (China); Howson, P. A. (United Kingdom); Sun, Q. (China); Hu, Y (China); Xia, Z (China)

P10.08 Protection Of Dopaminergic Neurons By Tetrahydrocannabinol And Other Cannabinoids Against MPP+ And Glutamate Induced Damages In Mesencephalic Cultures
Moldzio, R.; Krewenka, C.; Pacher, T.; Novak, J.; Rausch, WD. (Austria)

P10.09 Nitric Oxide Synthase Inhibition Does Not Reduce Priming For Dyskinesia By L-DOPA In A Primate Model Of Parkinson’s Disease
Hirsch, T; Hikima, A; Jackson, MJ; Tayarani-Binazir, K; Fisher, R; Rose, S; Jenner, P (United Kingdom)

Basic Science: Electrophysiology

P11.03 Using Multiple Electrophysiological Techniques For The Differentiation Of Parkinsonian Syndromes
Fisher, KM; Lai, HM; Baker, MR; Burn, DJ; Baker, SN (United Kingdom)
Thursday Scientific Posters (11:30 - 13:30)

P11.04 The Effect Of L-DOPA On The Firing Rate Of SNr Neurons In The Unilateral 6-OHDA Lesion Model Of Parkinson's Disease
Strauch, C; Seeger-Armbruster, S; von Ameln-Mayerhofer, A (Germany)

Clinical Science: Symptoms, Signs, Clinical Features and Progression

P13.14 Extranigral Extension Of Structural Midbrain Lesions Overshadows Parkinsonism

P13.15 Effects Of Turning And Backward Walking On Bilateral Coordination In Individuals With Parkinson Disease
Peterson, D (United States); Plotnik, M (Israel); Hausdorff, J (Israel); Earhart, G (United States)

P13.16 Dorsal Rather Than Ventral Visual Pathways Discriminate Freezing Status In Parkinson's Disease
Lord, S (United Kingdom); Lord, S (United Kingdom); Archibald, N (United Kingdom); Mosimann, U.P (Switzerland); Rochester, L (United Kingdom); Burn, D (United Kingdom)

P13.17 Turning Is Altered In People With Parkinson's Disease; Differences Can Distinguish Mild From Moderate Disease And Freezers From Non-freezers
Ashburn, A; Kampshoff, C; Burnett, M; Stack, E; Verheyden, G (United Kingdom)

P13.18 Lower Limb Corticobasal Degeneration
Noda, K; Miura, S; Kaku, Y; Ayabe, M; Aizawa, H; Taniwaki, T (Japan)

P13.19 Characteristics Of Freezing Of Gait In Community Dwelling People With Parkinson's Disease
Danoudis, M; McGinley, J.L; Watts, J; Menz, HB; Iansek, R; Murphy, AT; Tan, D; Morris, ME (Australia)

P13.20 Spinal Posture Is Altered In People With Parkinson’s Disease And Can Be Measured With A Small And Simple Hand-held Device (Spinalmouse®)
Verheyden, G; Tedesco Triccas, L; Kampshoff, C; Burnett, M; Ashburn, A (United Kingdom)

P13.21 Detection Of Gait Parameters, Bradykinesia And Falls In Patients With Parkinson’s Disease By Using A Unique Triaxial Accelerometer
Rodriguez-Molinero, A; Pérez-Martínez, D; Samà, D; Sanz, P; Calopa, M; Gálvez, C; Pérez-López, C; Romagosa, J; Catalá, A (Spain)

P13.22 Freezing Of Gait, Fear Of Falling, And Quality Of Life In People With Parkinson’s Disease
McGinley, J.L; Danoudis, M; Menz, H.B; Watts, J; Iansek, R; Murphy, A.T; Morris, M.E (Australia)

P13.23 Clinical Peculiarities Of Manganese-induced Encephalopathy
Shalikashvili, M; Lobjanidze, N; Akiashvili, N; Kapianidze, M; Beridze, M; Kvirvelia, N; Janelidze, M (Republic of Georgia)

P13.41 Dilated Virchow-robin Midbrain Spaces In A Patient With Parkinsonian Syndrome And Familial Frontotemporal Dementia
Tommasi, G (Italy); Yelnik, J (France); Alessandrini, F (Italy); Puoti, G (Italy); Fabrizi, GM (Italy); Zanusso, G (Italy); Bertolasi, L (Italy); Bardinet, E (France); Monaco, S (Italy)

P13.42 Gait Freezing And Speech Disturbance In Parkinson’s Disease: Correlation Analyses Using Cueing Effect
Park, Hee K.; Yoo, Jong Y.; Kwon, Miseon; Lee, Jae H.; Lee, Suk J.; Kim, Mi J.; Chung, Sun J. (Republic of Korea)
Thursday Scientific Posters (11:30 - 13:30)

P13.43 A Computational Model Of The Sensory Processing Deficits Observed During Hand Movements In Subjects With Parkinson’s Disease
Miller Koop, M; Hill, B C; Bronte-Stewart, H (United States)

P13.44 Apparently Ipsilateral Parkinsonism In A Patient With Chronic Subdural Hematoma
Ahn, TB (South Korea)

P13.47 Impaired Digital Dexterity In Parkinson’s Disease Is Associated With Higher-order Praxis Function
Vanbellingen, T; Bellion, M; Temperli, P; Baronti, F; Bohilhalter, S (Switzerland)

Clinical Science: Non-motor Features

P14.06 Influence Of Comorbidity, Complications And Nonmotor Symptoms On Quality Of Life In Parkinson’s Disease
Fischer, M; Jörg, J; Lange, S; Isenmann, S (Germany)

P14.07 Intrajejunal Levodopa Infusion Therapy For Advanced PD
Reddy, P (United Kingdom); Martin, A (United Kingdom); Martinez-Martin, P (Spain); Odin, P (Germany); Antonini, A (Italy); Chaudhuri, K R (United Kingdom)

P14.08 Body Fat Loss And HDL Cholesterol Improvement In Advanced Stages Of Parkinson Disease
Cassani, E; Barichella, M; Madio, C; Cancell, R; Cereto, E; Pusarni, C; Pezzoli, G (Italy)

P14.09 Body Weight In Parkinson’s Disease: A Systematic Review And Meta-analysis
Van der Marck, MA; Dicke, HC; Kentin, ZHA; Borm, G; Bloem, BR; Overeem, S; Munneke, M (Netherlands)

P14.10 Self-reported Non–motor Symptoms In A Cohort Of 139 Parkinson’s Disease Patients
Crosiers, D; Meeus, B; Nuytemans, K; Van Broeckhoven, C; Theuns, J; Cras, P (Belgium)

P14.22 Are There The Differences Of Loss Of Dopaminergic Neurons Between Idiopathic Parkinson Disease With Dementia And Without Dementia? A FP-CIT PET Study
Song, I; Kim, J; Kim, H; Lee, K (Republic of Korea)

Clinical Science: Biomarkers and Neuroimaging

P15.07 Functional Connectivity Of Nucleus Ventralis Intermedius In Parkinson’s Disease: Implications For Treatment
Schweder, P; Hansen, P; Joint, C; Green, A; Aziz, T (United Kingdom)

P15.08 Myocardial Uptake Of Meta-iodobenzylguanidine (MIBG) And Familial Parkinsonism
Furuya, H; Araki, E-I; Arahata, H; Kumazoe, H; Fujii, N (Japan)

P15.09 Serum Urate And Probability Of Dopaminergic Deficit In Early Parkinson’s Disease
Schwarzschild, M.A.; Marek, K; Eberly, S; Oakes, D; Shoulson, I; Jennings, D; Seibyl, J; Ascherio, A (United States)

P15.10 SYMPAR, A Web-based Application Project For Electronic Storage And Integration Of Genomic And Clinical Data For Parkinson’s Disease Patients
Calligaris, R; Banica, M; Ferigo, L; Cattaruzza, T; Roncaglia, P; Krmac, H; Lazarevic, D; Ceiner, A; Pangher, N; Pizzolato, G; Gustincich, S (Italy)

P15.11 Different Roles Of Caudate Nucleus And Putamen In Parkinsonism — Analysis Of TRODAT Study
Lin, YW; Wang, HC (Taiwan)
Thursday Scientific Posters (11:30 - 13:30)

P15.12 Susceptibility-weighted Imaging Of The Striatum In Multiple System Atrophy Compared To Parkinson's Disease
M aeda, T; Toyoshima, H; Nagata, K; Yamamoto, M (Japan)

P15.20 Occipital Hypoperfusion In Parkinson's Disease By Non-invasive Measurement, Arterial Spine Labering, Using 3T MRI
Motoi, Yumiko; Motoi, Y; Kamagata, K; Suzuki, M; Shimoji, K; Hori, M; Hattori, T; Nakanoishi, J; Suzuki, Y; Sato, S; Kurosawa, R; Sasai, K; Kambe, T; Aoki, S; Hattori, N (Japan)

P15.23 Investigating Adenosine A2A Receptor Availability In Parkinson’s Disease Patients With & Without Levodopa Induced Dyskinesias With [11C]SCH442416 PET
Ramlackhansingh, AF; Bose, SK; Ahmed, I; Turkheimer, FE; Pavses, N; Brooks, DJ (United Kingdom)

Clinical Science: Medical Therapy

P16.07 No Correlation Between COMT Genotype And Entacapone Benefits In Parkinson’s Disease
Jeon, BS; Kim, JS; Kim, JY; Kim, JM; Kim, JW; Chung, SJ; Kim, SR; Kim, MJ; Kim, HT; Choi, KG; Shin, DI; Sung, YH; Lee, KS; Kim, HJ; Cho, JW; Park, MY; Park, HY; Choi, SM; Park, KW; Lee, HW; Ahn, TB; Kwon, OD; Kim, SJ (Republic of Korea)

P16.08 Knowledge Of Parkinson’s Disease Among Physicians In Calabar, South-South Nigeria
Williams, UE; Opara, S; Agbulu, R; Umoh, V; Otokpa, D (Nigeria)

P16.09 Patients’ Perspective On Parkinson’s Disease Therapies – Results Of A Large-scale Japanese Survey
Fujimoto, K; Hattori, N; Kondo, T; Murata, M (Japan)

P16.10 Comparison Of Direct Switch To Levodopa/Carbidopa/Entacapone In Levodopa/Benserazide-treated And Levodopa/Carbidopa-treated Patients: A Meta-analysis
Brooks, DJ (United Kingdom); Leinonen, M (Sweden); Nissinen, H (Finland)

P16.11 Post Marketing Surveillance Study To Assess The Safety Profile Of L® (Tolcapone) Under European Marketed Conditions
MacMahon, D; Steiger, M; Fletcher, N; Lees, A; Esquivel, J (United Kingdom)

P16.19 Effects Of Apomorphine On Parkinsonian Tremor
Cinar, N; Sahin, S; Karsidag, S (Turkey)

Clinical Science: Surgical Therapy

P17.04 Transduction Of Dopamine Neurons By Adenoviral Vectors Is Modulated By CAR Expression: Rationale For Tropism Modified Vectors In PD Gene Therapy
Lewis, TB; Glasgow, J.N.; Glandon, A.M.; Curiel, D.T.; Standaert, D.G. (United States)

P17.05 Dissociated Effects Of Left, Right And Bilateral Stimulation Of The Subthalamic Nucleus On Motor, Speech And Language Function In Parkinson’s Disease
Schulz, G; Bradberry, TJ; Hosey, LA; Stager, S; Li-Ching, L; Pawha, R; Lyons, K; Verhagen, L; Braun, A (United States)

P17.06 Effects Of Dorsal Versus Ventral Subthalamic Nucleus Deep Brain Stimulation On Gait In Parkinson Disease
McNeely, ME; Tabbal, SD; Campbell, MC; Karimi, M; Hartlein, JM; Lugar, HM; Hershey, T; Revilla, FJ; Perlmutter, JS; Earhart, GE (United States)

P17.11 Dural Arteriovenous Fistula (DAVF) : Presenting As Progressive Parkinsonism And Cognitive Deficit
Di Ioia, M; Bifolchetti, S; Bonanni, L; Ciccocioppo, F; D’Amico, M C; Monaco, D; Mantenuto, M; Di Carmine, C; La Rover, F; Marchionno, L; Onofrj, V; Onofrj, M; Thomas, A (Italy)
Clinical Science: Complications of Therapy

P18.02 Serum Vitamin B12 And Folate Levels In Parkinson’s Disease Patients Treated With Duodenal Levodopa Infusion
Santos-García, D (Spain); Macías, M (Spain); Llaneza, M (Spain); Grande, M (Spain); Carpintero, P (Spain); de la Fuente-Fernández, R (Canada)

Clinical Science: Clinical Trials

P19.09 Physical Fitness In Patients With Parkinson’s Disease
Speelman, AD; Groothuis, JT; van Nimwegen, ML; Hopman, MTE; Bloem, BR; Munneke, M (Netherlands)

P19.10 The Natural Progression Of Clinical Symptoms In Early Parkinson’s Disease: Results From The ADAGIO Delayed-start Study
Rascol, O (France)

P19.11 The Use Of Apomorphine In The PD SURG Trial
Rick, C; Daniels, J; Patel, S; Ives, N; Gill, S; Varma, TRK; Jenkinson, C; Quinn, N; Williams, A; Wheatley, K (United Kingdom)

P19.12 Monitoring Treatment Fidelity In The ParkFit Study, A Multifaceted Behavioral Program To Increase Physical Activity In Parkinson Patients
van Nimwegen, ML; Speelman, AD; Gerrits, MS; Bloem, BR; Munneke, M (Netherlands)

P19.13 Rasagiline In Early Parkinson’s Disease (pd): Additional Efficacy And Safety Results From The ADAGIO Delayed-start Study
Rascol, O (France); Olanow, CW (United States)

P19.14 Rationale And Design Of The IMPACT Study: A Cluster Controlled Trial To Evaluate Cost-effectiveness Of Multidisciplinary Care In Parkinson’s Disease
Van der Marck, MA; Bloem, BR; Mulleners, W; Hoogerwaard, E; Overeem, S; Adang, E; Borm, G; Munneke, M (Netherlands)

P19.15 Physical Activity In Patients With Parkinson’s Disease
van Nimwegen, ML; Speelman, AD; van Rossum, EJM; Overeem, S; Deeg, DJH; van der Horst, M; Borm, GF; Bloem, BR; Munneke, M (Netherlands)

P19.23 Repetitive Transcranial Magnetic Stimulation Using The H-Coil For Parkinson’s Disease
Cohen, Oren; Cohen, OS; Hassin-Baer, S; Amiaz, R; Nitsan, Z; Ephraty, L; Avisor, I; Strauss, H; Kozlova, E; Zangen, A (Israel)

P19.24 Pharmacokinetic Modeling Of PYM50028 (Cogane™) Predicts Once Daily Dosing Can Achieve Plasma Levels In PD Patients Associated With Preclinical Efficacy
Brindley, C.; Howson, P. A.; Locker, J.; Ward, C. L. (United Kingdom)

P19.25 Effects Of Safinamide As Add-on To L-DOPA On Motor And Depressive Symptoms In Patients With Mid- To Late-stage Parkinson’s Disease
Borgohain, R (India); Mehta, N (India); Bajenaru, O (Romania); Quatrale, R (Italy); Lucini, V (Italy); Anand, R (Switzerland); for Study 016 Investigators, (India)
P19.26 Effects Of Droxidopa (Northera™ ) On 24 Hour Blood Pressure (BP) In Patients With Symptomatic Neurogenic Orthostatic Hypotension (NOH)
Kaufmann, H; Klos, K; Hutchman, R; Isaacson, S (United States)

Clinical Science: Non-pharmacologic Therapies

P20.03 An Evaluation Of A Cognitive Behavioural Therapy Group To Encourage The Self Management Of Parkinson's Disease
Johnson, C (United Kingdom)

P20.04 A Methodology To Improve Social Adjustment After Bilateral Subthalamic Nuclei (STN) Deep Brain Stimulation (DBS) In Parkinson’s Disease (PD)
Meyer, M; Spitz, E; Montel, S; Gospodaru, N; Barroche, G; Schwan, R; Colnat-Coulbois, S (France)

Clinical Science: Rating Scales

P21.05 Reliability And Validity Of The Ambulatory Self Confidence Questionnaire In People With Parkinson Disease
Brauer, SG (Australia); Lamont, RM (Australia); Morris, ME (Australia); Woollacott, MH (United States)

P21.06 Use Of Proxies To Measure Disability In Persons With Parkinson’s Disease
van der Marck, MA; Post, B; Laverman, L; Bloem, BR; Munneke, M (Netherlands)

P21.07 Relation Between Hoehn And Yahr Staging Scale And Postural Behavior In Parkinson Disease: A Dynamic Posturography Study
Godinho, C; Melo, F; Ferret-Sena, V; Dias, M; Colado, A; Semedo, C; Domingos, JMM; Fernandes, O (Portugal)

P21.08 Expression Of Psychotic Symptoms In Parkinson’s Disease As Assessed By The Scale For The Assessment Of Positive Symptoms (SAPS)
Williams, H; Bahr, D; Peters, P; Mills, R (United States)

Clinical Science: Behavioral Disorders

P22.03 Effect Of Subthalamic Nucleus Deep Brain Stimulation On Medication-induced Behavioral Disorders In Patients With Parkinson’s Disease
Kashihara, K; Imamura, T; Agari, T (Japan)

P22.06 Pathological Gambling In PD Is Reduced By Amantadine
Thomas, A; Bonanni, L; Gambi, F; Sepede, G; Cera, N; Bifulchetti, S; Onofri, V; D’Amico, MC; Monaco, D; Ciccocioppo, F; Onofri, M (Italy)

P22.08 Old Age, Lower Education, And Activity Of Daily Living Are The Predictors Of Cognitive Impairment In Mongolian Patients With Parkinson’s Disease
Tsedensodnom, B; Dashdorj, U (Mongolia)

Clinical Science: Cognition

P23.06 Dementia And Its Profile In A Care Of The Elderly Movement Disorder Clinic
Raha, S; Ebenezer, L (United Kingdom)

P23.07 Memory-guided Saccades, Cognitive Status And Dementia In Parkinson’s Disease
Graham, C; MacAskill, M R; Dairymple-Alford, J; Livingston, L; Pitcher, T; Anderson, TJ (New Zealand)
P23.08 Impaired Development Of Strategies Is Associated With Apathy In Parkinson’s Disease
Varanese, Sara; Varanese, S.; Perfetti, B.; Morrison, C.; Ghilardi, MF.; Di Rocco, A. (United States)

P23.09 Relationship Between Apathy And Cognitive Deficits In Parkinson's Disease Patients With Mild Cognitive Impairment
Petrova, M; Raycheva, M; Traykov, L (Bulgaria)

P23.10 Profiling Memory Impairment In Parkinson's Disease
Di Cesare, F (Italy); Di Carlo, C (United Kingdom); Radicati, G.F. (Italy); Stocchi, F (Italy); Fioravanti, M (Italy)

P23.18 Frontal Cognitive Functions Of Essential Tremor Patients
Demýray, D.Y; Ertan, S; Engýn, F; Kiziltan, M; Özekmekçý, S; Kziltan, G; Apaydin, H; Eker, E (Turkey)

Community & Quality of Life: Family Care, Caregiving, Relationships

P25.03 Quality Of Life Of People With Parkinson’s Disease And Their Caregivers
Kelly, DH; McGinley, JL; Galna, B; Watts, JJ; Menz, HB; Iansek, R; Murphy, A; Morris, ME (Australia)

P25.04 A Comparison Study Of Caregiver Burden In Family Members Of Parkinson’s Disease Versus Alzheimer’s Disease
Cho, JW; Lee, JY; Lee, JW; Shin, HY; Ahn, JY (Korea)

P25.08 Parkinson’s And Dementia: How Dancing Helps Ethel To Move And Be Happy
Le Messurier, M. B. (United Kingdom)

Community & Quality of Life: Fitness, Wellness, Nutrition

P26.03 Community Wellness Programs: A Model To Improve Quality Of Life And Daily Function In People With Parkinson Disease
Ellis, T; DeAngelis, T.R.; Hoover, E; Saint-Hilaire, M; Thomas, C.A. (United States)

Community & Quality of Life: Alternative and Complementary Therapies / Creativity, Music and Dance

P27.03 Short-term Effects Of A Community-based Tango Program On Motor And Non-motor Symptoms, Activities Of Daily Living, And Motor Complications In PD
Earhart, GM; Rotello, JMM; Duncan, RP (United States)

P27.05 Methodology Developed To Improve PD Patients’ Quality Of Life By Applying Theoretical Principles Of Paradoxical Phenomenon In The Parkinson Workshop
Dillon, JL; Bacigalupe, MA; Pujol, S (Argentina)

Community & Quality of Life: Education: Lay and Professional / Health Literacy

P28.05 The Role Of Online Tools In Delivering Education About Parkinson’s Disease To People With Parkinson’s And Care Partners
Evers, C; Elliott, R (United States)

P28.06 Education Of Health Professionals In Multidisciplinary Management Of Parkinson’s Disease
Lindop, FA (United Kingdom)
Thursday Scientific Posters (11:30 - 13:30)

P28.07 Disease-specific Training For Care Assistants: A Randomised Controlled Trial Comparing Two Approaches For Improving Understanding Of Parkinson’s
Gage, H; Ting, S; Chorley, C; Kaye, J; Bryan, K; Williams, P; Axelrod, L; Trend, P; Wade, D (United Kingdom)

P28.11 A Strategy to Move Forward in Parkinson’s Disease Patient Care: Visiting Nurse Faculty Program
Vernon, GV; Bunting-Perry, L (United States)

Community & Quality of Life: Disability and Quality of Life Outcome Measures

P29.05 Balance, Gait Speed Flexibility, And Physical Activity Predict Walking Capacity In People With Parkinson Disease
Ford, MP; Cavanagh, JT; Earhart, GM; Ellis, T; Foreman, KB; Dibble, LE (United States)

P29.06 Relational Quality Of Life In Moldavian Parkinson Disease Patients
Pavlic, G; Moldovanu, I; Odobescu, S; Rotaru, L; Corcea, G (Republic of Moldova)

P29.07 Long-term Benefits Of A Comprehensive Care Model For People With Parkinson (PWP)
Makoutonina, M; Prof. Iansek, R; Hardwick, L (Australia)

P29.08 Relationships Between Gait Hypokinesia And Disability In Community Dwelling Adults With Parkinson’s Disease
Tan, D; Soh, S; Danoudis, M; McGlinley, J; Menz, H; Iansek, R; Murphy, AT; Morris, ME (Australia)

P29.16 An Analysis Of Hope In Parkinson’s Disease
Giroux, ML; Glisky, ML; Farris, SM (United States)

P29.17 Instrumental Activities Of Daily Living Performance In Parkinson Disease Without Dementia
Foster, ER; Watkins, J (United States)

Community & Quality of Life:
Patient / Caregiver / Doctor Community or Healthcare Teams

P30.04 Improving Patient Care Through GP Online Education
Dixon & Hennessy, MT; Dixon, Miriam; Hennessy, T (Australia)

P30.05 Interdisciplinary Care In A Parkinson Disease Center: A Model For Patient Care, Education, Social Service And Community Outreach
Tarsy, D; Simon, D; Shih, L; VanderHorst, V; Silver, A; Gandelman, E; Kapust, L; Kraics, L; Thall, M; O’Connor, M; Harrier, D; Jefferson, D; Wagner, C; Piel, J; Whitmill, A; Matheson, J (United States)

P30.06 Cues To Meet Expectations: Patients From A Interprofessional Evaluation Program
Lepage, C; Lepage, C (Canada)

P30.11 Role Of Patient Support In Shaping Expectations And Decision Making With Deep Brain Stimulation (DBS) Surgery
Klepitskaya, O; Kelsall, K; Graham, VW; McRae, CA (United States)

Community & Quality of Life:
Health Services Accessibility/Underserved Populations

P32.03 Suspected Parkinson’s: Referral And First Clinic Visit To The Specialist In The United Kingdom
Drutyte, G; Breen, K; Robertson, D; Multi-professional Steering, Group (United Kingdom)
Community & Quality of Life: Speech Therapy

P34.01 Guidelines For Speech-language Therapy In Parkinson's Disease

P34.02 Quality Indicators For Speech-language Therapy In Parkinson's Disease
Kalf, J.G.; Munneke, M. (Netherlands)

Community & Quality of Life: Physical and Occupational Therapy

P35.08 Clinical Scales Of Balance And Turning Duration In Parkinson Disease
Rodrigues-de-Paula, F (Brazil); King, LA (United States); Salarian, A (United States); Horak, F (United States)

P35.09 Electromyographic Study Of The Sit-to-walk Movement In Individuals With And Without Parkinson's Disease
Rodrigues-de-Paula, F; Camargos, M; Lana, R; Teixeira-Salmela, LF; Oliveira Lima, L (Brazil)

P35.10 Kinetics And Kinematics Parameters Of The Sit-to-walk Movement In Individuals With Parkinson's Disease
Rodrigues-de-Paula, F; Lana, R; Camargos, M; Teixeira-Salmela, LF; Oliveira Lima, L (Brazil)

P35.11 Muscular Strength In Individuals With Early Parkinson's Disease
Oliveira Lima, L; Rodrigues-de-Paula, F; Teixeira-Salmela, LF (Brazil)

P35.12 The OTiP Pilot: Design Of A Trial Evaluating The Feasibility Of A Large Scale RCT On The Effectiveness Of Occupational Therapy In Parkinson's Disease
Sturkenboom, IHWM; Nijhuis-van der Sanden, MWG; Bloem, BR; Borm, GF; Graff, MJL; Munneke, M (Netherlands)

Late Breaking Abstracts

LBP36.02 Treatment With Duodenal L-dopa Infusion
Barbagli, D; Gusmaroli, G; Ravagnani, M; Mongiovetti, M; Capone, L; Tarletti, R; Massazza, U; Barbero, E (Italy)

LBP36.06 Mapping Of LRRK2 Phosphorylation Sites - The GTPase Domain Roc Represents A Primary Target For Autophosphorylation
Gloeckner, CJ; Boldt, K; von Zweydorf, F; Helm, S; Meixner, A; Sarioglu, H; Ueffing, M (Germany)

LBP36.07 The Application Of Multivariate Model-building To Derive Predictive Biomarker Signatures In Parkinson’s Disease Patients
Gunselman, SJ (United States); Woodford, TM (United States); Bromwell, DJ (United Kingdom); Chase, BA (United States); Tsintou, M (Greece); Markopoulou, K (Greece)

LBP36.08 Axonal Polyneuropathy During Duodenal Levodopa Teratment In A Woman With Idiopathic Parkinson Disease
Gusmaroli, Graziano; Barbagli, Davide; Ravagnani, Mara; Mongiovetti, Massimo; Capone, Lorenzo; Tarletti, Roberto; Massazza, Umberto; Barbero, Edoardo (Italy)
LBP36.09 The Montreal Cognitive Assessment (MoCA) And Korean Mini-mental State Examination (K-MMSE) In Parkinson's Disease
Kim, SJ; Chung, EJ (Republic of Korea)

LBP36.10 Comparison Of [18F]FDG-PET Findings In PIB(+) Lewy Body Dementia, PIB(-) Lewy Body Dementia And Alzheimer Disease
Kim, J (Republic of Korea); Kim, JS (Republic of Korea); Oh, SJ (Republic of Korea); Kim, SJ (Republic of Korea); You, S (Republic of Korea); Aarsland, D (Norway); Lee, CS (Republic of Korea)

LBP36.11 Long Term Program Of Social Theatre For The Management Of Motor And Motor Symptoms Of Parkinson’s Disease
Modugno, N; Lena, F; Kusch, I; Fiorilli, MG; Mirabella, G (Italy)

LBP36.13 Assessment Of Loneliness In Patients With Parkinson's Disease And Their Caregivers
Oo, MT; Thompson, S (United Kingdom)

LBP36.14 Melanoma And Breast Cancer Among Patients With Parkinson Disease: A Population Based Cohort Study
Rugbjerg, K (Denmark); Friis, S (Denmark); Funch Lassen, C (Denmark); Ritz, B (United States); Schernhammer, E (Denmark); Korbo, L (Denmark); Hansen, J (Denmark); Wermuth, L (Denmark); Bak Jylling, AM (Denmark); Jensen, M-B (Denmark); Olsen, JH (Denmark)
Friday, October 01, 2010 - 12:45 - 14:45

Basic Science: Etiology, Genetics, Epidemiology and Toxicants

P01.19 Sunlight Exposure And Parkinson's Disease In California
   Gatto, N; Cockburn, M; Bronstein, J; Ritz, B (United States)

P01.20 Diabetes Mellitus And Risk Of Parkinson's Disease
   Xu, Q (China); Park, Y (United States); Huang, X (United States); Umbach, D (United States); Hollenbeck, A (United States); Blair, A (United States); Schatzkin, A (United States); Chen, H (United States)

P01.21 Multivitamin Use And Risk Of Parkinson's Disease Among Older Adults
   Xu, Qun (China); Park, Yikyung (United States); Huang, Xuemei (United States); Hollenbeck, Albert (United States); Blair, Aaron (United States); Schatzkin, Arthur (United States); Chen, Honglei (United States)

P01.23 The Relationship Between Blood Levels Of Heavy Metals And Parkinson's Disease In China
   Tan, X; Luo, Y (China)

P01.24 Dietary Characterizes Of Chinese PD Patients: Food Intake Survey Results
   Tan, X; Luo, Y (China)

P01.25 Analysis Of Point Mutations And Single Nucleotide Polymorphisms Effects On Risk Of Development Of Parkinson's Disease In Russia
   Filatova, EV; Shadrina, MI; Slominsky, PA; Karabanov, AV; Illarioshkin, SN; Limborska, SA (Russian Federation)

P01.26 Analysis Of The PARK2 Gene Exon Rearrangements And The SNCA Gene Multiplications In Patients With Parkinson's Disease From Russia
   Semenova, E.V.; Slominsky, P.A.; Bagyeva, G.Kh.; Illarioshkin, S.N.; Shadrina, M.I. (Russia)

P01.33 SNP rs7684318 Of The α-synuclein Gene Is Associated With Parkinson's Disease In Chinese Han Population
   Xu, Y; Yu, L; Xu, P; He, X; Hu, F; Lin, Z; Zhu, M; Liu, Z; He, L (China)

P01.34 Pilot Study Of Nosological Spectrum Of Neurodegenerative Parkinsonism In Georgia
   Khatiashvili, I; Megrelishvili, M; Janelidze, M; Lobjanidze, N (Republic of Georgia)

P01.35 Parkinsonian Syndrome After Carbon Monoxide Poisoning With Good Response On Dopaminergic Therapy
   Miletie, V; Relja, M (Croatia)

P01.36 Total, LDL, And HDL Cholesterol And Parkinson's Disease In Men And Women
   O'Reilly, Elis J; Simon, KC; Gao, X; Ascherio, A (United States)

Basic Science: Cell Death Mechanisms, Neuroprotection and Trophic Factors

P02.11 Phosphatase Profile In Cassava (Manihot esculenta) Induced Neurotoxicity; Role In Neuronal Degeneration.
   Ogundele, OM; Jimoh, OR; Ghazal, OK; Caxton-Martins, EA (Nigeria)

P02.12 Mode Of Neuronal Cell Death In Potassium Hexacyanoferrate Induced Parkinson-like Symptoms In Adult Wistar Rats
   Ogundele, OM; Jimoh, OR; Ghazal, OK; Caxton-Martins, EA (Nigeria)
Friday Scientific Posters (12:45 - 14:45)

P02.13 Cannabinoids Are Neuroprotective In A Human Cell Culture Model Of Parkinson’s Disease
Carroll, CB; Zeissler, ML; Stone, V; Hanemann, CO; Zajicek, JP (United Kingdom)

P02.14 N-acetyl-L-cysteine Prevents Dopamine Toxicity In PC12 Cells: Role Of Toxic Quinones
Maiti, AK; Bagh, MB; Jana, S; Chakrabarti, S; Saha, NC; Paul, G (India)

P02.15 The Roles Of Pitx3 And MicroRNAs In The Differentiation Of Embryonic Stem Cells To Dopamine Neurons
Weidong, L (United States); Dehua, Y (China)

P02.16 GDNF Rescues Injured Da Neurons But Fails To Reduce The α-synuclein-containing Protein Aggregation In UPS Impairment Induced Neurodegeneration Models
Weidong, L (United States); Yuanlan, D (China); Xuping, L (China)

P02.22 Histone Deacetylation Inhibitor Exacerbates Hydrogen-peroxide-induced Cell Death In Neuroblastoma Cell Lines
Page, C; Rose, S; Jenner, P (United Kingdom)

P02.23 Potential Significance Of Oxyresveratrol As Neuroprotective Agent In Different Experimental Models Of Parkinson’s Disease
Chang, RC; Chao, J; Cheung, Y; Hung, CH; Wang, M (Hong Kong)

Basic Science: Protein Misfolding and Handling

P03.05 Alpha-synuclein Is Secreted, Taken Up By Neighbouring Cells And Induces Seeding Of Endogenous Alpha-synuclein
Bergström, AL (Denmark); Kallunki, P (Denmark); Hansen, C (Sweden); Angot, E (Sweden)

P03.08 Regulation Of LRRK2 Kinase Activity By GTP Is Indirect And Requires Upstream Binding Proteins
Taymans, J (Belgium); Gao, F (Belgium); Beilina, A (United States); Lobbestael, V (Belgium); Bekelandt, V (Belgium); Cookson, M (United States)

Basic Science: Mitochondria, Oxidative Stress, Inflammation & Other Pathogeneses

P04.12 Ablation Of Major Histocompatibility Complex II Provides Neuroprotection In The MPTP Mouse Model Of Parkinson’s Disease
Martin, HL; Sathe, K; Mustafa, S; Forrester, JV; Teismann, P (United Kingdom)

P04.13 Dopamine Metabolism By Monoamine Oxidase Is Connected To Oxidative Stress In The Rat Brain
Aluf, Y; Vaya, J; Khatib, S; Finberg, JPM (Israel)

P04.14 Changes In Iron-regulatory Gene Expression Occur In Human Cell Culture Models Of PD
Carroll, CB; Zeissler, ML; Chadborn, N; Gibson, K; Williams, GJ; Morrison, KE; Zajicek, JP; Hanemann, CO (United Kingdom)

P04.15 Promyelocytic Leukaemia Protein Inclusion Bodies In Parkinsonian Astrocytes
Evans, J (United Kingdom); Durrenberger, PF (United Kingdom); Reynolds, R (United Kingdom); Grünblatt, E (Germany); Dexter, DT (United Kingdom)

P04.16 Suppression Of MPTP-induced Neurotoxicity In Mice By NS-398, A Selective Cyclooxygenase (COX)-2 Inhibitor: Role Of Caspase–3 And NF-kB Cascade
Gupta, A; Kumar, A; Kulkarni, SK (India)
P04.21 Synuclein-mediated Microglial Activation And Oxidative Stress In Parkinson’s Disease
*Maguire-Zeiss, KA*; Joseph, D; Feng, LR; Trecki, J; Federoff, HJ; Yehling, E; Mhyre, T (United States)

P04.22 Mitochondrial Alterations In Parkinson’s Disease
*Baloyannis, S* (Greece)

**Basic Science: Pathology**

P05.05 Tissue Transglutaminase Locates To ER In Parkinson’s Disease: A Novel Mechanism Linking Neuronal Stress To Protein Aggregation?
*Wilhelmus, M* (Netherlands); Verhaar, R (Netherlands); Bol, J (Netherlands); Jongenelen, C (Netherlands); Andringa, G (Netherlands); Cras, P (Belgium); Hoozemans, J (Netherlands); Drukarch, B (Netherlands)

P05.06 Parkinson’s UK Tissue Bank: High Quality Human Brain, Spinal Cord And CSF Samples Available For Parkinson’s Research
*Dexter, D*; Gveric, D; Reynolds, R; Gentleman, S; Middleton, L; Roncaroli, F (United Kingdom)

**Basic Science: Animal and Cellular Models**

P06.01 Acute Effects Of Spinal Cord Stimulation In Large-scale Brain Circuits In A Transgenic Mouse Parkinson’s Model.
*Fuentes, R* (Brazil); Dzirasa, K; Nicolelis, MAL (Brazil)

P06.11 Characterisation Of Behavioural And Neurodegenerative Changes Induced By Intranigral 6-Hydroxydopamine Lesions In A Mouse Model Of Parkinson’s Disease
*Grealish, S*; Mattsson, B; Draxler, P; Björklund, A (Sweden)

P06.12 Characterization Of Transgenic Mice Overexpressing Human Mutated α-Synuclein Or With Mouse G2019S LRRK2
*O’Neill, MJ* (United Kingdom); Murray, TK (United Kingdom); Cooper, J (United Kingdom); Buckner, N (United Kingdom); Browne, E (United Kingdom); Cella, CV (United Kingdom); Knopp, KL (United States); Evans, C (United Kingdom); Ward, MA (United Kingdom); Poling, JD (United States); Bruce, C (United States); Eberle, E (United States); Mitchell, SN (United Kingdom); Merchant, KM (United States)

P06.13 Inhibition Of The Prostaglandin E2 Receptor Subtype P1 Provides Neuroroprotection In The Mptp-model Of Parkinson’s Disease
*Mustafa, S*; Mounsey, RB; Sathe, K; Martin, HL; Hsieh, Y-C; *Teismann, P* (United Kingdom)

P06.14 Biochemical Characterization Of Full-length Human Recombinant LRRK1 And LRRK2
*Civiero, L* (Italy); *Civiero, L* (Italy); Taymans, JM (Belgium); Beilina, A (United States); Cookson, MR (United States); Baekelandt, V (Belgium); Bubacco, L (Italy); Greggio, E (Italy)

P06.15 The Role Of Norepinephrine Neurons In Motor Symptoms Of Parkinson’s Disease And Development Of L-DOPA-induced Dyskinesia
*Shin, E*; Björklund, A; Carta, M (Sweden)

P06.16 Motor Recovery After Retinal Pigment Epithelial (RPE) Cells Implantation In The Rat Model Of Parkinson’s Disease (PD)
*Gambhir, H*; Vivekanandhan, S; Goyal, V; Mathur, R; Behari, M (India)
**Friday Scientific Posters (12:45 - 14:45)**

### Basic Science: Dopamine, Receptors and Other Neurotransmitters

**P08.03** The Contribution Of 123-I MIBG And 123 I-FP-CIT SPECT (DaTscan) Imaging In The Detection Of Early Parkinson's Disease The Contribution Of 123....
*Geronikola-Trapali, X; Armeniakos, I; Georgakopoulos, A; Karabina, P; Stefanoyannis, A; Bakalis, S; Lyra, V; Zotou, P; Labrakopoulos, G; Prentakis, A; Stefanis, L (Greece)*

**P08.04** Regulation Of AAV-mediated Continuous DOPA Delivery Using Destabilizing Domains
*Björklund, T; Ahlm Cederfjall, E; Kirik, D (Sweden)*

### Basic Science: Neuropharmacology

**P10.04** Protective Effect Of Flavonoids Against 3-nitropropionic Acid Induced Cognitive Dysfunction, Glutathione And Mitochondrial Alterations In Rats
*Bansal, P; Kalonia, H; Kumar, A (India)*

**P10.10** Substrate Kinetics Plasma Membrane Na, K-ATPase In Parkinson's Disease
*Ericjovicic, MM; Kostic, VS; Sterinic, N; Rakic, LJ (Serbia)*

**P10.11** Continuous Administration Of Rotigotine Enhances Wakefulness But May Deepen Sleep In 6-OHDA Lesioned Rats.
*Scheller, Dieter (Belgium); Dürmüller, N (France); Peyon, G (France); Esneault, E (France); Moser, P (France)*

**P10.12** Delivering Carbidopa Subcutaneously Enhances Levodopa Pharmacokinetics: A New Strategy For Controlling Motor Fluctuations
*Yacoby-Zeevi, O (Israel); Oren, S (Israel); LeWitt, P (United States)*

### Basic Science: Electrophysiology

**P11.02** Blink Reflex Excitability In Parkinson's Disease And Amyotrophic Lateral Sclerosis
*Gutierrez, J (Cuba); Lara, G (Cuba); Esteban, E M (Cuba); Zaldivar, T (Cuba); Garofalo, N (Cuba); Hernández, Héctor (Cuba); Hardiman, O (Ireland)*

**P11.05** Time-frequency Analysis Of Brain Electrical Activity In Early And Advanced Parkinson Patients By Wavelet Transform Method
*Gabova, AV; Kuznetsova, GD; Gnezditski, WV; Korolyov, MS; Obukhov, YuV (Russian Federation)*

### Clinical Science: Symptoms, Signs, Clinical Features and Progression

**P13.24** Young Onset Parkinson's: Characteristic Movement Disorders And Profile Of An Australian Sample
*Tan, JL; McGinley, JL; Danoudis, M; Watts, JJ; Menz, HB; Iansek, R; Murphy, AT; Morris, ME (Australia)*

**P13.25** Does Peripheral Neuropathy Worsen Balance Performance & Functional Mobility In Persons With Parkinson Disease?
*Dibble, LE; Covanaugh, JT; Earhart, GM; Ellis, T; Ford, MP; Foreman, KB (United States)*

**P13.26** Accumulation Of Comorbidities Worsens Functional Mobility, Motor Deficits, And Quality Of Life In Persons With Parkinson Disease
*Dibble, LE; Covanaugh, JT; Earhart, GM; Ellis, T; Ford, MP; Foreman, KB (United States)*

**P13.27** Amplitude And Duration Of Anticipatory Postural Adjustments Are Dependent On Acceleration And Remain Unchanged In Parkinson's Disease
*Hall, L; Brauer, S; Hodges, P (Australia)*
Friday Scientific Posters (12:45 - 14:45)

P13.28 Association Between Cancer And LRRK2 Mutations In Parkinson's Disease Patients
Inzelberg, R; Hassin-Boer, S; Cohen, OS; Aharon-Peretz, J; Schlesinger, I; Gershoni, R; Djaldetti, R; Schechtman, E; Friedman, E (Israel)

P13.29 An Unexpected Clinical Progression In A Parkinson’s Disease Patient.
Jackson, S J; Sheridan, R P (United Kingdom)

P13.30 PERFORM: A System For The Home Monitoring And Management Of Persons With Neurodegenerative Motor Disorders
Greenlaw, RBL (United Kingdom); Konitsiotis, S (Greece); Baga, D (Greece); Bougio, P (Greece); Pastor, M (Spain); Pansera, M (Spain); Fotiadis, D (Greece)

P13.31 A Rare Coincidental Case Of Early Onset Parkinson’s Disease And Multiple Sclerosis
Jackson, S J; Harrower, T P (United Kingdom)

P13.32 Gait Variability In Parkinson’s Disease: Influence Of Walking Speed And Medications
Bryant, M.S.; Rintala, D.H.; Fernandez, A.L.; Charness, A; Hou, J.G.; Lai, E.C.; Protas, E.J. (United States)

P13.33 What Combination Of Tests Best Identifies Fallers In People With Parkinson Disease?
Earhart, GM; Cavanaugh, JT; Ellis, T; Ford, MP; Foreman, KB; Dibble, LE (United States)

P13.34 The 9 Hole Peg Test: What Does It Really Measure In People With Parkinson Disease?
Earhart, GM; Cavanaugh, JT; Ellis, T; Ford, MP; Foreman, KB; Dibble, LE (United States)

P13.35 Diagnosing PSP-P In Clinical Practice- Clues To Diagnosis And Distinction From Richardson Syndrome And Idiopathic Parkinson's Disease
Nehru, R; Batla, A; Puri, SK (India)

P13.36 The Parkinson's Progression Markers Initiative: A Prospective Biomarkers Study
Sherer, T (United States); Chowdhury, S (United States); Frasier, M (United States); Eberling, J (United States); Ravina, B (United States); Siderowf, A (United States); Scherzer, C (United States); Jennings, D (United States); Tanner, C (United States); Kieburz, K (United States); Ansbach, A (United States); Mollenhauer, B (Germany); Seibyl, J (United States); Coffey, C (United States); Toga, A (United States); Shaw, L (United States); Trojanowski, J (United States); Marek, K (United States)

P13.37 Oculomotor And Visual Perceptual Changes Associated With Parkinson’s Disease Without Dementia
Zylstra, A; Glisky, M; Bollen, K (United States)

P13.38 Review And Intervention Of Patients With Parkinson’s Disease By Community Pharmacist
Benson, P; Cotton, PA; Miller, C (United Kingdom)

P13.45 Parkinson Disease, Clinic Characteristics In A Mexican Population. Prospective Observational Study, Preliminary Report
León-Jiménez, C; Martínez-Coronel, J; Shobe-Lim, G; Vega-Gaxiola, SB; Garcia-Bravo, MS; Cortes-Sanabria, L (Mexico)

Clinical Science: Non-motor Features

P14.11 A Community-based Study Of Parkinson's Non-motor Symptoms
Breen, K; Drutyte, G (United Kingdom)

P14.12 Poor Executive Function, Neuron Loss, And Gliosis In The Locus Coeruleus: The Honolulu-Asia Aging Study
Petrovitch, H; Abbott, RD; Ross, GW; Uyehara-Lock, J; White, LR (United States)
Friday Scientific Posters (12:45 - 14:45)

P14.13 Anhedonia In Parkinson's Disease: Analysis Using Snaith-Hamilton Pleasure Scale
Miura, S; Kida, H; Noda, K; Kaku, Y; Nagasato, K; Ayabe, M; Aizawa, H; Taniwaki, T (Japan)

P14.14 The Prevalence And Frequency Of Gastrointestinal Symptoms In Patients With Newly Diagnosed Parkinson's Disease
Kim, JS; Sung, HY; Song, IU; Lee, KS; Kim, HT (Republic of Korea)

P14.15 Non-motor Symptoms In Thai Parkinson's Disease Patients
Vongvaivanich, K; Nidhinandana, S; Sithinamsuwan, P (Thailand)

P14.16 Restless Leg Syndrome On Various Stages Of Parkinson's Disease (Pilot Study)
Akhvlediani, K; Khatiashvili, I; Kasradze, S; Kapianidze, M (Republic of Georgia)

P14.17 Autonomic Dysfunctions In Parkinsonian Disorders
Kim, Jae W; Bae, HJ; Cheon, SM (Republic of Korea)

P14.18 Somatoform Disorders In Parkinson's Disease And Dementia With Lewy Bodies
Onofrj, M; Manzoli, L; Bonanni, L; Gambi, F; Onofrj, V; Bifolchetti, S; Thomas, A (Italy)

P14.19 Frequency Of Non-motor Symptoms In Parkinson's Disease Patients
Manso, R.; Sevillano, M.D. (Spain)

Clinical Science: Biomarkers and Neuroimaging

P15.13 Putaminal Abnormality On 3T Magnetic Resonance Imaging In Early Parkinsonism Predominant Multiple System Atrophy
Lee, JY; Yun, JY; Shin, CW; Kim, HJ; Jeon, BS (Republic of Korea)

P15.14 Regional Cerebral Blood Flow In Parkinson's Disease
Horiuchi, E; Hasegawa, K; Yokoyama, T (Japan)

P15.15 Parkinson's Disease Markers In REM Sleep Behavior Disorder
Schiess, M; Hood, AJ; Bick, RJ; Ephron, VJ; Castriotta, R; Furr-Stimming, E; Ellmore, T (United States)

P15.16 Ephedrine Encephalopathy: Correlation Between Clinical Course And Hyperintensivity Of The Basal Ganglia On The T1-weighted MRI Images
Lobjanidze, N; Khatiashvili, I; Janelidze, M; Melikidze, E; Kvirvelia, N; Beridze, Maia; Shalikashvili, Maia (Republic of Georgia)

P15.17 Identification Of Plasma Glycoproteins Unique To Diagnosis And Correlated With Severity Of Parkinson's Disease
Pan, C; Hwang, H; Zhang, J; Hancock, A; Shi, M; Chung, K; Leverenz, J; Zabetian, C; Peskind, E; Jankovic, J; Quinn, J; Galasko, D; Zhang, J (United States)

P15.18 Olfactory Testing And Diffusion Tensor Imaging Of Olfactory Tract And Substantia Nigra In Early Parkinson's Disease
Robertson, HA (Canada); Rolheiser, TM (Canada); Fulton, H. (Canada); Good, KP (Canada); Leslie, RA (Canada); Fisk, J.D. (Canada); Mc Kelvey, J.R. (Canada); Schoffer, K (Canada); Khan, N.M. (Canada); Scherfler, C (Austria)

P15.21 Cerebrospinal Fluid Alpha-synuclein Levels As A Biomarker For Lewy Body Disease
Mann, D; Foulds, P; Allsop, D (United Kingdom)

P15.22 Identification And Characterization Of Parkinson's Disease In Asymptomatic Patients
Pasinetti, G (United States)
Clinical Science: Medical Therapy

P16.12 Apomorphine Infusion In An Advanced Parkinson's Disease Patient With Prominent Tremor Refractory To Oral Treatment Strategies
Aygun, D; Gungor, L; Onar, M; Yazici, D (Turkey)

P16.13 H Pylori Eradication For Parkinson's Disease
Rees, K; Stowe, R; Patel, S; Ives, N; Breen, K; Clarke, CE; Ben-Shlomo, Y (United Kingdom)

P16.14 Anti-hypertensive Drugs As Disease-modifying Agents For Parkinson's Disease: Evidence From Observational Studies And Clinical Trials
Rees, K; Stowe, R; Patel, S; Ives, N; Breen, K; Ben-Shlomo, Y; Clarke, CE (United Kingdom)

P16.15 Non-steroidal Anti-inflammatory Drugs As Disease Modifying Agents For Parkinson’s Disease: Evidence From Observational Studies
Rees, K; Stowe, R; Patel, S; Ives, N; Breen, K; Ben-Shlomo, Y; Clarke, CE (United Kingdom)

P16.16 Systematic Review Of Levodopa Dose Equivalency Reporting In Parkinson’s Disease
Tomlinson, CL; Stowe, R; Patel, S; Rick, C; Gray, R; Clarke, CE (United Kingdom)

P16.17 Gastrointestinal Disorders In Patients With Parkinson’s Disease (PD): A Double-edged Sword
Richy, Florent (Belgium); Gunn, A (Belgium); Makaroff, L (Belgium); Gervasoni, C (Belgium); Helmers, S (United States)

P16.18 Initial Diagnosis And Treatment Patterns In Parkinson’s Disease
Tarrants, ML; Lage, MJ; Castelli-Haley, J (United States)

Clinical Science: Surgical Therapy

P17.07 Deep Brain Stimulation For Early Parkinson’s Disease
Kao, C; Remple, M; Charles, D; Neimat, J; Konrad, P (United States)

P17.08 Effect Of Deep Brain Stimulation Of The STN On Novel Metrics Of Habitual Physical Activity Patterns In Advanced Parkinson’s Disease
Rochester, L; Chastin, SFM; Baker, K; Jones, D; Burn, DJ (United Kingdom)

P17.12 Economic Evaluation Of Deep Brain Stimulation: Results From The PDSURG Trial
McIntosh, E (United Kingdom)

P17.13 Comparison Of Microelectrode Versus Magnetic Resonance Imaging Targeting In Parkinson’s Disease Patients Undergoing Pallidal Deep Brain Stimulation
Evidente, VG; Ziemba, K; Lyons, M (United States)

Clinical Science: Complications of Therapy

P18.03 Immunohistochemical Detection Of Fosb/Δfosb-like Proteins Maps Areas Of Maladaptive Neuroplasticity In The Post-mortem Parkinsonian Brain
Lindgren, HS (Sweden); O’Sullivan, SS (United Kingdom); Lees, AJ (United Kingdom); Cenci, MA (Sweden)
Clinical Science: Clinical Trials

P19.16 Design Of A Randomized Controlled Trial Evaluating The Effectiveness Of A Multifaceted Program To Increase Physical Activity In Parkinson Patients
Speelman, AD; van Nimwegen, ML; Smulders, K; Overeem, S; Born, GF; Backx, FJG; Bloem, BR; Munneke, M (Netherlands)

P19.17 Study Of Intracerebroventricular Administration Of SNN0031 (rhPDGF-BB) To Patients With Parkinson’s Disease (PD), Using An Implanted Pump System
Paul, G; Widner, H; Pålhagen, S; Rehncrona, S; Lind, G; Linderoth, B; Bjartmarz, H; Jansson, K; Herne, N; Zachrisson, O; Haegerstrand, A; Almqvist, P (Sweden)

P19.18 A Multicenter Randomized, Double-blind, Placebo-controlled Trial Of Paroxetine And Venlafaxine Extended Release For Depression In Parkinson’s Disease
Richard, IH; McDermott, M; McDonald, W.M. (United States)

P19.19 Transcranial Magnetic Stimulation In Parkinsons Disease Improvement In Motor Symptoms And Correlation With fMRI
Soto, J (Mexico)

P19.20 Systematic Overview Of Randomised Trials Of Physiotherapy In Parkinson’s Disease
Patel, S; Tomlinson, CL; Stowe, R; Meek, C; Clarke, CE; Sackley, C; Ives, N (United Kingdom)

P19.21 Should PD Treatment Be Started Immediately On Diagnosis Or Delayed Until Functional Disability Develops? Meta-analysis Of Delayed-start Design Trials
Clarke, CE; Ives, N; Patel, S; Rick, C; Wheatley, K; Gray, R (United Kingdom)

P19.22 A Large Randomised Assessment Of The Relative Cost-effectiveness Of Different Classes Of Drugs For Parkinson’s Disease (PD MED Trial)
Patel, S; Cheed, V; Ives, N; Clarke, CE; Rick, C; Wheatley, K; Gray, R (United Kingdom)

P19.28 Camptocormia And Abnormal Axial Posture: Clinical, Fisiopathological Characterization And Therapy
Pimazzoni, F; Ferlisi, M; Tommasi, G; Fiaschi, A; Bertolasi, L (Italy)

Clinical Science: Non-pharmacologic Therapies

P20.05 The Effectiveness Of Different Cueing Devices For People With Parkinson's Disease And Gait Initiation Difficulties
McCandless, P; Evans, B; Richards, J; Selfe, J; Churchill, A (United Kingdom)

Clinical Science: Rating Scales

P21.09 Patient Versus Informant Reporting Of ICD Symptoms In Parkinson’s Disease: Agreement And Validity
Weintraub, D; Papay, K; Mamikonyan, E; Siderowf, A; Duda, J; Stern, M (United States)

P21.10 Typical Physical Activity Levels In People With Parkinson Disease: Effect Of Disease State, Gender And Age
Ellis, T; Cavanaugh, JT; Earhart, GM; Ford, MP; Foreman, KB; Dibble, LE (United States)

P21.11 Which UPDRS Motor / Mobility Items Best Predict Quality Of Life In People With Parkinson’s Disease?
Ellis, T; Cavanaugh, JT; Earhart, GM; Ford, MP; Foreman, KB; Dibble, LE (United States)
Friday Scientific Posters (12:45 - 14:45)

P21.12 Initial Validation Of A Self Administered Version Of The Freezing Of Gait Questionnaire (FOGQsa)
Nilsson, MH; Wictorin, K; Bladh, S; Högstedt, Å; Eliasson, M; Toreld, C; Reimer, J; Hagell, P (Sweden)

Clinical Science: Behavioral Disorders

P22.04 Prevalence And Peculiarities Of Neuropsychiatry In Not Treated Non-demented Parkinson Disease
Lobjanidze, N; Janelidze, M; Beridze, M; Kvirvelia, N; Maisuradze, T; Akiashvili, N (Republic of Georgia)

P22.05 Clinical Characteristics Of Impulse Control Disorders In People With Idiopathic Parkinson’s Disease
Kim, JY; Kim, MJ; Baik, JS; Koh, SB (Republic of Korea)

Clinical Science: Cognition

P23.11 How Well Can Screening Instruments Discriminate Among PD Patients With Normal Cognition, Mild Impairments, And Dementia?
Watson, GS; Thomas, S; Zabetian, CP; Gerton, BK; Kim, HM; Samii, A; Schantz, A; Leverenz, JB (United States)

P23.12 Clinico-Demographical Correlations Of Dementia In Pathologically Confirmed PD
Selikhova, M (United Kingdom); O’Sullivan, SS (United Kingdom); Guekht, A (Russia); Revesz, T (United Kingdom); Lees, A (United Kingdom)

P23.13 Applause Sign And Cognitive Deficit In Parkinson Disease Patients
Tomic, S; Vladetic, M; Cosic, A; Butkovic-Soldo, S; Misevic, S; Soldo, A (Croatia)

P23.14 Gray Matter Atrophy And Severity Of Cognitive Impairment In Parkinson’s Disease
Weintraub, D; Weintraub, D; Doshi, J; Davatzikos, C; Siderowf, A; Duda, J; Xie, S; Clark, C (United States)

P23.15 Study About Relationship Between Depression And Cognitive Impairment In Parkinson Disease Patients
Pirscoveanu, Denisa; Pirscoveanu, D; Zaharia, C; Tudorica, V; Trifan, F; Matcau, D (Romania)

P23.19 Old Age, Lower Education, And Activity Of Daily Living Are The Predictors Of Cognitive Impairment In Mongolian Patients With Parkinson's Disease
Baatar, K; Tserensodnom, B (Mongolia)

Community & Quality of Life: Family Care, Caregiving, Relationships

P25.05 Community Administered Of PD In Xiangfan, Hubei, China
Luo, Y; Tan, X (China)

P25.06 Elderly Couples In Transition: Their Experiences At The Moderate Stage Of Parkinson’s
Beaudet, L; Ducharme, F (Canada)

Community & Quality of Life: Fitness, Wellness, Nutrition

P26.04 Serum Cu Fe Mn Zn Levels And Parkinsons’s Disease
Tan, Xiaodong; Luo, Yunwen (China)
Community & Quality of Life: Education: Lay and Professional/Health Literacy

P28.08 Learning About Parkinson’s Disease (PD) Through Poetry And Pictures
Jones, D.E.; Powell, S.; Taylor, T. (United Kingdom)

P28.09 Information Seeking Behavior Of People With Parkinson’s And Their Care Partners
Wiener, P; Elliott, R (United States)

P28.10 Measuring The Readability Of Online Patient Orientated Parkinson’s Disease Information
Fitzsimmons, P; Michael, BD; Hulley, J; Horner, M; Scott, GO (United Kingdom)

Community & Quality of Life: Disability and Quality of Life Outcome Measures

P29.09 Activity Levels In Parkinson Disease: Self-assessment And Predictive Factors
Rotello, JMM; Earhart, GM (United States)

P29.10 Relationships Between Participation, Quality Of Life And Mobility In Individuals With Parkinson Disease
Duncan, RP; Earhart, GM (United States)

P29.11 Ten-meter Walking Time And Six-minute Walking Distance In Thai Non-disabled Elderly
Foongchomcheay, A (Thailand)

P29.12 What Features Of Parkinson Disease Impact Disability And Quality Of Life?
Shulman, LM; Gruber-Baldini, AL; Anderson, KE; Robottom, B; Fishman, PS; Reich, SG; Weiner, WJ (United States)

P29.18 Clinically Relevant Difference In Health-related Quality Of Life Following 24-hour Transdermal Delivery Of Rotigotine In Parkinson’s Disease Patients
Kulich, K; Mueller, K (Belgium)

P29.19 Disability In Newly Diagnosed PD. Symptoms Associated With Reception Of Public Home Care Service
Brønnick, K; Alves, G.; Dahle, H.A.; Leiknes, I; Tysnes, O.B.; Larsen, J.P. (Norway)

Community & Quality of Life: Patient / Caregiver / Doctor Community or Healthcare Teams

P30.07 Moving Towards Patient Centered Healthcare For Patients With Parkinson’s Disease In The Netherlands
van der Eijk, M; Faber, MJ; Munneke, M; Bloem, B R. (Netherlands)

P30.08 Developing Northumbria Parkinson’s Disease Information Service
Hand, A; Walker, R; Greenwell, K; Corbett, S; Hulland, E; Finlayson, A (United Kingdom)

P30.12 A Web Application For Follow-up Of Results From A Mobile Device Test Battery For Parkinson’s Disease Patients
Memedi, M; Westin, J; Nyholm, D; Dougherty, M; Groth, T (Sweden)

Community & Quality of Life: Health Services Accessibility/Underserved Populations

P32.05 Knowledge Of Disease And Attitude Toward Treatment In Patients With Parkinson Disease: A Hospital–based Questionnaire Study
Kim, HJ; Kim, J; Jeon, BS; Cho, J; Yun, JY; Lee, JY (Republic of Korea)
Friday Scientific Posters (12:45 - 14:45)

P32.06 An Analysis Of The Needs Of Homebound Patients With Parkinson's Disease And Their Caregivers In The Indian Subcontinent - A Qualitative Study
Barretto, M; Singhal, BS; Lalkaka, J; Wadia, P; Devare, S (India)

P32.07A Parkinson's Review Clinic Within A Care Home Setting
Edmonds, P P; Ullyart, K A (United Kingdom)

Community & Quality of Life: Physical and Occupational Therapy

P35.14 Effectiveness Of An Enhanced Multidisciplinary Community Based Group Program For Parkinson's Disease
Peters, C; Currin, M; Rogers, A; Tyson, S; Comans, T; Healy, S; McPhail, S; Heathcote, K; Brauer, S (Australia)

P35.15 Assessment Of Upper Limb Function In People With Parkinson's Disease: A Survey Of Therapist Practice
Proud, EL; Miller, KJ; Martin, CL; Morris, ME (Australia)

P35.16 Effects Of An Intensive Multitask Gait Training Program On Spatiotemporal Gait Parameters And Falls In Parkinson Disease: A Case Study
Domingos, J.M.M; Melo, F; Godinho, C; Castro-Caldas, A (Portugal)

P35.17 PD REHAB: Randomised Controlled Trial To Study The Effectiveness And Cost-effectiveness Of Physiotherapy And Occupational Therapy For People With PD
Rick, C; Clarke, C; Sackley, C; Walker, M; Ives, N; Patel, Smita; Meek, Charmaine; Yao, Guiping; Wheatley, Keith; On behalf of the PD REHAB, Collaborative Group (United Kingdom)

P35.18 Feasibility Of Abdominal Massage For The Alleviation Of The Symptoms Of Constipation In People With Parkinson's Disease
McClurg, D; Hagen, S; Cunnington, AL; Paul, L (United Kingdom)

P35.19 An Evaluation Of The Benefits Of A Physiotherapist Accompanying The Occupational Therapist On Home Assessment Visits For Parkinson's Patients
Cunnington, AL; Patterson, F (United Kingdom)

P35.21 The Impact Of A 3– Month Group Physiotherapy Exercise Program In Functional Capacity Of Patients With Parkinson Disease
Aftosmidis, D; Rosbaglou, S; Skamagki, G; Sotirelis, A; Pavlou, D; Stefanis, H; Bonstantzopoulou, S; Katsarou, Z (Greece)

Late Breaking Abstracts

LBP36.17 Astrocyte-dependent Protection By Inosine And Urate In A Cellular Model Of Parkinson's Disease
Cipriani, S; Desjardins, CA; Burdett, TC; Xu, Y; Xu, K; Schwarzschild, MA (United States)

LBP36.18 Vascular Endothelial Growth Factor-b186 Improves Motor Behavior In Vivo In A Rat Model Of Parkinson's Disease
Sherman, S.J.; Falk, T; Zhang, S.; Yue, X. (United States)

LBP36.19 The Neurobiology Of Glucocerebrosidase Associated PD: Studies Of Dopamine Synthesis And RCBF In GBA Mutation Carriers With And Without Parkinsonism
Goker-Alpan, O; Masdeu, J; Kohn, P; Lopez, G; Eisenberg, D; Groden, C; Chalfin, M; Ianni, A; Berman, KF; Sidransky, E (United States)
LBP36.20 Umbelliferone And Esculetin Prevent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Nigrostriatal Neurotoxicity In C57BL/6J Mice
Subramaniam, SR; Ellis, EM (United Kingdom)

LBP36.21 Somatosensory Processing In Parkinson's Disease
Sun, Xing; Hoque, T; Gunraj, C; Nelson, AJ; Chen, R (Canada)

LBP36.22 Indirect Comparison Of Adverse Events And Dropout Rates For Early Parkinson's Disease (PD) Monotherapy Trials: Pramipexole, Ropinirole And Rasagiline
Tarrant, MT; Zagmutt, FJ (United States)

LBP36.24 Medullo-spinal Circuitries Controlling Different Aspects Of Gait
VanderHorst, VG; Saper, CB (United States)

LBP36.25 Impulse Control Disorders Subtypes In Parkinson’s Disease: Clinical And Pet Correlations
Wu, K; Politis, M; O’Sullivan, S; Bose, S; Lees, A; Piccini, P (United Kingdom)

LBP36.26 A Molecular Genetic Study Of Parkinson’s Disease In Zambia
Yonova, E (Netherlands); Atadzhanov, M (Zambia); Kelly, P (Zambia); Mwaba, P (Zambia); Kamanga, B (Zambia); Shawa, N (Zambia); Simons, E (Netherlands); Breedveld, G (Netherlands); Bonifati, V (Netherlands)
Wednesday, September 29, 2010 – 12:30 – 14:30

Educational and Awareness Raising Programs

LWP1.01 Partnerships Between Movement Disorders Clinics Nurses And Parkinson Societies Across Canada: Positive Impact On Service Delivery
   Lachance, L (Canada)

LWP1.02 Conductive Education And Parkinson’s Disease
   Heine, M (United Kingdom)

LWP1.04 Addressing The Needs Of Newly Diagnosed PD Patients: Development Of A Model Curriculum
   Cook, DG ; Vierck, E (United States)

LWP1.05 Test Your Parkinson’s Iq: Parkinson Society Canada Awareness Campaign 2010
   Snelgrove, B ; Zacks, M (Canada)

LWP1.06 The Neurowriters’ Guide To The Peripatetic Pursuit Of Parkinson’s Disease (PD): A Preview
   Muralidhar, G (United States); Wittekind, P (United States); Kell, P (United States); Huseman, K (United States); Wheeler, J (United States); Brooks, L (United States); Herman, L (United States); Citron, J (United States); Willacks, P (United States); Ashford, L (United Kingdom); Cummings, R (United States)

Living Healthier with PD

LWP3.01 Partnering With A Community-based Agency To Develop A Comprehensive Parkinson’s Wellness Program
   Gonzalez-Ramos, G ; Di Rocco, A ; Lemen, A ; Cohen, E ; Rossi, R (United States)

LWP3.02 The Layne Library, Using Social Networking To Improve The Lives Of Parkinson’s Patients
   Bernard, CR Layne , RB ; Gupta, A ; (United States)

LWP3.03 Faster, Longer And Stronger
   Kancilija Stanièiæ, A (Slovenia)

LWP3.04 “Think Big” And “Feel Big” With Parkinson’s Disease
   Tamir, R; Pessach, L; Lif Kimchi, O (Israel)

LWP3.05 Beyond Medication: An Integral Rehabilitation Program For Patients With Parkinson’s Disease
   Costa, AR ; Martins, FC ; Marques, JM ; Ferreira, LS ; Kummer, W ; Moreira, HBT ; Alves, PG ; Paranhos, T ; Verissimo, MV ; Barbosa, AP (Brazil)

LWP3.06 How The Power And Safety Of Water Helps People Cope With Parkinson’s Disease
   Williams, DT (United Kingdom)

LWP3.07 S.O.S -Electronic Passport For Parkinson’s
   Raican, D (Romania)

LWP3.14 European Parkinson’s Disease Association (EPDA) Multilingual Website On Coping Strategies. Tricks Created By People With Parkinson’s Disease
   Graziano, M (Luxembourg)
Influencing Research Through Fundraising, Clinical Trials, Grassroots Campaigns

LWP4.01 Declaration Of Clinical Rights And Responsibilities For People With Parkinson’s
Burns, JE; Herman, LA; Jedlinski, S; Cohen, P; DeCamp, W; Planton, S; Stephenson, C; Willocks, P (United States)

General Topics

LWP5.01 Rural Outreach Clinic In Rural Otago (New Zealand)
Ryan, PV (New Zealand)

LWP5.02 Quality Criteria From The Patient’s Perspective
van der Koik, TA; Struiksma, AJC (Netherlands)

Thursday, September 30, 2010 – 11:30 – 13:30

Educational and Awareness Raising Programs

LWP1.03 Communication, Cooperation, Community. The “Triple C” Rule To Raise Awareness On YOPD
Capitanio, F (Spain)

LWP1.07 Blogging By People With Parkinson’s Disease: An Assessment Of Two “Motivational” Patient Blogs In Terms Of Purpose, Positivity And Popularity
Stamford, JA (United Kingdom); Kuhn, RG (Canada)

LWP1.08 Working And Crossing National And Cultural Boundaries To Spread Parkinson’s Awareness
Capitanio, F (Spain); Burns, JE (United States); Martinez, C (United States)

LWP1.09 “Pop-in” A Rolling Educational Programme For Parkinson’s Disease Patients And Their Families
Thompson, C; Atkins, S; Utting, B; Amar, Khaled (United Kingdom)

LWP1.10 Music And Parkinson’s Disease: “My Life”
Griffith, G (United States)

LWP1.11 Simulation Based On An Unfolding Case Study “Living With Parkinson’s Disease: An American Experience”
McCormick, M (United States)

Living Healthier with PD

LWP3.08 Dream! Act! Live! Life After Diagnosis: How To Live Your Best Life Now!
Bischoff, T (United States)

LWP3.09 How Team Parkinson Helps PD Patients Achieve A Better Quality Of Life
Ball, John G. (United States)

LWP3.10 Every Victory Counts: A Patient Care Program Offering Inspiration And Self Care Support For Living Well With Parkinson’s Disease
Howard, A; Giroux, ML; Farris, SM (United States)
Living with Parkinson’s Posters

LWP3.11 The Parkinson’s Self Assessment Tool
Matthews, H; Ashton, J; Heisters, D (United Kingdom)

LWP3.12 Parkinson’s Stepping Forward Salsa And The Benefits Of Dance
Côté, D; Tano, NB; Rowat, KM; Grimes, DA (Canada)

LWP3.13 Creating A Specialist Speech And Language Therapy Service For People With PD In East Dorset: Making A Difference
Owens, S; Reynolds, H; Amar, K (United Kingdom)

LWP3.19 Examining The Potential Of A Shared Education And Training Program To Increase The Psycho-social Quality Of Life In PwPs
Morgan, L; Todaro, V; Hunter, C (United States)

Influencing Research Through Fundraising, Clinical Trials, Grassroots Campaigns

LWP4.02 Patient Involvement In Parkinson’s Research - 20 Years Of Spring
Hill, F; Holme, CA; Telford, JR (United Kingdom)

General Topics

LWP5.03 Reducing The Burden Of Parkinson’s Disease
Emr, M; Sieber, B-A (United States)

LWP5.04 From Car Park To Commissioning
Huston, C; Looker, J (United Kingdom)

Friday, October 01, 2010 – 12:45 – 14:45

Educational and Awareness Raising Programs

LWP1.12 Facing The Future With Parkinson’s
Dixon, M (Australia)

LWP1.13 The Grassroots Effort To Make The PD Tulip The National Symbol For Parkinson’s Awareness In The United States
Burns, JE (United States)

Robledo, I (United States)

LWP1.15 A Picture Can Make A Movement
Zikos, P; Berri, S; Zouroudis, D; Papatriantafylou, Y; Papageorgiou, K (Greece)

LWP1.16 Parkinson Partners: Coordinate Local Resources For Best Care
Sutherland, DP; Sutherland, DT (United States)
Government Advocacy/Campaigns/Public Policy

LWP2.02  Awareness Of The Need For More Focused Research Into Parkinson's Disease  
Lindvall, S; Skoog, K-G (Sweden)

LWP2.03  www.parkinsonsmovement.org — A Hub For The Parkinson’s Community  
Stamford, J A; & the CPT Patient Advisory Gp, (United Kingdom)

LWP2.01  Life With Parkinson’s Awareness Campaign  
Lindvall, S; Graham, L; Browne, K (United Kingdom)

Living Healthier with PD

LWP3.15  Painting With Parkinson’s: Art As A Therapy For Parkinson’s  
Watson, C; Atkin, AL; Knowles, S; Aimers, N (Australia)

LWP3.16  Sleep Self Management Project - Scotland  
Lynall, A (United Kingdom)

LWP3.17  Achieving The Impossible Together  
Young, H; Dumitru, E; Hernandez, AJ (United States)

Farley, BG; Stepan, K; Urquhart, M; Christenson, S; Nelson, M (United States)

General Topics

LWP5.05  Learning From Online Discussions About Parkinson’s Disease Amongst People With Parkinson’s And Their Carers  
Verhaeghe, A; Elleboudt, L (Belgium)

LWP5.06  A Qualitative Assessment Of The Educational And Support Needs Of People Living With Parkinson’s Disease  
Lindvall, S (United Kingdom); Graham, L (United Kingdom); O’Brien, E (Belgium); Davis, U (Belgium)
Faculty

Dag Aarseland | Norway ........................................... 28
Patrick Aeberli | Switzerland ............................... 32, 34
Karen Anderson | US ..................................................... 31
Ana Aragon | UK ........................................... 20
Alberto Ascherio | US ........................................... 24
Krystof Bankiewicz | US ........................................ 34
Roger Barker | UK ........................................... 31
Paolo Barone | Italy ........................................... 29
Flint Beal | US ..................................................... 25
Alim Benabd | France ........................................ 29
Henk W. Berendsen | The Netherlands ............. 31
Daniela Berg | Germany ........................................ 24
Anders Björklund | Sweden ........................................ 25
Bastiaan Bloem | The Netherlands ........................................ 24, 27, 31, 34
Vincenzo Bonifati | The Netherlands ............. 31
Melanie Brandabur | US ........................................ 28
Bastiaan Brekenridge | UK ........................................ 35
Kieran Breen | UK ..................................................... 23, 25, 33
Susan Bressman | US ........................................... 30
David Brooks | UK ..................................................... 20, 24
Gila Bronner | Israel ........................................... 19
Jonathan Brotchie | Canada ........................................ 20, 25
Patrik Brundin | Sweden ........................................... 20, 31
Lisette Bunting-Perry | US ........................................ 34
Robert Burke | US ..................................................... 23
David Burn | UK ..................................................... 25, 28, 33, 35
Jean Burns | US ..................................................... 25, 29, 32
Paolo Calabresi | Italy ........................................... 25
Fulvio Capitanio | Spain ........................................... 29
Haley Carpenter | US ..................................................... 26
Manolo Carta | US ..................................................... 25
Julie Carter | US ..................................................... 28, 30
Angela Cenci-Nilsson | Sweden ........................................ 25
Ray Chaudhuri | UK ..................................................... 18, 20, 30
Marie-Françoise Chesselet | US ........................................ 26, 32
Roberto Cilia | Italy ..................................................... 33
David Colin-Thomé | UK ........................................... 26
Cynthia Comella | US ..................................................... 30
Mark Cookson | US ..................................................... 30
Rachel Connor | UK ..................................................... 25
Nabila Dahodwala | US ........................................... 28
Ted Dawson | US ..................................................... 30
Valina Dawson | US ..................................................... 30
Dennis Dickson | US ..................................................... 24
Alessandro Di Rocco | US ........................................... 28
Marlier Dorlöchter | Germany ........................................ 23
Joanne Duff | UK ..................................................... 27
Deborah Elkis-Abuhoff | US ........................................ 25
Robin Elliott | US ..................................................... 25, 35
Andrew Evans | Australia ........................................... 30
Stanley Fahn | US ..................................................... 20, 27, 32, 33
Matt Farrer | US ..................................................... 24, 30, 34
Howard Federoff | US ..................................................... 23, 25
Joaquim Ferreira | Portugal ........................................ 32, 35
Amanda Fogg | UK ..................................................... 27
Steve Ford | UK ..................................................... 20, 23, 26, 31
Cynthia Fox | US ..................................................... 20, 35
Susan Fox | Canada ..................................................... 29, 32
Karl Friedl | US ..................................................... 23, 34
Thomas Gasser | Germany ........................................ 23, 24, 30
Howard Gendelman | US ..................................................... 26
Nir Giladi | Israel ..................................................... 19, 24
Anna Gillespie | UK ..................................................... 27
Richard Glasspool | UK ..................................................... 28
David S. Goldstein | US ..................................................... 32
Mariella Graziano | Luxembourg ........................................ 33, 34
Jim Greene | US ..................................................... 32
Grace Griffith | US ..................................................... 34
Donald Grosset | UK ..................................................... 18, 27, 31
Ming Guo | US ..................................................... 30
Joel Gutierrez | Cuba ..................................................... 28
Barbara Habermann | US ..................................................... 25, 30
Peter Hagell | Sweden ..................................................... 28, 30, 32
Glenda Halliday | Australia ........................................ 24, 27
John Hardy | UK ..................................................... 23, 28
Nobutaka Hattori | Japan ..................................................... 28
Susan Heath | US ..................................................... 29, 34
Peter Heutink | The Netherlands ........................................ 24
Etienne Hirsch | France ..................................................... 26, 32
Katie Hood | US ..................................................... 25
Robert Iansek | Australia ........................................ 19, 28
Lyndsey Isaacs | UK ..................................................... 19
Tom Isaacs | UK ..................................................... 20, 25, 27, 32
Ole Isacson | US ..................................................... 33
David Iverson | US ..................................................... 23
Marjan Jahanshahi | UK ..................................................... 29
Joseph Jankovic | US ..................................................... 18, 26
Carole Joint | UK ..................................................... 29, 30
Ed Kalkman | UK ..................................................... 24
Mark Kaplitt | US ..................................................... 33, 34
Horacio Kaufmann | US ..................................................... 18
Ann Keilthy | Ireland ..................................................... 29, 30
Christopher Kennard | UK ..................................................... 23
Jackie Kennedy | UK ..................................................... 19
Samyra Keus | Netherlands ........................................ 20, 31, 34
Karl Kieburtz | US ..................................................... 32, 33
Deniz Kirik | Sweden ..................................................... 33, 34
Christine Klein | Germany ..................................................... 23
Jeffrey Kordower | US ..................................................... 20, 34
Joachim K. Krauss | Germany ........................................ 18, 20
Faculty

Jaime Kulisevsky | Spain ................................................................. 18
Story Landis | US ............................................................................. 23
Anthony Lang | Canada ................................................ 27
Lucile Leader | UK ........................................................................ 19, 30, 34
Virginia Lee | US .......................................................................... 34
Albert Leentjens | Netherlands ................................................... 29
Andrew Lees | UK ............................................................................ 23
Amy Lemen | US .............................................................................. 25
Susanna Lindvall | Sweden ...................................................... 25
Phillip Low | US ........................................................................... 18
Christy Ludlow | US ..................................................................... 31
Shannon MacDonald | Canada ................................................... 26
Graeme Macphee | UK ...................................................................... 20
Margarita Makoutonina | Australia ........................................... 19, 30
Yael Manor | Israel .................................................................... 19, 29, 35
Karen Marder | US ........................................................................... 24, 28
Ken Marek | US ............................................................................. 24, 27
Laura Marsh | US ........................................................................... 18, 28, 29
Ronald McKay | US ......................................................................... 33
Eldad Melamed | Israel .............................................................. 26
Nicholas Miller | UK ......................................................................... 35
Yoshikuni Mizuno | Japan ........................................................................ 28
Orna Moore | Israel ..................................................................... 19, 24, 28
Meg Morris | Australia ..................................................................... 29, 34
Carol Moskowitz | US ........................................................................... 23
Maral Mouradian | US ............................................................................... 32
Marten Munneke | The Netherlands ............................................... 19
Uday Muthane | India ......................................................................... 28
Ken Nakamura | US ............................................................................. 34
Alice Nieuwboer | Belgium .............................................................. 34
Robert Nussbaum | US ............................................................................. 24, 34
John Nutt | US ............................................................................. 18, 26
Wolfgang Oertel | Germany ...................................................................... 32
Njideka Okubadejo | Nigeria .............................................................. 28
Michael Okun | US ............................................................................. 18, 26
C. Warren Olanow | US ............................................................................. 18, 31, 32
Knut-Johan Onarheim | Norway .............................................................. 30
Coro Paisan-Ruiz | UK ......................................................................... 28
Stephane Palfi | France ......................................................................... 34
Giselle Petzinger | US ........................................................................... 27, 31
Ronald Pfeiffer | US ........................................................................... 30, 33
Davis Phinney | US ........................................................................... 27, 29, 30
Werner Poewe | Austria ........................................................................... 18, 27, 31, 32
Elizabeth Pollard | US ............................................................................. 20
Jenny Posen | Israel .............................................................................. 25, 30
Serge Przedborski | US ........................................................................... 26, 30
Pamela Quinn | US ............................................................................. 30
Lorraine Ramig | US ........................................................................... 29, 35
Bernard Ravina | US ............................................................................... 32
Heinz Reichmann | Germany ................................................................. 18
Joy Reid | UK ...................................................................................... 27, 30
Tamas Revesz | UK ............................................................................. 23
Beate Ritz | US ............................................................................. 24
Trevor Robbins | UK ............................................................................. 28
Lynn Rochester | UK ............................................................................. 31, 34
Webster Ross | US ............................................................................. 24, 33
Christina Sampaio | Portugal .............................................................. 35
Lucianne Sawyer | UK ............................................................................. 24
Anthony Schapira | UK ............................................................................. 30, 31, 32
Clemens Scherzer | US ............................................................................. 25
Michael Schlossmacher | US ............................................................................. 25
Michael Schwarzschild | US ............................................................................. 24
Jie Shen | US ............................................................................... 30
Ira Shoulson | US ............................................................................. 20, 31, 35
Lisa Shulman | US ............................................................................. 20, 23, 30
Andrew Siderowf | US ............................................................................. 24
Ellen Sidransky | US ............................................................................. 24
John Silk | Australia ............................................................................. 25
Andrew Singleton | US ............................................................................. 24
Mark Stacy | US ............................................................................. 18
David Standaert | US ............................................................................. 26
Fabrizio Stocchi | Italy ............................................................................. 18, 32
Lorenz Studer | US ............................................................................. 33
Oksana Suchowersky | Canada .............................................................. 23
James Surmeier | US ............................................................................. 30
Caroline Tanner | US ............................................................................. 24, 28, 33
Malú Gámez Tansey | US ............................................................................. 26
Deborah Theodores | Australia .............................................................. 35
Lidy Tinselboer | Netherlands .............................................................. 19, 28
Concetta Tomaino | US ............................................................................. 30, 34
Eduardo Tolosa | Spain ............................................................................. 18, 20, 23, 26
John Trojanowski | US ............................................................................. 34
Alex Tröster | US ............................................................................. 29
David Vaillancourt | US ............................................................................. 24
Greg Wasson | US ............................................................................. 26, 29, 32
Daniel Weintraub | US ............................................................................. 18, 29, 33
Olie Westheimer | US ............................................................................. 27
Bryn Williams | UK ............................................................................. 29
Peggy Willocks | US ............................................................................. 32
Liz Wolstenholme | UK ............................................................................. 29
Erik Wolters | The Netherlands .............................................................. 20, 32
Nicholas Wood | UK ............................................................................. 23, 30
John Zajicek | UK ............................................................................. 32
Jing Zhang | US ............................................................................. 25
### Social and Tours Program

<table>
<thead>
<tr>
<th>Day/Date</th>
<th>Inclusive or Optional</th>
<th>Social Event</th>
<th>Tour Program</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday,</td>
<td>Included in the registration fee of delegates and accompanying persons</td>
<td>Opening Ceremony</td>
<td></td>
<td>18:15 - 19:30</td>
</tr>
<tr>
<td>September 28</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wednesday,</td>
<td>Included in the registration fee of delegates and accompanying persons</td>
<td>Welcome Reception</td>
<td>Glasgow City Tour</td>
<td>09:30 - 12:30</td>
</tr>
<tr>
<td>September 29</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thursday,</td>
<td>Optional Price £54.00</td>
<td>Edinburgh City Tour</td>
<td></td>
<td>09:30 - 17:30</td>
</tr>
<tr>
<td>September 30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friday,</td>
<td>Optional Price £54.00</td>
<td>Stirling and the Trossachs</td>
<td></td>
<td>09:30 - 17:30</td>
</tr>
<tr>
<td>October 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saturday,</td>
<td>Optional Price £40.00</td>
<td>Glengoyne Distillery &amp; Loch Lomond</td>
<td></td>
<td>09:30 - 12:30</td>
</tr>
<tr>
<td>October 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Optional Price £395.00 / £485.00</td>
<td>Post Congress Tours</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Opening Ceremony

**Tuesday, September 28 18:15 – 19:30**

The Opening Ceremony will take place at the Scottish Exhibition & Conference Centre in the Clyde Auditorium.

*Included in registration fee*

### Welcome Reception

**Tuesday, September 28 19:30 – 21:30**

The Welcome Reception will be held immediately after the Opening Ceremony in the Exhibit Hall. The evening will allow delegates to relax and socialise, renewing old friendships and making new ones. Wine and canapés will be served.

*Included in registration fee*

### Optional Tours

#### Edinburgh City Tour

![Edinburgh City Tour Image](image)

A full day tour, which will travel to Edinburgh past historic Linlithgow, where we can see over to Linlithgow Palace, the birthplace of Mary Queen of Scots. On arrival in Edinburgh we will have a panoramic tour of the sweeping Georgian terraces and crescents of the New Town, followed by an interior visit to Edinburgh Castle. After the castle there will be some free time to have lunch and do some independent sightseeing and/or shopping before heading back to Glasgow.

Accessibility note: The walkways at Edinburgh Castle are steep in places and are cobbled, however, there is transport available at the Castle to take you up to the top and back to the Esplanade.

*Price: £54.00 (exclusive of lunch)*
Social and Tours Program

Stirling and the Trossachs
Thursday, September 30  09:30 – 17:30

The historic town of Stirling, once the home of the Scottish Kings and Queens, is overlooked by Stirling Castle, the most strategically important of all the castles in Scotland. Hence it has been fought over and changed hands more than any other Scottish castle. It is at the landward end of the Firth of Forth, and controls movement across the Lowlands and into the Highlands. He who controlled Stirling, effectively controlled Scotland. Following time in Stirling and a guided tour of the Castle, the tour will continue through Callander before the dramatic climb over the Duke's Pass to Aberfoyle for lunch in the heart of the Trossachs. There will be time for shopping in the Scottish Sheep Centre woollen shop before the scenic drive over the Campsie Fells and back to Glasgow.

Accessibility note: Some of the walkways at Stirling Castle are cobbled with a small incline leading up to the Castle.

Price: £54.00 (exclusive of lunch)

Glengoyne Distillery & Loch Lomond
Friday, October 1  09:30 – 12:30

A morning tour to the Loch Lomond area; the coach will depart from Glasgow and head toward the Campsie Hills to the Glengoyne Distillery for a tour and explanation of how Scotland's national drink is produced. After a whisky sampling, the tour will stop at Loch Lomond Shores to enjoy the panoramic views of Loch Lomond and Ben Lomond before returning to Glasgow.

Accessibility note: Some areas of the Distillery have narrow walkways and steps.

Price: £40.00

Sail on Loch Lomond
Friday, October 1  09:30 – 12:30

From Glasgow the tour will travel along the banks of the river Clyde to Helensburgh and then by way of scenic Glen Fruin to Loch Lomond and on to Tarbet. From here we will board a cruiser for a sail on the Loch, in the shadow of Ben Lomond. Our final drive takes us along the banks of the Loch, with magnificent views to the islands, on the homeward journey to Glasgow.

Accessibility note: Access onto the boat will be by a sloped gangplank.

Price: £40.00

Inclusive Tour

Glasgow City Tour
Wednesday, September 29  09:30 – 12:30

A morning coach tour offering an introduction to the City of Glasgow, including the historic Cathedral and the Merchant City, the River Clyde, Blytheswood Square, Kelvingrove Art Gallery and the University Campus. The tour ends with a visit to the world famous Burrell Collection.

Price: Included in accompanying persons fee. Additional tickets may be purchased for £35.00
Post Congress Tours

Golf Tour  Saturday, October 2
Golf tours can be tailored to individual needs. Should you wish to play golf after the Congress, contact the organizers at golfqueries@worldpdcongress.org.

Please note that tours are non-refundable and non-transferable.

Highlands & Isle of Skye  Saturday, October 2 – Monday, October 4
The Highlands & Isle of Skye tour will depart from Glasgow at approximately 08:30 hrs on Saturday, October 2 and will return to Glasgow at approximately 17:00 hrs on Monday, October 4, 2010.

A three day, two night tour to the West Coast of Scotland and the Isle of Skye, experiencing the magnificent scenery and history of this beautiful country.

Places and sights visited will include Perth, Pitlochry, Inverness, Loch Ness (and maybe a glimpse of Nessie herself!), Drumnadrochit, over the sea to the Isle of Skye, Fort William, Glen Coe, Rannoch Moor and Loch Lomond. There will be overnight stays in the Inverness area.

Price: £395.00 per person, for two sharing or £485.00 per person

Tour includes:

- 2 nights accommodation in rooms with private facilities
- 2 full Scottish breakfasts
- 2 table d’hôte dinners
- Admission to Eilean Donan Castle
- Admission to Scone Palace
- Visit to a malt whisky distillery (and a wee dram!)
- Full day excursion to Isle of Skye
- Sail on Loch Lomond
- Luxury coach transfers
- Specially trained driver/guides
- Porterage based on one suitcase per person
- VAT at prevailing rate

Tour does not include:

- Items of a personal nature such as newspapers, room service, telephone calls etc.
- Drinks, other than as mentioned in the itinerary
- Gratuity to driver/guide
# Alphabetic List of Exhibitors

## Medical Exhibition

<table>
<thead>
<tr>
<th>Exhibitor Name</th>
<th>Stand No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Products Operations AG</td>
<td>411</td>
</tr>
<tr>
<td>Archimedes Pharma</td>
<td>117</td>
</tr>
<tr>
<td>Britannia Pharmaceuticals Ltd / Genus Pharmaceuticals Ltd</td>
<td>500</td>
</tr>
<tr>
<td>Boehringer Ingelheim Limited</td>
<td>520</td>
</tr>
<tr>
<td>CPS Research</td>
<td>113</td>
</tr>
<tr>
<td>EMS Physio Ltd</td>
<td>107</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>300</td>
</tr>
<tr>
<td>GlaxoSmithKline UK</td>
<td>400</td>
</tr>
<tr>
<td>H. Lundbeck A/S</td>
<td>210</td>
</tr>
<tr>
<td>IPRS Mediquipe Ltd</td>
<td>524</td>
</tr>
<tr>
<td>Luminaud Inc</td>
<td>111</td>
</tr>
<tr>
<td>Meda Pharmaceuticals Ltd</td>
<td>525</td>
</tr>
<tr>
<td>Medtronic International Trading Sàrl</td>
<td>410</td>
</tr>
<tr>
<td>Novartis Pharma AG</td>
<td>310</td>
</tr>
<tr>
<td>Orion Corporation</td>
<td>310</td>
</tr>
<tr>
<td>Patients Direct</td>
<td>115</td>
</tr>
<tr>
<td>SOMNOmedics GmbH</td>
<td>200</td>
</tr>
<tr>
<td>St. Jude Medical</td>
<td>100</td>
</tr>
<tr>
<td>Teva Pharmaceutical Industries Ltd</td>
<td>210</td>
</tr>
<tr>
<td>The Movement Disorder Society (MDS)</td>
<td>201</td>
</tr>
<tr>
<td>We Move</td>
<td>109</td>
</tr>
<tr>
<td>Wisepress Ltd</td>
<td>102</td>
</tr>
</tbody>
</table>

## Non Medical Exhibition

<table>
<thead>
<tr>
<th>Exhibitor Name</th>
<th>Stand No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>3rd World Parkinson Congress</td>
<td>M32</td>
</tr>
<tr>
<td>Abbott Products Operations AG</td>
<td>M28</td>
</tr>
<tr>
<td>AGILE</td>
<td>M44</td>
</tr>
<tr>
<td>Alliance of Scottish Parkinson's Disease Nurse Specialists</td>
<td>M18</td>
</tr>
<tr>
<td>Attainability UK Ltd</td>
<td>M30</td>
</tr>
<tr>
<td>Davis Phinney Foundation</td>
<td>M49</td>
</tr>
<tr>
<td>European Parkinson's Disease Association</td>
<td>M34</td>
</tr>
<tr>
<td>Fondazione Grigioni per il Morbo di Parkinson</td>
<td>M52</td>
</tr>
<tr>
<td>Get A Move On Centre</td>
<td>M8</td>
</tr>
<tr>
<td>GlaxoSmithKline UK</td>
<td>M26</td>
</tr>
<tr>
<td>H. Lundbeck A/S</td>
<td>M41</td>
</tr>
<tr>
<td>Hong Kong Parkinson's Disease Foundation</td>
<td>M46</td>
</tr>
<tr>
<td>In - Step Mobility Products</td>
<td>M31</td>
</tr>
<tr>
<td>Internaional Parkinson Fonds Nederland</td>
<td>M47</td>
</tr>
<tr>
<td>Internationale Parkinson Fonds Deutschland</td>
<td>M47</td>
</tr>
<tr>
<td>IOS Press BV</td>
<td>M51</td>
</tr>
<tr>
<td>LSVT Global, Inc</td>
<td>M17</td>
</tr>
<tr>
<td>Medtronic International Trading Sàrl</td>
<td>M39</td>
</tr>
<tr>
<td>National Parkinson Foundation</td>
<td>M53</td>
</tr>
<tr>
<td>NeuroFit Networks, Inc</td>
<td>M33</td>
</tr>
<tr>
<td>Neuroscience Nursing Foundation</td>
<td>M48</td>
</tr>
<tr>
<td>Novartis Pharma AG</td>
<td>M43</td>
</tr>
<tr>
<td>Orion Corporation</td>
<td>M43</td>
</tr>
<tr>
<td>Parkinson-Hilfe Deutschland e.V.</td>
<td>M44</td>
</tr>
<tr>
<td>Parkinson's Action Network</td>
<td>M48</td>
</tr>
<tr>
<td>Parkinson's Austrialia</td>
<td>M46</td>
</tr>
<tr>
<td>Parkinson's Disease Foundation</td>
<td>M16</td>
</tr>
<tr>
<td>Parkinson's Disease and Movement Disorder Society (India)</td>
<td>M45</td>
</tr>
<tr>
<td>Parkinson's Disease Nurse Specialist Association</td>
<td>M18</td>
</tr>
<tr>
<td>Parkinson's UK</td>
<td>M29</td>
</tr>
<tr>
<td>Parkinson's UK Interactive Game Area</td>
<td>M9</td>
</tr>
<tr>
<td>Romanian Antiparkinson Association</td>
<td>M45</td>
</tr>
<tr>
<td>Teva Pharmaceutical Industries Ltd</td>
<td>M41</td>
</tr>
<tr>
<td>The Cure Parkinson's Trust</td>
<td>M14</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation for Parkinson's Research</td>
<td>M15</td>
</tr>
<tr>
<td>UCB Pharma SA</td>
<td>M42</td>
</tr>
<tr>
<td>World Federation of Neuroscience Nurses</td>
<td>M49</td>
</tr>
<tr>
<td>XIX WFN World Congress on Parkinson's Disease and Related Disorders / XXth Congress of Neurology</td>
<td>M13</td>
</tr>
</tbody>
</table>
### Medical Exhibition

<table>
<thead>
<tr>
<th>Stand No.</th>
<th>Exhibitor Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>St. Jude Medical</td>
</tr>
<tr>
<td>102</td>
<td>Wisepress Ltd</td>
</tr>
<tr>
<td>107</td>
<td>EMS Physio Ltd</td>
</tr>
<tr>
<td>109</td>
<td>We Move</td>
</tr>
<tr>
<td>111</td>
<td>Luminaud Inc</td>
</tr>
<tr>
<td>113</td>
<td>CPS Research</td>
</tr>
<tr>
<td>115</td>
<td>Patients Direct</td>
</tr>
<tr>
<td>117</td>
<td>Archimedes Pharma</td>
</tr>
<tr>
<td>200</td>
<td>SOMNOmedics GmbH</td>
</tr>
<tr>
<td>201</td>
<td>The <em>Movement Disorder Society</em> (MDS)</td>
</tr>
<tr>
<td>210</td>
<td>H. Lundbeck A/S</td>
</tr>
<tr>
<td>210</td>
<td>Teva Pharmaceutical Industries Ltd</td>
</tr>
<tr>
<td>300</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>310</td>
<td>Novartis Pharma AG</td>
</tr>
<tr>
<td>310</td>
<td>Orion Corporation</td>
</tr>
<tr>
<td>400</td>
<td>GlaxoSmithKline UK</td>
</tr>
<tr>
<td>410</td>
<td>Medtronic International Trading Sàrl</td>
</tr>
<tr>
<td>411</td>
<td>Abbott Products Operations AG</td>
</tr>
<tr>
<td>500</td>
<td>Britannia Pharmaceuticals Ltd / Genus Pharmaceuticals Ltd</td>
</tr>
<tr>
<td>520</td>
<td>Boehringer Ingelheim Limited</td>
</tr>
<tr>
<td>524</td>
<td>IPRS Mediquipe Ltd</td>
</tr>
<tr>
<td>525</td>
<td>Meda Pharmaceuticals Ltd</td>
</tr>
</tbody>
</table>

### Non Medical Exhibition

<table>
<thead>
<tr>
<th>Stand No.</th>
<th>Exhibitor Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>M8</td>
<td>Get A Move On Centre</td>
</tr>
<tr>
<td>M9</td>
<td>Parkinson's UK Interactive Game Area</td>
</tr>
<tr>
<td>M13</td>
<td>XIX WFN World Congress on Parkinson's Disease and Related Disorders / XXth Congress of Neurology</td>
</tr>
<tr>
<td>M14</td>
<td>The Cure Parkinson’s Trust</td>
</tr>
<tr>
<td>M15</td>
<td>The Michael J. Fox Foundation for Parkinson's Research</td>
</tr>
<tr>
<td>M16</td>
<td>Parkinson's Disease Foundation</td>
</tr>
<tr>
<td>M17</td>
<td>LSVT Global, Inc</td>
</tr>
<tr>
<td>M18</td>
<td>Alliance of Scottish Parkinson's Disease Nurse Specialists</td>
</tr>
<tr>
<td>M18</td>
<td>Parkinson's Disease Nurse Specialist Association</td>
</tr>
<tr>
<td>M26</td>
<td>GlaxoSmithKline UK</td>
</tr>
<tr>
<td>M28</td>
<td>Abbott Products Operations AG</td>
</tr>
<tr>
<td>M29</td>
<td>Parkinson's UK</td>
</tr>
<tr>
<td>M30</td>
<td>Attainability UK Ltd</td>
</tr>
<tr>
<td>M31</td>
<td>In - Step Mobility Products</td>
</tr>
<tr>
<td>M32</td>
<td>3rd World Parkinson Congress</td>
</tr>
<tr>
<td>M33</td>
<td>NeuroFit Networks, Inc</td>
</tr>
<tr>
<td>M34</td>
<td>European Parkinson's Disease Association</td>
</tr>
<tr>
<td>M39</td>
<td>Medtronic International Trading Sàrl</td>
</tr>
<tr>
<td>M41</td>
<td>H. Lundbeck A/S</td>
</tr>
<tr>
<td>M41</td>
<td>Teva Pharmaceutical Industries Ltd</td>
</tr>
<tr>
<td>M42</td>
<td>UCB Pharma SA</td>
</tr>
<tr>
<td>M43</td>
<td>Novartis Pharma AG</td>
</tr>
<tr>
<td>M43</td>
<td>Orion Corporation</td>
</tr>
<tr>
<td>M44</td>
<td>AGILE</td>
</tr>
<tr>
<td>M44</td>
<td>Parkinson-Hilfe Deutschland e.V.</td>
</tr>
<tr>
<td>M45</td>
<td>Parkinson's Disease and Movement Disorder Society (India)</td>
</tr>
<tr>
<td>M45</td>
<td>Romanian Antiparkinson Asociation</td>
</tr>
<tr>
<td>M46</td>
<td>Hong Kong Parkinson’s Disease Foundation</td>
</tr>
<tr>
<td>M46</td>
<td>Parkinson's Australria</td>
</tr>
<tr>
<td>M47</td>
<td>Internationale Parkinson Fonds Deutschland</td>
</tr>
<tr>
<td>M47</td>
<td>Internationaal Parkinson Fonds Nederland</td>
</tr>
<tr>
<td>M48</td>
<td>Parkinson’s Action Network</td>
</tr>
<tr>
<td>M48</td>
<td>Neuroscience Nursing Foundation</td>
</tr>
<tr>
<td>M49</td>
<td>World Federation of Neuroscience Nurses</td>
</tr>
<tr>
<td>M49</td>
<td>Davis Phinney Foundation</td>
</tr>
<tr>
<td>M51</td>
<td>IOS Press BV</td>
</tr>
<tr>
<td>M52</td>
<td>Fondazione Grigioni per il Morbo di Parkinson</td>
</tr>
<tr>
<td>M53</td>
<td>National Parkinson Foundation</td>
</tr>
</tbody>
</table>
Sponsors

Platinum Sponsor

Abbott Products Operations AG
Hegenheimermattweg 127
4123 Allschwil
Switzerland
Tel: +41 (0) 61 487 02 00
Fax: +41 (0) 61 487 02 99
Email: daniela.ryter@solvay.com
Web: www.abbott.com

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 83,000 people and markets its products in more than 130 countries.

Gold Sponsors

Boehringer Ingelheim Limited
Ellesfield Avenue
Bracknell
Berkshire
RG12 8YS
UK
Tel: +44 (0) 1344 424 600
Fax: +44 (0) 1344 741 444
Email: UK company enquiries: communications@bra.boehringer-ingelheim.com
UK Medical information enquiries: medinfo@bra.boehringer-ingelheim.com

Boehringer Ingelheim was founded in 1885 by Albert Boehringer and remains a family-owned company. Today we are one of the fastest growing of the world’s 15 leading pharmaceutical companies with 142 affiliated companies in 50 countries around the globe.

Our vision, ‘Value through Innovation’, mirrors our founder’s own belief in the importance of innovative thinking and that, as well as being financially profitable, products should be pioneering and of genuine benefit to patients.

H. Lundbeck A/S
Ottilieavej 7-9
2500 Valby
Denmark
Tel: +45 (0) 36 30 13 11
Fax: +45 (0) 36 43 82 50
Email: information@lundbeck.com
Web: www.lundbeck.com

Lundbeck - The Specialist in Psychiatry - Pioneer in Neurology

H. Lundbeck A/S is an international pharmaceutical company dedicated in research and development of new drugs for treatment of CNS disorders including depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. Research has been the foundation of Lundbeck activities for more than 50 years, and the company’s mission is to improve the quality of life for people suffering from psychiatric and neurological disorders.

Novartis Pharma AG
CH-4002 Basel
Switzerland
Tel: +41 (0) 61 324 11 11
Fax: +41 (0) 61 324 80 01
Web: www.novartis.com

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Orion Corporation
Orionintie 1A, FI-02200 Espoo
P.O. Box 65, FI-02101 Espoo
Finland
Tel: +35 (0) 81 042 61
Email: corporate@orionpharma.com
Web: www.orion.fi/en/

Orion Corporation is a Finnish listed company which is dedicated to treating and preventing disease by discovery and developing innovative medicinal treatments. For more information please visit www.orion.fi/en.
Teva Pharmaceutical Industries Ltd
Teva Corporate Headquarters
5 Basel St.
Petach Tikva 49131
Israel
Tel: +97 (0) 23 92 672 67
Fax: +97 (0) 23 92 340 50
Web: www.tevapharm.com

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients. Teva’s innovative products include therapies for Parkinson’s disease and Multiple Sclerosis. Teva is among the top 15 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.

Silver Sponsors

Chelsea Therapeutics International Ltd.
3530 Toringdon Way - Suite 200
Charlotte, NC 28277
USA
Tel: +1 704 341 1516
Fax: +1 704 752 1479
Email: webemail06@chelseatherapeutics.com
Web: www.chelseatherapeutics.com

Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea’s most advanced drug candidate, droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson’s Disease, Multiple System Atrophy, Pure Autonomic Failure) dopamine α-hydroxylation deficiency, and non-diabetic autonomic neuropathies.

GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and healthcare companies. We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.

Medtronic International Trading Sàrl
Route de Molliau 31
1131 Tolochenaz
Switzerland
Tel: +41 (0) 21 802 77 18
Fax: +41 (0) 21 802 79 15
Web: www.medtronic.com

At Medtronic (www.medtronic.com), we’re committed to Innovating for life by pushing the boundaries of medical technology and changing the way the world treats chronic disease. To do that, we’re thinking beyond products and beyond the status quo – to continually find more ways to help people live better, longer.

Bronze Sponsor

Merck Serono S.A
9 Chemin des Mines
Geneva, 1202
Switzerland
Tel: +41 (0) 22 414 3000
Email: Natascha.Knoblich@merckserono.net
Web: www.merckserono.net

Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono is active on all continents.

Merck Serono has a long-term commitment to the development of innovative treatments to help manage neurological disorders such as multiple sclerosis (MS) and Parkinson’s disease (PD). Through groundbreaking science and patient-friendly drug delivery systems, we help patients with neurodegenerative diseases.
Medical Exhibition

**Abbott Products Operations AG**
Hegenheimermattweg 127
4123 Allschwil
Switzerland
Tel: +41 (0) 61 487 02 00
Fax: +41 (0) 61 487 02 99
Email: daniela.ryter@solvay.com
Web: www.abbott.com
Please refer to sponsor page for company editorial.

**Archimedes Pharma**
250 South Oak Way
Green Park
Reading
RG2 6UG
UK
Tel: +44 (0) 118 931 5050
Fax: +44 (0) 118 931 5065
Web: www.archimedespharma.com
Archimedes is a European specialty pharmaceutical company with an established commercial organisation. Archimedes is growing its commercial presence and is developing a robust pipeline of novel near and longer-term products to support its commercial organisation.

**Britannia Pharmaceuticals Ltd/Genus Pharmaceuticals Ltd**
Park View House
65 London Road
Newbury
Berkshire
RG14 1JN
UK
Tel: +44 (0) 1635 568 400
Fax: +44 (0) 1635 568 401
Email: samantha.burton@britannia-pharm.com
Web: www.britannia-pharm.com / www.genuspharma.com
Globally Britannia specialises in innovative products for niche medical conditions with particular focus on treatment of patients with complex Parkinson’s disease. Marketed in the UK by Genus, our products for Parkinson’s disease are available as an intermittent injection and continuous infusion. Combined with the Genus Package-of-Care, this represents true value to both NHS and Private sectors.

**Boehringer Ingelheim Limited**
Ellesfield Avenue
Bracknell
Berkshire
RG12 8YS
UK
Tel: +44 (0) 1344 424 600
Fax: +44 (0) 1344 741 444
Email: UK company enquiries: communications@bra.boehringer-ingelheim.com
UK Medical information enquiries: medinfo@bra.boehringer-ingelheim.com
Please refer to sponsor page for company editorial.

**CPS Research**
3, Todd Campus
West of Scotland Science Park
Glasgow
G20 0XA
UK
Tel: + 44 (0) 141 946 7888
Fax: + 44 (0) 141 946 1324
Email: info@cpsresearch.co.uk
Web: www.cpsresearch.co.uk
An elite stand-alone clinical research company with 20 + years experience.
CPS Research provides fast reliable recruitment to Phase II, III, IV studies combined with quality backed ISO 9001 : 2000. Our services are provided at costs unrivalled in Western Europe. CPS Services include: Study Design & Protocol, Regulatory Affairs, Fully Trained Staff, Patient Management, Statistical Reporting.

**EMS Physio Ltd**
Grove Technology Park
Downsview Road
Wantage
Oxfordshire
OX12 9FE
UK
Tel: +44 (0) 1235 772 272
Fax: +44 (0) 1235 763 518
Email: sales@emsphysio.co.uk
Web: www.emsphysio.co.uk
Stand Personnel: Roy Bennett & Albert Gaudin
Visit our stand to see the world-class GaitRite analysis system and understand how it can benefit your clinic in treating Parkinson’s disease.
Established since 1924, EMS Physio is a leader in the field of physiotherapy and rehabilitation equipment, recognised around the world for providing high quality equipment and service.
GE Healthcare
Chalfont, St. Giles
Buckinghamshire
UK
Tel: +44 (0) 1494 544 000
Fax: +44 (0) 1494 498 234
Web: www.gehealthcare.com

GE Healthcare is dedicated to helping you transform healthcare delivery by driving critical breakthroughs in biology and technology. Our expertise in medical imaging and information technologies, diagnostics, patient monitoring systems, drug discovery, and biopharmaceutical manufacturing technologies is enabling healthcare professionals around the world discover new ways to diagnose and treat disease earlier. We call this model “Early Health”. Our goal is more targeted treatments, so they can help their patients live their lives to the fullest. For additional information, please visit our booth while at WPC 2010.

GlaxoSmithKline UK
Stockley Park West
Uxbridge
Middlesex
UB11 1BT
UK
Tel: +44 (0) 208 990 9000
Web: www.gsk.co.uk

Please refer to sponsor page for company editorial.

H. Lundbeck A/S
Ottiliavej 7-9
2500 Valby
Denmark
Tel: +45 (0) 36 30 13 11
Fax: +45 (0) 36 43 82 50
Email: information@lundbeck.com
Web: www.lundbeck.com

Please refer to sponsor page for company editorial.
Exhibitors

IPRS Mediquipe Ltd. 524
Suffolk House
Ipswich
Suffolk
IP8 4JU
UK
Email: Mediquipe@iprsroup.com

IPRS Mediquipe exclusively sells, services, and clinically supports Biodex and BTE objective testing and training rehabilitation equipment. This equipment is used for both assessment and treatment, in all aspects of physical rehabilitation. The objective data it provides is invaluable for outcome measures. Clients range from universities, elite sports clubs, private practices and leading hospitals throughout the UK, Ireland and South Africa.

Luminaud, Inc. 111
8688 Tyler Blvd.
Mentor, OH 44060
USA
Tel: +1 440 255 9082
Fax: +1 440 255 2250
Email: info@luminaud.com
Web: www.luminaud.com

We offer a wide variety of personal voice amplifiers and microphones to increase voice volume and make conversation easier and less tiring. Also electrolarynges, devices to assist with swallowing disorders and unique switches to provide control, with very minimal movement and pressure, of many battery and line power devices.

Meda Pharmaceuticals Ltd 525
Skyway House
Parsonage Road
Takeley
Bishop's Stortford
CM22 6PU
UK
Tel: +44 (0) 845 460 0000
Email: Medical@medapharma.co.uk

MEDA Pharmaceuticals Ltd (UK affiliate of MEDA AB), is a leading international speciality pharmaceutical company.
Therapy areas - asthma, cardiology, oncology, haematology, dermatology, gastroenterology, movement disorders, pain, sexual health, women's health and virology.
MEDA's Medical Department can provide medical liaison, information, product knowledge, product training and Investigator Initiated Study support.
Medical@medapharma.co.uk

Medtronic International Trading Sàrl 410
Route de Molliau 31
1131 Tolochenaz
Switzerland
Tel: +41 (0) 21 802 77 18
Fax: +41 (0) 21 802 79 15
Web: www.medtronic.com

Please refer to sponsor page for company editorial.

Novartis Pharma AG 310
CH-4002 Basel
Switzerland
Tel: +41 (0) 61 324 11 11
Fax: +41 (0) 61 324 80 01
Web: www.novartis.com

Please refer to sponsor page for company editorial.

Orion Corporation 310
Orionintie 1A, FI-02200 Espoo
P.O.Box 65, FI-02101 Espoo
Finland
Tel: +35 (0) 81 042 61
Email: corporate@orionpharma.com
Web: www.orion.fi/en/

Please refer to sponsor page for company editorial.

Patients Direct 115
3, Todd Campus
West of Scotland Science Park
Glasgow
G20 0XA
UK
Tel: + 44 (0) 141 946 8618
Fax: + 44 (0) 141 946 1324
Email: angela@patientsdirect.org
Web: www.patientsdirect.org

Patients Direct are specialists in recruiting patients for patient reported outcomes. Our web based systems collect information directly for:

- Strategic planning e.g. disease modelling
- Regulatory e.g. in risk management plans
- pharmaco-economics e.g. in HTA’s
- Marketing e.g. product and competitor analysis
- Pharmaco-vigilance e.g. post marketing surveillance.
SOMNOmedics GmbH
Am Sonnenstuhl 63,
97236 Randersacker
Germany
Tel: +49 (0) 931 359 0940
Fax: +49 (0) 931 359 09439
Email: info@somnomedics.de
Web: www.somnomedics.eu

SOMNOmedics designs, manufactures, markets, distributes and services products dedicated to sleep diagnostics.

Our products are utilized for a variety of sleep related tests and comply with the AASM standards. SOMNOmedics devices are small, light weight and are worn by the patient. We are compatible with in lab diagnostics as well as home sleep testing.

St. Jude Medical
Neuromodulation Division Headquarters
6901 Preston Road
Plano, Texas 75024
USA
Tel: +1 972 309 8000
Fax: +1 972 309 8150
Web: www.sjm.com

St. Jude Medical develops medical technology designed to put more control into the hands of those who treat neurological, cardiac and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful patient outcomes.
Exhibitors

Teva Pharmaceutical Industries Ltd  210
Teva Corporate Headquarters
5 Basel St.
Petach Tikva 49131
Israel
Tel: +97 (0) 23 92 672 67
Fax: +97 (0) 23 92 340 50
Web: www.tevapharm.com

Please refer to sponsor page for company editorial.

The Movement Disorder Society  201
555 E. Wells Street, Suite 1100
Milwaukee, WI 53202
USA
Tel: +1 414 276 2145
Fax: +1 414 276 3349
Email: info@movementdisorders.org
Web: www.movementdisorders.org

The Movement Disorder Society is an international, professional society of clinicians, scientists, and healthcare professionals interested in Parkinson's disease, related neurodegenerative and neurodevelopmental disorders and hyperkinetic Movement Disorders. Goals of the Society are to disseminate knowledge and promote research into causes, prevention and treatment of these disorders.

Wisepress Ltd  102
Wisepress Bookshop
25 High Path
Merton Abbey
London
SW19 2JL
UK
Tel: +44 (0) 208 715 1812
Fax: +44 (0) 208 715 1722
Email: bookshop@wisepress.com
Web: www.wisepress.com

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you. Wisepress has a comprehensive medical and scientific bookshop online with great offers. For further information, please visit www.wiley.com/go/ihe.
Exhibitors

Non Medical Exhibition

3rd World Parkinson Congress M32
Email: info@worldpdcongress.org
Web: www.worldpdcongress.org

Visit Stand M32 to learn more about our next destination Montréal, Canada and the 3rd World Parkinson Congress.

Abbott Products Operations AG M28
Hegenheimermattweg 127
4123 Allschwil
Switzerland
Tel: +41 (0) 61 487 02 00
Fax: +41 (0) 61 487 02 99
Email: daniela.ryter@solvay.com
Web: www.abbott.com

AGILE M44
Physiotherapy Department
Whitefield Day Hospital
Queen Margaret Hospital
Dunfermline
KY12 0SU
UK
Web: www.agile-uk.org

Alliance of Scottish Parkinson's Disease Nurse Specialists M18
c/o Parkinson's Nurse Specialist
Moncrieffe Ward
Perth Royal Infirmary
Perth
UK

Attainability UK Ltd M30
Killara
Racecourse Lane
Shrewsbury
Shropshire
SY3 5BJ
UK
Tel: +44 (0) 1743 245 277
Email: sales@attainability.co.uk
Web: www.attainability.co.uk

Attainability distributes specialist walking aids designed to assist people with Parkinson's disease and similar conditions. The U-Step is an advanced walker that offers unrivalled support and manoeuvrability and has an optional laser cueing system to overcome "freezing". The LaserCane is a lightweight walking stick with an inbuilt laser cueing system.

Davis Phinney Foundation M49
4676 Broadway
Boulder, CO 80304
USA
Web: www.davisphinneyfoundation.org

European Parkinson's Disease Association M34
1 Northumberland Avenue
Trafalgar Square
London
WC2N 5BW
UK
Tel: +44 (0) 207 872 5510
Fax: +44 (0) 207 872 5611
Email: info@epda.eu.com
Web: www.epda.eu.com

A non-political, non-religious, and non-profit making organisation with a membership of 43 European Organisations and 7 Associate members, concerned with the health and welfare of people with Parkinson's and their families. EPDA partners extensively with European patient and neurological organisations, European Commission, WHO, World Federation of Neurology, and treatment industry.

Fondazione Grigioni per il Morbo di Parkinson M52
Via Zuretti 35
20125 Milan
Italy
Tel: +39 (0) 26 67 104 23
Fax: +39 (0) 26 70 528 3
Email: aip@fondazioneparkinson.com
Web: www.parkinson.it

The Grigioni Foundation for Parkinson's disease is a non-profit organization in Italy with the mission of raising funds exclusively for scientific research projects designed to improve our knowledge on Parkinson's disease and parkinsonism. It has recently extended its scope to include cultural initiatives for patients and caregivers.
Exhibitors

Get A Move On Centre M8
The hub for people with Parkinson's. Designed and run by experienced Parkinson's advocates, this stand pledges to answer questions you may have about the condition or the Congress. Meet other like minded people or test your skills on Wii-Fit. Welcome packs will also be available for people with Parkinson's to ensure you make the most of your WPC 2010.

GlaxoSmithKline UK M26
Stockley Park West
Uxbridge
Middlesex
UB11 1BT
UK
Tel: +44 (0) 208 990 9000
Web: www.gsk.co.uk

H. Lundbeck A/S M41
Ottaliavej 7-9
2500 Valby
Denmark
Tel: + 45 (0) 36 30 13 11
Fax: +45 (0) 36 43 82 50
Email: information@lundbeck.com
Web: www.lundbeck.com

Hong Kong Parkinson's Disease Foundation M46
c/o Division of Neurology
University Department of Medicine
Queen Mary Hospital
102 Pokfulam Road
Hong Kong
Web: www.hkpdf.org.hk

In – Step Mobility Products M31
8027 N. Monticello Ave.
Skokie, IL 60076
USA
Tel: +1 847 676 1275
Fax: +1 847 676 1202
Email: walkers@ustep.com
Web: www.ustep.com

Manufacturer of “U-Step Walking Stabilizer” and “Lasercane”.
The U-Step, an advanced walker, prevents falls among people with neurological disorders. The U-Step's innovative design provides superior stability and control. For Parkinson's disease, we can attach a laser module to the U-Step to reduce Parkinson's freezing. The Lasercane is effective at reducing freezing.

Hong Kong Parkinson's Disease Foundation

The symptoms and feelings associated with Parkinson's disease are uniquely important to you. Sharing experiences and learning from others with this disease can be important ways to better understand living with Parkinson's disease and overcome any challenges that you may face, such as symptom re-emergence or ‘wearing-off’. Through the use of simple educational tools and interaction with other patients, this new website aims to help support you in your everyday life and facilitate dialog among the Parkinson's disease community.

August 2010
Developed and licensed by Orion Pharma
IOS Press BV
Nieuwe Hemweg 6b
1013 BG Amsterdam
The Netherlands
Tel: +31 (0) 20 688 33 55
Fax: +31 (0) 20 687 00 19
Email: info@iospress.nl
Web: www.iospress.nl

IOS Press headquartered in Amsterdam, publishes some 100 international journals and approximately 130 book titles a year, in a broad range of subjects. IOS Press has a strong neurosciences package, with one of the top journals being the Journal of Alzheimer’s Disease. In 2010, the Journal of Parkinson’s Disease is launched. All journals are available in print and electronic format and an online book platform has been launched in the first half of 2006.

LSVT Global, Inc
6890 E Sunrise Dr.
STE 120-241
Tucson, AZ, 85750
USA
Tel: +1 520 975 8915
Fax: +1 520 615 8559
Email: info@lsvtglobal.com
Web: www.lsvtglobal.com

LSVT Global provides speech and whole-body treatments for people with neurological disorders, such as PD, enabling them to communicate and move more effectively. We offer clinical training, telemedicine and the LSVT Companion, an FDA cleared medical device that guides and tracks client speech performance and allows for client home use.

Medtronic International Trading Sàrl
Route de Mollierau 31
1131 Tolochenaz
Switzerland
Tel: +41 (0) 21 802 77 18
Fax: +41 (0) 21 802 79 15
Web: www.medtronic.com

National Parkinson Foundation
1501 N.W. 9th Avenue
Bob Hope Road
Miami, FL 33136
USA
Tel: +1 800 327 4545
Fax: +1 305 243 6073
Email: contact@parkinson.org
Web: www.parkinson.org

The National Parkinson Foundation (NPF) works every day to improve the quality of Parkinson’s care through research, education and outreach. NPF supports a strong network of Centers of Excellence across the United States and internationally that delivers care to more than 50,000 Parkinson’s disease patients.

NeuroFit NetWorks, Inc
Department of Physiology
College of Medicine
University of Arizona
Tucson, AZ 85724 5051
USA
Tel: +1 520 626 8773
Fax: +1 520 626 2383
Email: becky@nfnw.org
Web: www.nfnw.org

NeuroFit NetWorks advocates access to Exercise4BrainChange(tm) programs. Our Parkinson Wellness Recovery (PWR!) project promotes early intervention and research-based exercise approaches that target the unique physical, emotional, and cognitive challenges for individuals with PD. PWR! programs train PWR! experts (clinicians, trainers, coaches), establish community-based PWR!GYM(tm) centers, and link those resources together.
# Exhibitors

<table>
<thead>
<tr>
<th><strong>Neuroscience Nursing Foundation</strong></th>
<th><strong>Parkinson's Disease Foundation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>3007 Marx Road, Rice, WA 99167, USA</td>
<td>1359 Broadway, Suite 1509, New York, NY 10018, USA</td>
</tr>
<tr>
<td>Web: <a href="http://www.nnfoundation.net">www.nnfoundation.net</a></td>
<td>Tel: +1 212 923 4700, Fax: +1 212 923 4778, Email: <a href="mailto:info@pdf.org">info@pdf.org</a>, Web: <a href="http://www.pdf.org">www.pdf.org</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Novartis Pharma AG</strong></th>
<th><strong>Orion Corporation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CH-4002 Basel, Switzerland</td>
<td>Orionintie 1A, FI-02200 Espoo, P.O.Box 65, FI-02101 Espoo, Finland</td>
</tr>
<tr>
<td>Tel: +41 (0) 61 324 11 11, Fax: +41 (0) 61 324 80 01</td>
<td>Tel: +35 (0) 810 4261, Email: <a href="mailto:corporate@orionpharma.com">corporate@orionpharma.com</a>, Web: <a href="http://www.orion.fi/en/">www.orion.fi/en/</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Parkinson's Disease and Movement Disorder Society (India)</strong></th>
<th><strong>Parkinson's Disease Nurse Specialist Association</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>6, Jasville, 1st floor, Opp Liberty Cinema, Marine Lines, Mumbai 400 020, India</td>
<td>c/o Alison Leake, Neurology Outpatients, AMW, St Georges Hospital, Blackshaw Road, London, SW17 0QT, UK</td>
</tr>
<tr>
<td>Web: <a href="http://www.parkinsonssocietyindia.com">www.parkinsonssocietyindia.com</a></td>
<td>Web: <a href="http://www.pdnsa.net">www.pdnsa.net</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Parkinson's Action Network</strong></th>
<th><strong>Parkinson's UK</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1025 Vermont Avenue, NW, Suite 1120, Washington, DC 20005, USA</td>
<td>215 Vauxhall Bridge Road, London, SW1V 1EJ, UK</td>
</tr>
<tr>
<td>Tel: +1 202 783 8080, Fax: +1 202 7233 9908, Email: <a href="mailto:hello@parkinsons.org.uk">hello@parkinsons.org.uk</a>, Web: <a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a></td>
<td>Tel: +44 (0) 20 7931 8080, Fax: +44 (0) 20 7233 9908, Email: <a href="mailto:hello@parkinsons.org.uk">hello@parkinsons.org.uk</a>, Web: <a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Parkinson's Australia</strong></th>
<th><strong>The Parkinson's Disease Foundation (PDF)</strong> is a leader in Parkinson's research, education and patient advocacy. Since our founding in 1957, PDF has dedicated over $85 million to fund promising research in Parkinson's disease, supporting the work of leading scientists throughout the world, and over $30 million to support people with Parkinson's and their families and caregivers through our educational and advocacy programs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frewin Centre, Frewin Place, Scullin ACT 2614, Australia</td>
<td>Web: <a href="http://www.pdf.org">www.pdf.org</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Parkinson's UK</strong></th>
<th><strong>Parkinson's Disease Foundation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>215 Vauxhall Bridge Road, London, SW1V 1EJ, UK</td>
<td>1359 Broadway, Suite 1509, New York, NY 10018, USA</td>
</tr>
<tr>
<td>Tel: +44 (0) 20 7931 8080, Fax: +44 (0) 20 7233 9908, Email: <a href="mailto:hello@parkinsons.org.uk">hello@parkinsons.org.uk</a>, Web: <a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a></td>
<td>Tel: +1 212 923 4700, Fax: +1 212 923 4778, Email: <a href="mailto:info@pdf.org">info@pdf.org</a>, Web: <a href="http://www.pdf.org">www.pdf.org</a></td>
</tr>
</tbody>
</table>
As the UK’s Parkinson’s support and research charity, Parkinson’s UK is leading the work to find a cure, as well as campaigning to change attitudes and demand better services. The charity brings people with Parkinson’s, their carers and families together via its network of local groups, website and free confidential helpline. Specialist nurses, supporters and staff provide information and training on every aspect of Parkinson’s. Free confidential helpline 0808 800 0303 / www.parkinsons.org.uk.

The CPT funds innovative science and inspirational scientists. It supports and galvanises pilot studies of novel therapies. It believes that the key ingredients to achieving its only goal - “a cure” - are teamwork, communication and urgency. People with Parkinson’s were integral to its formation and continue to be the focal point for every decision made.

The Michael J. Fox Foundation for Parkinson’s Research M15
Church Street Station
Post Office Box 780
New York, NY 10008-0780
USA
Tel: +1 212 509 0995
Fax: +1 212 509 2390
Web: www.michaeljfox.org

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today. Find out how you can get involved by visiting the MJFF booth #M15 or www.michaeljfox.org.

UCB Pharma SA M42
60 Allée de la Recherche
1070 Brussels
Belgium
Tel: +32 (0) 2 559 99 99
Web: www.ucb.com

Headquartered in Brussels, Belgium, UCB is a biopharmaceutical company dedicated to the research, development and commercialisation of innovative medicines with a focus on the diseases of the central nervous system (CNS) and immunology disorders. UCB is driven by a passionate desire to liberate families living with severe disease so that they can enjoy normal, everyday lives. Employing more than 9 000 people in over 40 countries, UCB achieved revenue of €3.1 billion in 2009.
Web: www.wcn-neurology.org

World Federation of Neuroscience Nurses M49
3007 Marx Road
Rice, WA 99167
USA
Web: www.wfnn.nu

The new resource has been developed to provide an innovative educational experience for patients, relatives and caregivers through a unique combination of user-friendly educational material, short educational videos, links to social networking sites and online symptom monitoring tools. The ultimate aim is to raise awareness about Parkinson’s and help patients play an active role in the management of their disease.
Thank you to the following supporters for helping to make the WPC 2010 possible. Without their support, this unique Congress would not take place.

Platinum

SOLVAY PHARMACEUTICALS
Solvay Pharmaceuticals is now Abbott

Gold

Boehringer Ingelheim
Orion Pharma
Novartis

Silver

Chelsea Therapeutics
GSK
Medtronic

Bronze

Merck Serono

Associate Educational Grants

- Emerson Process Management
- Ipsen
Thank you to the following supporters for helping to make the WPC 2010 possible. Without their support, this unique Congress would not take place.

Diamond

Platinum

Gold

Silver

Friends & Additional Supporters

- American Speech–Hearing–Language Association
- Glasgow City Marketing Bureau
- Glasgow College of Holistic Medicine
- James & Wanda Hollensteiner Foundation
- Internationaal Parkinson Fonds Nederland
- Internationale Parkinson Fonds Deutschland
- The Parkinson Alliance
See you all in Montréal, Canada in September 2013 for WPC 2013